

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
1 August 2002 (01.08.2002)

PCT

(10) International Publication Number
WO 02/059306 A2(51) International Patent Classification⁷: C12N 15/12, 15/11, 15/63, 1/21, 5/10, C07K 14/705, 16/28, A01K 67/027, C12Q 1/68, G01N 33/68

(21) International Application Number: PCT/US01/42809

(22) International Filing Date: 26 October 2001 (26.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 09/765,344 22 January 2001 (22.01.2001) US

(71) Applicant: APPLERA CORPORATION [US/US]; 761 Main Avenue, Norwalk, CT 068559 (US).

(72) Inventors: WEI, Ming-Hui; Celera Genomics, 45 West Gude Drive C2-4#21, Rockville, MD 20850 (US). KETCHUM, Karen, A.; Celera Genomics, 45 West Gude Drive C2-4#21, Rockville, MD 20850 (US). DI FRANCESCO, Valentina; Celera Genomics, 45 West Gude Drive C2-4#21, Rockville, MD 20850 (US). BEASLEY, Ellen, M.; Celera Genomics, 45 West Gude Drive C2-4#21, Rockville, MD 20850 (US).

(74) Agent: MILLMAN, Robert, A.; Genomics Celera, Chief Intellectual Property Counsel, 45 West Gude Drive C2-4#21, Rockville, MD 20850 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,

[Continued on next page]

(54) Title: ISOLATED HUMAN TRANSPORTER PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN TRANSPORTER PROTEINS, AND USES THEREOF

SEQUENCE FROM 1:

```

1  AACACGACGAG  GGGCGACCC  AGCTGTGGG  AGCGCAGAG  AGCTGAGCT
51  GCGATCGTCA  GTGGAAACA  CTAGAACTCC  AGGCTGTGCA  AAGCCACAGG
101  TGGGGGCTGA  GCGAGGGGTG  GCGTCAAGAG  GCGAGGACCC  CCGCACTCTC
151  CCGTCAAGCC  GCGAGTCCAG  GCGAGGAGGT  GCGAGGACCC  TGGGTGAGCA
201  GTTGGAGAG  GTGGAGGACC  GCGTGGATCT  CCGTGGCTGC  ACCCGAGACC
251  CCGCGGCGCC  TACGCGCCAG  CCGTGGAGAT  CCGTGGCTGC  TACCGGCGCT
301  GCGTCAAGCC  AGCTGTGGG  GCGTGGAGAT  GCGTGGCTGC  GCGTGGCTGC
351  GCGTGGCTGC  GCGTGGAGAT  GCGTGGAGAT  GCGTGGAGAT  GCGTGGAGAT
401  AGGATGCTCC  TCGATGCTCC  GCGTGGAGAT  TCGATGCTCC  GCGTGGAGAT
451  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
501  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
551  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
601  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
651  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
701  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
751  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
801  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
851  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
901  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
951  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
1001  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
1051  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
1101  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
1151  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
1201  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
1251  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
1301  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
1351  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
1401  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
1451  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
1501  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
1551  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
1601  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
1651  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
1701  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
1751  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
1801  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
1851  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
1901  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
1951  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
2001  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
2051  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
2101  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
2151  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
2201  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
2251  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
2301  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
2351  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
2401  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
2451  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
2501  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
2551  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
2601  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
2651  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
2701  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
2751  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
2801  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
2851  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
2901  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
2951  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC
3001  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC  TCGATGCTCC

```

(57) Abstract: The present invention provides amino acid sequences acid sequences of peptides that are encoded by genes within the human genome, the transporter peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the transporter peptides, and methods of identifying modulators of the transporter peptides.

WO 02/059306 A2

FEATURES:
 SEQUENCE: 1-277
 INVENTOR: 278
 RECIPIENT: 2096
 PCT/US: 2096-2513



SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

ISOLATED HUMAN TRANSPORTER PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN TRANSPORTER PROTEINS, AND USES THEREOF

RELATED APPLICATIONS

The present application is a Continuation-In-Part of U.S. Serial No.09/630,719, filed August 2, 2000 and Continuation-In-Part of U.S. Serial No. 09/765,344.

FIELD OF THE INVENTION

The present invention is in the field of transporter proteins that are related to the sulfate transporter subfamily, recombinant DNA molecules, and protein production. The present invention specifically provides novel peptides and proteins, representing two splice forms of a novel sulfate transporter, that effect ligand transport and nucleic acid molecules encoding such peptide and protein molecules, all of which are useful in the development of human therapeutics and diagnostic compositions and methods.

BACKGROUND OF THE INVENTION

Transporters

Transporter proteins regulate many different functions of a cell, including cell proliferation, differentiation, and signaling processes, by regulating the flow of molecules such as ions and macromolecules, into and out of cells. Transporters are found in the plasma membranes of virtually every cell in eukaryotic organisms. Transporters mediate a variety of cellular functions including regulation of membrane potentials and absorption and secretion of molecules and ion across cell membranes. When present in intracellular membranes of the Golgi apparatus and endocytic vesicles, transporters, such as chloride channels, also regulate organelle pH. For a review, see Greger, R. (1988) *Annu. Rev. Physiol.* 50:111-122.

Transporters are generally classified by structure and the type of mode of action. In addition, transporters are sometimes classified by the molecule type that is transported, for example, sugar transporters, chlorine channels, potassium channels, etc. There may be many classes of channels for transporting a single type of molecule (a detailed review of channel types can be found at Alexander, S.P.H. and J.A. Peters: *Receptor and transporter nomenclature*

supplement. Trends Pharmacol. Sci., Elsevier, pp. 65-68 (1997) and <http://www-biology.ucsd.edu/~msaier/transport/titlepage2.html>.

Ion channels

An important type of transporter is the ion channel. Ion channels regulate many different cell proliferation, differentiation, and signaling processes by regulating the flow of ions into and out of cells. Ion channels are found in the plasma membranes of virtually every cell in eukaryotic organisms. Ion channels mediate a variety of cellular functions including regulation of membrane potentials and absorption and secretion of ion across epithelial membranes. When present in intracellular membranes of the Golgi apparatus and endocytic vesicles, ion channels, such as chloride channels, also regulate organelle pH. For a review, see Greger, R. (1988) Annu. Rev. Physiol. 50:111-122.

Ion channels are generally classified by structure and the type of mode of action. For example, extracellular ligand gated channels (ELGs) are comprised of five polypeptide subunits, with each subunit having 4 membrane spanning domains, and are activated by the binding of an extracellular ligand to the channel. In addition, channels are sometimes classified by the ion type that is transported, for example, chlorine channels, potassium channels, etc. There may be many classes of channels for transporting a single type of ion (a detailed review of channel types can be found at Alexander, S.P.H. and J.A. Peters (1997). Receptor and ion channel nomenclature supplement. Trends Pharmacol. Sci., Elsevier, pp. 65-68 and <http://www-biology.ucsd.edu/~msaier/transport/toc.html>.

There are many types of ion channels based on structure. For example, many ion channels fall within one of the following groups: extracellular ligand-gated channels (ELG), intracellular ligand-gated channels (ILG), inward rectifying channels (INR), intercellular (gap junction) channels, and voltage gated channels (VIC). There are additionally recognized other channel families based on ion-type transported, cellular location and drug sensitivity. Detailed information on each of these, their activity, ligand type, ion type, disease association, drugability, and other information pertinent to the present invention, is well known in the art.

Anion transport proteins

The present invention provides two splice forms of a novel human anion transport protein that shows a particularly high degree of similarity to sulfate transporters. The alternative splice forms are herein referred to as splice forms 1 and 2. Splice form 1 has been previously disclosed by applicant in U.S. application 09/630,719, filed August 2, 2000.

Anion transport proteins in mammalian cells participate in a wide variety of cell and intracellular organelle functions, including regulation of electrical activity, pH, volume, and the transport of osmolites and metabolites. These proteins also have essential physiological roles in the control of immunological responses, cell migration, cell proliferation, and differentiation. Several classes of anion transporters have been characterized with varying molecular structures and mechanisms for mediating anion flux. One of the most prominent anion transporter super-families is the multiple membrane-spanning permeases, which include Na⁺- or H⁺-dependent anion coanion transporters (symporters), anion/anion exchangers (antiporters), and cation-independent anion uniporters. This super-family is also referred to as the Carrier-type anion transporters <<http://www-biology.ucsd.edu/~msaier/transport/titlepage2.html>>. Typically, proteins within this group contain 8-14 hydrophobic alpha-helical peptide segments that allow the protein to reside in the membrane bilayer. These helices also establish the pathway for ion translocation. Both broad-substrate and substrate-specific anion transporters are known: the former type enables multiple anion species (chloride, iodide, sulfate, bromide, etc.) to permeate the bounding membrane, while anion transporters in the latter class restrict ion movement to one chemical species.

Anion transporter genes and gene products are potential causative agents of disease and disease phenotypes may be actuated both by alterations in gene transcription and by mutations in the protein sequence. For example, the down-regulated in adenoma (DRA) gene was originally identified as a gene that was down-regulated in colon tumors. It encodes a protein with anion transporter function that is expressed in the intestinal tract (duodenum, ileum, cecum, distal colon), but not in the esophagus or stomach (Antalis T.M., Reeder J.A., Gotley D.C. *et al.*, *Clin Cancer Res* (1998) Aug;4(8):1857-63; Byeon M.K., Westerman M.A., Maroulakou I.G. *et al.*, *Oncogene* (1996) Jan 18;12(2):387-96). A second illustration of the biomedical significance of anion transporters is found with patients presenting severe hypothyroidism caused by a congenital lack of iodide transport. These individuals do not accumulate iodide in their thyroids. A single amino acid substitution in the thyroid Na⁺/I⁻ symporter, where proline replaced threonine at position 354, has been identified as the cause of this condition in two independent patients (Levy O., Ginter C.S., De la Vieja A. *et al.*, *FEBS Lett* (1998) Jun 5;429(1):36-40). Equally compelling are two well-documented autosomal recessive disorders Pendred syndrome and Diastrophic dysplasia (DTD). Pendred syndrome is the most common form of syndromic deafness and characterized by congenital sensorineural hearing loss and goitre. This disorder has been mapped to chromosome 7 and the gene product causing Pendred syndrome (PDS) has been

identified as a anion transporter for iodide and chloride (Scott D.A., Wang R., Kreman T.M. *et al.*, *Nat Genet* (1999)Apr;21(4):440-3). DTD is a well-characterized osteochondrodysplasia with clinical features including dwarfism, spinal deformation, and specific joint abnormalities. The disease occurs in most populations. The gene has been mapped to distal chromosome 5q and it encodes a sulfate anion transporter (Hastbacka J., de la Chapelle A., Mahtani M.M. *et al.*, *Cell* 1994 Sep 23;78(6):1073-87).

Issued US Patents that demonstrate the utility for this group of protein/DNA molecules include, but are not limited to, 6,054,558 "Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd534 as a target"; 6,048,709 "Compositions and methods for the treatment and diagnosis of cardiovascular disease"; 6,046,030 "Human LIG-1 homolog (HLIG-1)"; 6,025,160 "Polynucleotide and polypeptide sequences encoding rat mdrlb2 and screening methods thereof"; 6,013,672 "Agonists of metabotropic glutamate receptors and uses thereof"; 6,008,015 "Glycine transporter"; 5,989,825 "Excitatory amino acid transporter gene and uses"; and 5,928,926 "Isolation and cloning of the human ARSA-I gene and uses thereof".

Transporter proteins, particularly members of the sulfate transporter subfamily, are a major target for drug action and development, particularly members that are expressed in the tissue types noted in Figure 1 (e.g. neoplastic cells)). Accordingly, it is valuable to the field of pharmaceutical development to identify and characterize previously unknown transport proteins. The present invention advances the state of the art by providing a previously unidentified human transport protein.

SUMMARY OF THE INVENTION

The present invention is based in part on the identification of amino acid sequences of human transporter peptides and proteins that are related to the sulfate transporter subfamily, as well as allelic variants and other mammalian orthologs thereof. Specifically, the present invention provides two splice forms of a novel human sulfate transporter protein. These unique peptide sequences, and nucleic acid sequences that encode these peptides, can be used as models for the development of human therapeutic targets, aid in the identification of therapeutic proteins, and serve as targets for the development of human therapeutic agents that modulate transporter activity in cells and tissues that express the transporter. Independent lines of evidence show expression of splice form 1 in fetal tissues such as brain and kidney; differentiated tissues such as brain, pituitary gland, heart, leukocytes, kidney, liver, thyroid, lung, placenta, skeletal

muscle, small intestine, prostate, testis, adrenal gland, bone marrow, and pancreas; and neoplastic tissues such as germ cell tumors, lung carcinoid tissue, brain anaplastic oligodendrogliomas, chronic lymphocytic leukemic B-cells, glioblastomas, and well-differentiated endometrial adenocarcinomas.

DESCRIPTION OF THE FIGURE SHEETS

FIGURE 1 provides the nucleotide sequences of cDNA molecules that encode splice forms 1 and 2 of the transporter protein of the present invention (splice form 1 = SEQ ID NO:1, splice form 2 = SEQ ID NO:4). In addition, structure and functional information is provided, such as ATG start, stop and tissue distribution, where available, that allows one to readily determine specific uses of the inventions based on these molecular sequences. Independent lines of evidence show expression of splice form 1 in fetal tissues such as brain and kidney; differentiated tissues such as brain, pituitary gland, heart, leukocytes, kidney, liver, thyroid, lung, placenta, skeletal muscle, small intestine, prostate, testis, adrenal gland, bone marrow, and pancreas; and neoplastic tissues such as germ cell tumors, lung carcinoid tissue, brain anaplastic oligodendrogliomas, chronic lymphocytic leukemic B-cells, glioblastomas, and well-differentiated endometrial adenocarcinomas.

FIGURE 2 provides the predicted amino acid sequences of splice forms 1 and 2 of the transporter of the present invention (splice form 1 = SEQ ID NO:2, splice form 2 = SEQ ID NO:5). In addition, structure and functional information such as protein family, function, and modification sites is provided where available, allowing one to readily determine specific uses of the inventions based on these molecular sequences.

FIGURE 3 provides a genomic sequence SEQ ID NO:3) that spans the gene encoding splice forms 1 and 2 of the transporter protein of the present invention. In addition, structure and functional information, such as intron/exon structure, promoter location, etc., is provided where available, allowing one to readily determine specific uses of the inventions based on this molecular sequence. As illustrated in Figure 3, identified SNP variations include g30344a, a31170g, c16256t, a13376t, t12210c, g12072c, g11922t, -11903a, c10009g, c4519t, a4181g, a20952c, t20987c, g21620a, t21795c, a22753t, g22945a, g23032a, g23738a, t23952g, a24123g, c24527-, c24691t, g25015a, and g25191t. Figure 3 also provides structural information for splice form 2, derived from the Genewise computer program.

DETAILED DESCRIPTION OF THE INVENTION

General Description

The present invention is based on the sequencing of the human genome. During the sequencing and assembly of the human genome, analysis of the sequence information revealed previously unidentified fragments of the human genome that encode peptides that share structural and/or sequence homology to protein/peptide/domains identified and characterized within the art as being a transporter protein or part of a transporter protein and are related to the sulfate transporter subfamily. Specifically, the present invention provides two splice forms of a novel human sulfate transporter. Utilizing these sequences, additional genomic sequences were assembled and transcript and/or cDNA sequences were isolated and characterized. Based on this analysis, the present invention provides amino acid sequences of human transporter peptides and proteins that are related to the sulfate transporter subfamily, nucleic acid sequences in the form of transcript sequences, cDNA sequences and/or genomic sequences that encode these transporter peptides and proteins, nucleic acid variation (allelic information), tissue distribution of expression, and information about the closest art known protein/peptide/domain that has structural or sequence homology to the transporter of the present invention.

In addition to being previously unknown, the peptides that are provided in the present invention are selected based on their ability to be used for the development of commercially important products and services. Specifically, the present peptides are selected based on homology and/or structural relatedness to known transporter proteins of the sulfate transporter subfamily and the expression pattern observed. Independent lines of evidence show expression of splice form 1 in fetal tissues such as brain and kidney; differentiated tissues such as brain, pituitary gland, heart, leukocytes, kidney, liver, thyroid, lung, placenta, skeletal muscle, small intestine, prostate, testis, adrenal gland, bone marrow, and pancreas; and neoplastic tissues such as germ cell tumors, lung carcinoid tissue, brain anaplastic oligodendrogliomas, chronic lymphocytic leukemic B-cells, glioblastomas, and well-differentiated endometrial adenocarcinomas.. The art has clearly established the commercial importance of members of this family of proteins and proteins that have expression patterns similar to that of the present gene. Some of the more specific features of the peptides of the present invention, and the uses thereof, are described herein, particularly in the Background of the Invention and in the annotation provided in the Figures, and/or are known within the art for each of the known sulfate transporter family or subfamily of transporter proteins.

Specific Embodiments

Peptide Molecules

The present invention provides nucleic acid sequences that encode protein molecules that have been identified as being members of the transporter family of proteins and are related to the sulfate transporter subfamily (protein sequences are provided in Figure 2, cDNA sequences are provided in Figures 1 and genomic sequences are provided in Figure 3). Specifically, the present invention provides two splice forms of a novel human sulfate transporter. The peptide sequences provided in Figure 2, as well as the obvious variants described herein, particularly allelic variants as identified herein and using the information in Figure 3, will be referred herein as the transporter peptides of the present invention, transporter peptides, or peptides/proteins of the present invention.

The present invention provides isolated peptide and protein molecules that consist of, consist essentially of, or comprising the amino acid sequences of the transporter peptides disclosed in the Figure 2, (encoded by the nucleic acid molecule shown in Figure 1, transcript/cDNA or Figure 3, genomic sequence), as well as all obvious variants of these peptides that are within the art to make and use. Some of these variants are described in detail below.

As used herein, a peptide is said to be "isolated" or "purified" when it is substantially free of cellular material or free of chemical precursors or other chemicals. The peptides of the present invention can be purified to homogeneity or other degrees of purity. The level of purification will be based on the intended use. The critical feature is that the preparation allows for the desired function of the peptide, even if in the presence of considerable amounts of other components (the features of an isolated nucleic acid molecule is discussed below).

In some uses, "substantially free of cellular material" includes preparations of the peptide having less than about 30% (by dry weight) other proteins (i.e., contaminating protein), less than about 20% other proteins, less than about 10% other proteins, or less than about 5% other proteins. When the peptide is recombinantly produced, it can also be substantially free of culture medium, i.e., culture medium represents less than about 20% of the volume of the protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of the peptide in which it is separated from chemical precursors or other chemicals that are involved in its synthesis. In one embodiment, the language "substantially free of chemical

precursors or other chemicals" includes preparations of the transporter peptide having less than about 30% (by dry weight) chemical precursors or other chemicals, less than about 20% chemical precursors or other chemicals, less than about 10% chemical precursors or other chemicals, or less than about 5% chemical precursors or other chemicals.

The isolated transporter peptide can be purified from cells that naturally express it, purified from cells that have been altered to express it (recombinant), or synthesized using known protein synthesis methods. Independent lines of evidence show expression of splice form 1 in fetal tissues such as brain and kidney; differentiated tissues such as brain, pituitary gland, heart, leukocytes, kidney, liver, thyroid, lung, placenta, skeletal muscle, small intestine, prostate, testis, adrenal gland, bone marrow, and pancreas; and neoplastic tissues such as germ cell tumors, lung carcinoid tissue, brain anaplastic oligodendrogliomas, chronic lymphocytic leukemic B-cells, glioblastomas, and well-differentiated endometrial adenocarcinomas. For example, a nucleic acid molecule encoding the transporter peptide is cloned into an expression vector, the expression vector introduced into a host cell and the protein expressed in the host cell. The protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Many of these techniques are described in detail below.

Accordingly, the present invention provides proteins that consist of the amino acid sequences provided in Figure 2 (SEQ ID NOS:2 and 5), for example, proteins encoded by the cDNA nucleic acid sequences shown in Figure 1 (SEQ ID NOS:1 and 4) and the genomic sequences provided in Figure 3 (SEQ ID NO:3). The amino acid sequence of such a protein is provided in Figure 2. A protein consists of an amino acid sequence when the amino acid sequence is the final amino acid sequence of the protein.

The present invention further provides proteins that consist essentially of the amino acid sequences provided in Figure 2 (SEQ ID NOS:2 and 5), for example, proteins encoded by the cDNA nucleic acid sequences shown in Figure 1 (SEQ ID NOS:1 and 4) and the genomic sequences provided in Figure 3 (SEQ ID NO:3). A protein consists essentially of an amino acid sequence when such an amino acid sequence is present with only a few additional amino acid residues, for example from about 1 to about 100 or so additional residues, typically from 1 to about 20 additional residues in the final protein.

The present invention further provides proteins that comprise the amino acid sequences provided in Figure 2 (SEQ ID NOS:2 and 5), for example, proteins encoded by the cDNA nucleic acid sequences shown in Figure 1 (SEQ ID NOS:1 and 4) and the genomic sequences provided in Figure 3 (SEQ ID NO:3). A protein comprises an amino acid sequence when the amino acid

sequence is at least part of the final amino acid sequence of the protein. In such a fashion, the protein can be only the peptide or have additional amino acid molecules, such as amino acid residues (contiguous encoded sequence) that are naturally associated with it or heterologous amino acid residues/peptide sequences. Such a protein can have a few additional amino acid residues or can comprise several hundred or more additional amino acids. The preferred classes of proteins that are comprised of the transporter peptides of the present invention are the naturally occurring mature proteins. A brief description of how various types of these proteins can be made/isolated is provided below.

The transporter peptides of the present invention can be attached to heterologous sequences to form chimeric or fusion proteins. Such chimeric and fusion proteins comprise a transporter peptide operatively linked to a heterologous protein having an amino acid sequence not substantially homologous to the transporter peptide. "Operatively linked" indicates that the transporter peptide and the heterologous protein are fused in-frame. The heterologous protein can be fused to the N-terminus or C-terminus of the transporter peptide.

In some uses, the fusion protein does not affect the activity of the transporter peptide *per se*. For example, the fusion protein can include, but is not limited to, enzymatic fusion proteins, for example beta-galactosidase fusions, yeast two-hybrid GAL fusions, poly-His fusions, MYC-tagged, HI-tagged and Ig fusions. Such fusion proteins, particularly poly-His fusions, can facilitate the purification of recombinant transporter peptide. In certain host cells (e.g., mammalian host cells), expression and/or secretion of a protein can be increased by using a heterologous signal sequence.

A chimeric or fusion protein can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different protein sequences are ligated together in-frame in accordance with conventional techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-amplified to generate a chimeric gene sequence (see Ausubel *et al.*, *Current Protocols in Molecular Biology*, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST protein). A transporter peptide-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the transporter peptide.

As mentioned above, the present invention also provides and enables obvious variants of the amino acid sequence of the proteins of the present invention, such as naturally occurring mature

forms of the peptide, allelic/sequence variants of the peptides, non-naturally occurring recombinantly derived variants of the peptides, and orthologs and paralogs of the peptides. Such variants can readily be generated using art-known techniques in the fields of recombinant nucleic acid technology and protein biochemistry. It is understood, however, that variants exclude any amino acid sequences disclosed prior to the invention.

Such variants can readily be identified/made using molecular techniques and the sequence information disclosed herein. Further, such variants can readily be distinguished from other peptides based on sequence and/or structural homology to the transporter peptides of the present invention. The degree of homology/identity present will be based primarily on whether the peptide is a functional variant or non-functional variant, the amount of divergence present in the paralog family and the evolutionary distance between the orthologs.

To determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% or more of a reference sequence is aligned for comparison purposes. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity and similarity between two sequences can be accomplished using a mathematical algorithm. (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data, Part I*, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (*J. Mol. Biol.* (48):444-453 (1970)) algorithm

which has been incorporated into the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (Devereux, J., *et al.*, *Nucleic Acids Res.* 12(1):387 (1984)) (available at <http://www.gcg.com>), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Myers and W. Miller (CABIOS, 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against sequence databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, *et al.* (*J. Mol. Biol.* 215:403-10 (1990)). BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to the nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to the proteins of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.* (*Nucleic Acids Res.* 25(17):3389-3402 (1997)). When utilizing BLAST and gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.

Full-length pre-processed forms, as well as mature processed forms, of proteins that comprise one of the peptides of the present invention can readily be identified as having complete sequence identity to one of the transporter peptides of the present invention as well as being encoded by the same genetic locus as the transporter peptide provided herein. RH panel mapping shows the gene encoding the transporter proteins of the present invention is found on chromosome 17 near markers SHGC-56719 and SHGC-58932 (LOD=15.9 and 15.68).

Allelic variants of a transporter peptide can readily be identified as being a human protein having a high degree (significant) of sequence homology/identity to at least a portion of the transporter peptide as well as being encoded by the same genetic locus as the transporter peptide provided herein. Genetic locus can readily be determined based on the genomic information

provided in Figure 3, such as the genomic sequence mapped to the reference human. RH panel mapping shows the gene encoding the transporter proteins of the present invention is found on chromosome 17 near markers SHGC-56719 and SHGC-58932 (LOD=15.9 and 15.68). As used herein, two proteins (or a region of the proteins) have significant homology when the amino acid sequences are typically at least about 70-80%, 80-90%, and more typically at least about 90-95% or more homologous. A significantly homologous amino acid sequence, according to the present invention, will be encoded by a nucleic acid sequence that will hybridize to a transporter peptide encoding nucleic acid molecule under stringent conditions as more fully described below.

Figure 3 provides information on SNPs that have been found in the gene encoding the transporter proteins of the present invention. The following variations were seen: g30344a, a31170g, c16256t, a13376t, t12210c, g12072c, g11922t, -11903a, c10009g, c4519t, a4181g, a20952c, t20987c, g21620a, t21795c, a22753t, g22945a, g23032a, g23738a, t23952g, a24123g, c24527-, c24691t, g25015a, and g25191t.

Paralogs of a transporter peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the transporter peptide, as being encoded by a gene from humans, and as having similar activity or function. Two proteins will typically be considered paralogs when the amino acid sequences are typically at least about 60% or greater, and more typically at least about 70% or greater homology through a given region or domain. Such paralogs will be encoded by a nucleic acid sequence that will hybridize to a transporter peptide encoding nucleic acid molecule under moderate to stringent conditions as more fully described below.

Orthologs of a transporter peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the transporter peptide as well as being encoded by a gene from another organism. Preferred orthologs will be isolated from mammals, preferably primates, for the development of human therapeutic targets and agents. Such orthologs will be encoded by a nucleic acid sequence that will hybridize to a transporter peptide encoding nucleic acid molecule under moderate to stringent conditions, as more fully described below, depending on the degree of relatedness of the two organisms yielding the proteins.

Non-naturally occurring variants of the transporter peptides of the present invention can readily be generated using recombinant techniques. Such variants include, but are not limited to deletions, additions and substitutions in the amino acid sequence of the transporter peptide. For example, one class of substitutions are conserved amino acid substitution. Such substitutions are those that substitute a given amino acid in a transporter peptide by another amino acid of like

characteristics. Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile; interchange of the hydroxyl residues Ser and Thr; exchange of the acidic residues Asp and Glu; substitution between the amide residues Asn and Gln; exchange of the basic residues Lys and Arg; and replacements among the aromatic residues Phe and Tyr. Guidance concerning which amino acid changes are likely to be phenotypically silent are found in Bowie *et al.*, *Science* 247:1306-1310 (1990).

Variant transporter peptides can be fully functional or can lack function in one or more activities, e.g. ability to bind ligand, ability to transport ligand, ability to mediate signaling, etc. Fully functional variants typically contain only conservative variation or variation in non-critical residues or in non-critical regions. Figure 2 provides the result of protein analysis and can be used to identify critical domains/regions. Functional variants can also contain substitution of similar amino acids that result in no change or an insignificant change in function. Alternatively, such substitutions may positively or negatively affect function to some degree.

Non-functional variants typically contain one or more non-conservative amino acid substitutions, deletions, insertions, inversions, or truncation or a substitution, insertion, inversion, or deletion in a critical residue or critical region.

Amino acids that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham *et al.*, *Science* 244:1081-1085 (1989)), particularly using the results provided in Figure 2. The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as transporter activity or in assays such as an *in vitro* proliferative activity. Sites that are critical for binding partner/substrate binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith *et al.*, *J. Mol. Biol.* 224:899-904 (1992); de Vos *et al.* *Science* 255:306-312 (1992)).

The present invention further provides fragments of the transporter peptides, in addition to proteins and peptides that comprise and consist of such fragments, particularly those comprising the residues identified in Figure 2. The fragments to which the invention pertains, however, are not to be construed as encompassing fragments that may be disclosed publicly prior to the present invention.

As used herein, a fragment comprises at least 8, 10, 12, 14, 16, or more contiguous amino acid residues from a transporter peptide. Such fragments can be chosen based on the ability to retain one or more of the biological activities of the transporter peptide or could be chosen for the

ability to perform a function, e.g. bind a substrate or act as an immunogen. Particularly important fragments are biologically active fragments, peptides that are, for example, about 8 or more amino acids in length. Such fragments will typically comprise a domain or motif of the transporter peptide, e.g., active site, a transmembrane domain or a substrate-binding domain. Further, possible fragments include, but are not limited to, domain or motif containing fragments, soluble peptide fragments, and fragments containing immunogenic structures. Predicted domains and functional sites are readily identifiable by computer programs well known and readily available to those of skill in the art (e.g., PROSITE analysis). The results of one such analysis are provided in Figure 2.

Polypeptides often contain amino acids other than the 20 amino acids commonly referred to as the 20 naturally occurring amino acids. Further, many amino acids, including the terminal amino acids, may be modified by natural processes, such as processing and other post-translational modifications, or by chemical modification techniques well known in the art. Common modifications that occur naturally in transporter peptides are described in basic texts, detailed monographs, and the research literature, and they are well known to those of skill in the art (some of these features are identified in Figure 2).

Known modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

Such modifications are well known to those of skill in the art and have been described in great detail in the scientific literature. Several particularly common modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as *Proteins - Structure and Molecular Properties*, 2nd Ed., T.E. Creighton, W. H. Freeman and Company, New York (1993). Many detailed reviews are available on this subject, such as by Wold, F., *Posttranslational Covalent Modification of Proteins*, B.C. Johnson, Ed., Academic Press, New York 1-12 (1983); Seifter *et al.* (*Meth. Enzymol.* 182: 626-646 (1990)) and Rattan *et al.* (*Ann. N.Y. Acad. Sci.* 663:48-62 (1992)).

Accordingly, the transporter peptides of the present invention also encompass derivatives or analogs in which a substituted amino acid residue is not one encoded by the genetic code, in which a substituent group is included, in which the mature transporter peptide is fused with another compound, such as a compound to increase the half-life of the transporter peptide (for example, polyethylene glycol), or in which the additional amino acids are fused to the mature transporter peptide, such as a leader or secretory sequence or a sequence for purification of the mature transporter peptide or a pro-protein sequence.

Protein/Peptide Uses

The proteins of the present invention can be used in substantial and specific assays related to the functional information provided in the Figures; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its binding partner or ligand) in biological fluids; and as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state). Where the protein binds or potentially binds to another protein or ligand (such as, for example, in a transporter-effector protein interaction or transporter-ligand interaction), the protein can be used to identify the binding partner/ligand so as to develop a system to identify inhibitors of the binding interaction. Any or all of these uses are capable of being developed into reagent grade or kit format for commercialization as commercial products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987.

The potential uses of the peptides of the present invention are based primarily on the source of the protein as well as the class/action of the protein. For example, transporters isolated from humans and their human/mammalian orthologs serve as targets for identifying agents for use in mammalian therapeutic applications, e.g. a human drug, particularly in modulating a biological or pathological response in a cell or tissue that expresses the transporter. Screening of tissue specific cDNA libraries for cDNA retrieval showed expression of splice form 1 in fetal brain, brain, pituitary gland, heart, leukocytes, kidney, liver, thyroid, lung, placenta, skeletal muscle, fetal kidney, small intestine, prostate, testis, adrenal gland, bone marrow, and pancreas.

Additionally, BLAST hits to ESTs derived from tissue specific libraries shows expression of splice form 1 in germ cell tumors, lung carcinoid tissue, brain anaplastic oligodendroglioma, chronic lymphocytic leukemia B-cells, infant brain (73 days post natal), placenta, glioblastoma, well-differentiated endometrial adenocarcinoma, and fetal liver and spleen. A large percentage of pharmaceutical agents are being developed that modulate the activity of transporter proteins, particularly members of the sulfate transporter subfamily (see Background of the Invention). The structural and functional information provided in the Background and Figures provide specific and substantial uses for the molecules of the present invention, particularly in combination with the expression information provided in Figure 1. Independent lines of evidence show expression of splice form 1 in fetal tissues such as brain and kidney; differentiated tissues such as brain, pituitary gland, heart, leukocytes, kidney, liver, thyroid, lung, placenta, skeletal muscle, small intestine, prostate, testis, adrenal gland, bone marrow, and pancreas; and neoplastic tissues such as germ cell tumors, lung carcinoid tissue, brain anaplastic oligodendrogliomas, chronic lymphocytic leukemia B-cells, glioblastomas, and well-differentiated endometrial adenocarcinomas. Such uses can readily be determined using the information provided herein, that known in the art and routine experimentation.

The proteins of the present invention (including variants and fragments that may have been disclosed prior to the present invention) are useful for biological assays related to transporters that are related to members of the sulfate transporter subfamily. Such assays involve any of the known transporter functions or activities or properties useful for diagnosis and treatment of transporter-related conditions that are specific for the subfamily of transporters that the one of the present invention belongs to, particularly in cells and tissues that express the transporter. Screening of tissue specific cDNA libraries for cDNA retrieval showed expression of splice form 1 in fetal brain, brain, pituitary gland, heart, leukocytes, kidney, liver, thyroid, lung, placenta, skeletal muscle, fetal kidney, small intestine, prostate, testis, adrenal gland, bone marrow, and pancreas. Additionally, BLAST hits to ESTs derived from tissue specific libraries shows expression of splice form 1 in germ cell tumors, lung carcinoid tissue, brain anaplastic oligodendroglioma, chronic lymphocytic leukemia B-cells, infant brain (73 days post natal), placenta, glioblastoma, well-differentiated endometrial adenocarcinoma, and fetal liver and spleen. The proteins of the present invention are also useful in drug screening assays, in cell-based or cell-free systems ((Hodgson, Bio/technology, 1992, Sept 10(9);973-80). Cell-based systems can be native, i.e., cells that normally express the transporter, as a biopsy or expanded in cell culture. Independent lines of evidence show expression of splice form 1 in fetal tissues such as brain and kidney; differentiated

tissues such as brain, pituitary gland, heart, leukocytes, kidney, liver, thyroid, lung, placenta, skeletal muscle, small intestine, prostate, testis, adrenal gland, bone marrow, and pancreas; and neoplastic tissues such as germ cell tumors, lung carcinoid tissue, brain anaplastic oligodendrogliomas, chronic lymphocytic leukemic B-cells, glioblastomas, and well-differentiated endometrial adenocarcinomas. In an alternate embodiment, cell-based assays involve recombinant host cells expressing the transporter protein.

The polypeptides can be used to identify compounds that modulate transporter activity of the protein in its natural state or an altered form that causes a specific disease or pathology associated with the transporter. Both the transporters of the present invention and appropriate variants and fragments can be used in high-throughput screens to assay candidate compounds for the ability to bind to the transporter. These compounds can be further screened against a functional transporter to determine the effect of the compound on the transporter activity. Further, these compounds can be tested in animal or invertebrate systems to determine activity/effectiveness. Compounds can be identified that activate (agonist) or inactivate (antagonist) the transporter to a desired degree.

Further, the proteins of the present invention can be used to screen a compound for the ability to stimulate or inhibit interaction between the transporter protein and a molecule that normally interacts with the transporter protein, e.g. a substrate or a component of the signal pathway that the transporter protein normally interacts (for example, another transporter). Such assays typically include the steps of combining the transporter protein with a candidate compound under conditions that allow the transporter protein, or fragment, to interact with the target molecule, and to detect the formation of a complex between the protein and the target or to detect the biochemical consequence of the interaction with the transporter protein and the target, such as any of the associated effects of signal transduction such as changes in membrane potential, protein phosphorylation, cAMP turnover, and adenylate cyclase activation, etc.

Candidate compounds include, for example, 1) peptides such as soluble peptides, including Ig-tailed fusion peptides and members of random peptide libraries (see, e.g., Lam *et al.*, *Nature* 354:82-84 (1991); Houghten *et al.*, *Nature* 354:84-86 (1991)) and combinatorial chemistry-derived molecular libraries made of D- and/or L- configuration amino acids; 2) phosphopeptides (e.g., members of random and partially degenerate, directed phosphopeptide libraries, see, e.g., Songyang *et al.*, *Cell* 72:767-778 (1993)); 3) antibodies (e.g., polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, and single chain antibodies as well as Fab, F(ab')₂, Fab expression library

fragments, and epitope-binding fragments of antibodies); and 4) small organic and inorganic molecules (e.g., molecules obtained from combinatorial and natural product libraries).

One candidate compound is a soluble fragment of the receptor that competes for ligand binding. Other candidate compounds include mutant transporters or appropriate fragments containing mutations that affect transporter function and thus compete for ligand. Accordingly, a fragment that competes for ligand, for example with a higher affinity, or a fragment that binds ligand but does not allow release, is encompassed by the invention.

The invention further includes other end point assays to identify compounds that modulate (stimulate or inhibit) transporter activity. The assays typically involve an assay of events in the signal transduction pathway that indicate transporter activity. Thus, the transport of a ligand, change in cell membrane potential, activation of a protein, a change in the expression of genes that are up- or down-regulated in response to the transporter protein dependent signal cascade can be assayed.

Any of the biological or biochemical functions mediated by the transporter can be used as an endpoint assay. These include all of the biochemical or biochemical/biological events described herein, in the references cited herein, incorporated by reference for these endpoint assay targets, and other functions known to those of ordinary skill in the art or that can be readily identified using the information provided in the Figures, particularly Figure 2. Specifically, a biological function of a cell or tissues that expresses the transporter can be assayed. Screening of tissue specific cDNA libraries for cDNA retrieval showed expression of splice form 1 in fetal brain, brain, pituitary gland, heart, leukocytes, kidney, liver, thyroid, lung, placenta, skeletal muscle, fetal kidney, small intestine, prostate, testis, adrenal gland, bone marrow, and pancreas. Additionally, BLAST hits to ESTs derived from tissue specific libraries shows expression of splice form 1 in germ cell tumors, lung carcinoid tissue, brain anaplastic oligodendroglioma, chronic lymphocytic leukemia B-cells, infant brain (73 days post natal), placenta, glioblastoma, well-differentiated endometrial adenocarcinoma, and fetal liver and spleen.

Binding and/or activating compounds can also be screened by using chimeric transporter proteins in which the amino terminal extracellular domain, or parts thereof, the entire transmembrane domain or subregions, such as any of the seven transmembrane segments or any of the intracellular or extracellular loops and the carboxy terminal intracellular domain, or parts thereof, can be replaced by heterologous domains or subregions. For example, a ligand-binding region can be used that interacts with a different ligand than that which is recognized by the native transporter. Accordingly, a different set of signal transduction components is available as an end-

point assay for activation. This allows for assays to be performed in other than the specific host cell from which the transporter is derived.

The proteins of the present invention are also useful in competition binding assays in methods designed to discover compounds that interact with the transporter (e.g. binding partners and/or ligands). Thus, a compound is exposed to a transporter polypeptide under conditions that allow the compound to bind or to otherwise interact with the polypeptide. Soluble transporter polypeptide is also added to the mixture. If the test compound interacts with the soluble transporter polypeptide, it decreases the amount of complex formed or activity from the transporter target. This type of assay is particularly useful in cases in which compounds are sought that interact with specific regions of the transporter. Thus, the soluble polypeptide that competes with the target transporter region is designed to contain peptide sequences corresponding to the region of interest.

To perform cell free drug screening assays, it is sometimes desirable to immobilize either the transporter protein, or fragment, or its target molecule to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay.

Techniques for immobilizing proteins on matrices can be used in the drug screening assays. In one embodiment, a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix. For example, glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the cell lysates (e.g., ³⁵S-labeled) and the candidate compound, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads are washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated. Alternatively, the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of transporter-binding protein found in the bead fraction quantitated from the gel using standard electrophoretic techniques. For example, either the polypeptide or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin using techniques well known in the art. Alternatively, antibodies reactive with the protein but which do not interfere with binding of the protein to its target molecule can be derivatized to the wells of the plate, and the protein trapped in the wells by antibody conjugation. Preparations of a transporter-binding protein and a candidate compound are incubated in the transporter protein-presenting wells and the amount of complex trapped in the well can be quantitated. Methods for detecting such complexes, in addition to those described above for the

GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the transporter protein target molecule, or which are reactive with transporter protein and compete with the target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the target molecule.

Agents that modulate one of the transporters of the present invention can be identified using one or more of the above assays, alone or in combination. It is generally preferable to use a cell-based or cell free system first and then confirm activity in an animal or other model system. Such model systems are well known in the art and can readily be employed in this context.

Modulators of transporter protein activity identified according to these drug screening assays can be used to treat a subject with a disorder mediated by the transporter pathway, by treating cells or tissues that express the transporter. Independent lines of evidence show expression of splice form 1 in fetal tissues such as brain and kidney; differentiated tissues such as brain, pituitary gland, heart, leukocytes, kidney, liver, thyroid, lung, placenta, skeletal muscle, small intestine, prostate, testis, adrenal gland, bone marrow, and pancreas; and neoplastic tissues such as germ cell tumors, lung carcinoid tissue, brain anaplastic oligodendrogliomas, chronic lymphocytic leukemic B-cells, glioblastomas, and well-differentiated endometrial adenocarcinomas. These methods of treatment include the steps of administering a modulator of transporter activity in a pharmaceutical composition to a subject in need of such treatment, the modulator being identified as described herein.

In yet another aspect of the invention, the transporter proteins can be used as "bait proteins" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos *et al.* (1993) *Cell* 72:223-232; Madura *et al.* (1993) *J. Biol. Chem.* 268:12046-12054; Bartel *et al.* (1993) *Biotechniques* 14:920-924; Iwabuchi *et al.* (1993) *Oncogene* 8:1693-1696; and Brent WO94/10300), to identify other proteins, which bind to or interact with the transporter and are involved in transporter activity. Such transporter-binding proteins are also likely to be involved in the propagation of signals by the transporter proteins or transporter targets as, for example, downstream elements of a transporter-mediated signaling pathway. Alternatively, such transporter-binding proteins are likely to be transporter inhibitors.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for a transporter protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an

unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming a transporter-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., *LacZ*) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the transporter protein.

This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein (e.g., a transporter-modulating agent, an antisense transporter nucleic acid molecule, a transporter-specific antibody, or a transporter-binding partner) can be used in an animal or other model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal or other model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

The transporter proteins of the present invention are also useful to provide a target for diagnosing a disease or predisposition to disease mediated by the peptide. Accordingly, the invention provides methods for detecting the presence, or levels of, the protein (or encoding mRNA) in a cell, tissue, or organism. Independent lines of evidence show expression of splice form 1 in fetal tissues such as brain and kidney; differentiated tissues such as brain, pituitary gland, heart, leukocytes, kidney, liver, thyroid, lung, placenta, skeletal muscle, small intestine, prostate, testis, adrenal gland, bone marrow, and pancreas; and neoplastic tissues such as germ cell tumors, lung carcinoid tissue, brain anaplastic oligodendrogliomas, chronic lymphocytic leukemic B-cells, glioblastomas, and well-differentiated endometrial adenocarcinomas. The method involves contacting a biological sample with a compound capable of interacting with the transporter protein such that the interaction can be detected. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

One agent for detecting a protein in a sample is an antibody capable of selectively binding to protein. A biological sample includes tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject.

The peptides of the present invention also provide targets for diagnosing active protein activity, disease, or predisposition to disease, in a patient having a variant peptide, particularly activities and conditions that are known for other members of the family of proteins to which the present one belongs. Thus, the peptide can be isolated from a biological sample and assayed for the presence of a genetic mutation that results in aberrant peptide. This includes amino acid substitution, deletion, insertion, rearrangement, (as the result of aberrant splicing events), and inappropriate post-translational modification. Analytic methods include altered electrophoretic mobility, altered tryptic peptide digest, altered transporter activity in cell-based or cell-free assay, alteration in ligand or antibody-binding pattern, altered isoelectric point, direct amino acid sequencing, and any other of the known assay techniques useful for detecting mutations in a protein. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

In vitro techniques for detection of peptide include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence using a detection reagent, such as an antibody or protein binding agent. Alternatively, the peptide can be detected *in vivo* in a subject by introducing into the subject a labeled anti-peptide antibody or other types of detection agent. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. Particularly useful are methods that detect the allelic variant of a peptide expressed in a subject and methods which detect fragments of a peptide in a sample.

The peptides are also useful in pharmacogenomic analysis. Pharmacogenomics deal with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Eichelbaum, M. (*Clin. Exp. Pharmacol. Physiol.* 23(10-11):983-985 (1996)), and Linder, M.W. (*Clin. Chem.* 43(2):254-266 (1997)). The clinical outcomes of these variations result in severe toxicity of therapeutic drugs in certain individuals or therapeutic failure of drugs in certain individuals as a result of individual variation in metabolism. Thus, the genotype of the individual can determine the way a therapeutic compound acts on the body or the way the body metabolizes the compound. Further, the activity of drug metabolizing enzymes effects both the intensity and duration of drug action. Thus, the pharmacogenomics of the individual permit the selection of effective compounds and effective dosages of such compounds for prophylactic or therapeutic treatment based on the individual's genotype. The discovery of genetic polymorphisms in some drug metabolizing enzymes has explained why some patients do not obtain the expected drug effects, show an exaggerated drug effect, or experience serious toxicity from

standard drug dosages. Polymorphisms can be expressed in the phenotype of the extensive metabolizer and the phenotype of the poor metabolizer. Accordingly, genetic polymorphism may lead to allelic protein variants of the transporter protein in which one or more of the transporter functions in one population is different from those in another population. The peptides thus allow a target to ascertain a genetic predisposition that can affect treatment modality. Thus, in a ligand-based treatment, polymorphism may give rise to amino terminal extracellular domains and/or other ligand-binding regions that are more or less active in ligand binding, and transporter activation. Accordingly, ligand dosage would necessarily be modified to maximize the therapeutic effect within a given population containing a polymorphism. As an alternative to genotyping, specific polymorphic peptides could be identified.

The peptides are also useful for treating a disorder characterized by an absence of, inappropriate, or unwanted expression of the protein. Independent lines of evidence show expression of splice form 1 in fetal tissues such as brain and kidney; differentiated tissues such as brain, pituitary gland, heart, leukocytes, kidney, liver, thyroid, lung, placenta, skeletal muscle, small intestine, prostate, testis, adrenal gland, bone marrow, and pancreas; and neoplastic tissues such as germ cell tumors, lung carcinoid tissue, brain anaplastic oligodendrogliomas, chronic lymphocytic leukemic B-cells, glioblastomas, and well-differentiated endometrial adenocarcinomas. Accordingly, methods for treatment include the use of the transporter protein or fragments.

Antibodies

The invention also provides antibodies that selectively bind to one of the peptides of the present invention, a protein comprising such a peptide, as well as variants and fragments thereof. As used herein, an antibody selectively binds a target peptide when it binds the target peptide and does not significantly bind to unrelated proteins. An antibody is still considered to selectively bind a peptide even if it also binds to other proteins that are not substantially homologous with the target peptide so long as such proteins share homology with a fragment or domain of the peptide target of the antibody. In this case, it would be understood that antibody binding to the peptide is still selective despite some degree of cross-reactivity.

As used herein, an antibody is defined in terms consistent with that recognized within the art: they are multi-subunit proteins produced by a mammalian organism in response to an antigen challenge. The antibodies of the present invention include polyclonal antibodies and monoclonal antibodies, as well as fragments of such antibodies, including, but not limited to, Fab or F(ab')₂, and Fv fragments.

Many methods are known for generating and/or identifying antibodies to a given target peptide. Several such methods are described by Harlow, *Antibodies*, Cold Spring Harbor Press, (1989).

In general, to generate antibodies, an isolated peptide is used as an immunogen and is administered to a mammalian organism, such as a rat, rabbit or mouse. The full-length protein, an antigenic peptide fragment or a fusion protein can be used. Particularly important fragments are those covering functional domains, such as the domains identified in Figure 2, and domain of sequence homology or divergence amongst the family, such as those that can readily be identified using protein alignment methods and as presented in the Figures.

Antibodies are preferably prepared from regions or discrete fragments of the transporter proteins. Antibodies can be prepared from any region of the peptide as described herein. However, preferred regions will include those involved in function/activity and/or transporter/binding partner interaction. Figure 2 can be used to identify particularly important regions while sequence alignment can be used to identify conserved and unique sequence fragments.

An antigenic fragment will typically comprise at least 8 contiguous amino acid residues. The antigenic peptide can comprise, however, at least 10, 12, 14, 16 or more amino acid residues. Such fragments can be selected on a physical property, such as fragments correspond to regions that are located on the surface of the protein, e.g., hydrophilic regions or can be selected based on sequence uniqueness (see Figure 2).

Detection on an antibody of the present invention can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

Antibody Uses

The antibodies can be used to isolate one of the proteins of the present invention by standard techniques, such as affinity chromatography or immunoprecipitation. The antibodies can facilitate the purification of the natural protein from cells and recombinantly produced protein expressed in host cells. In addition, such antibodies are useful to detect the presence of one of the proteins of the present invention in cells or tissues to determine the pattern of expression of the protein among various tissues in an organism and over the course of normal development. Screening of tissue specific cDNA libraries for cDNA retrieval showed expression of splice form 1 in fetal brain, brain, pituitary gland, heart, leukocytes, kidney, liver, thyroid, lung, placenta, skeletal muscle, fetal kidney, small intestine, prostate, testis, adrenal gland, bone marrow, and pancreas. Additionally, BLAST hits to ESTs derived from tissue specific libraries shows expression of splice form 1 in germ cell tumors, lung carcinoid tissue, brain anaplastic oligodendroglioma, chronic lymphocytic leukemia B-cells, infant brain (73 days post natal), placenta, glioblastoma, well-differentiated endometrial adenocarcinoma, and fetal liver and spleen. Further, such antibodies can be used to detect protein *in situ*, *in vitro*, or in a cell lysate or supernatant in order to evaluate the abundance and pattern of expression. Also, such antibodies can be used to assess abnormal tissue distribution or abnormal expression during development or progression of a biological condition. Antibody detection of circulating fragments of the full length protein can be used to identify turnover.

Further, the antibodies can be used to assess expression in disease states such as in active stages of the disease or in an individual with a predisposition toward disease related to the protein's function. When a disorder is caused by an inappropriate tissue distribution, developmental expression, level of expression of the protein, or expressed/processed form, the antibody can be prepared against the normal protein. Independent lines of evidence show expression of splice form 1 in fetal tissues such as brain and kidney; differentiated tissues such as brain, pituitary gland, heart, leukocytes, kidney, liver, thyroid, lung, placenta, skeletal muscle, small intestine, prostate, testis, adrenal gland, bone marrow, and pancreas; and neoplastic tissues such as germ cell tumors, lung carcinoid tissue, brain anaplastic oligodendrogliomas, chronic lymphocytic leukemic B-cells, glioblastomas, and well-differentiated endometrial adenocarcinomas. If a disorder is characterized by a specific mutation in the protein, antibodies specific for this mutant protein can be used to assay for the presence of the specific mutant protein.

The antibodies can also be used to assess normal and aberrant subcellular localization of cells in the various tissues in an organism. Independent lines of evidence show expression of splice

form 1 in fetal tissues such as brain and kidney; differentiated tissues such as brain, pituitary gland, heart, leukocytes, kidney, liver, thyroid, lung, placenta, skeletal muscle, small intestine, prostate, testis, adrenal gland, bone marrow, and pancreas; and neoplastic tissues such as germ cell tumors, lung carcinoid tissue, brain anaplastic oligodendrogliomas, chronic lymphocytic leukemic B-cells, glioblastomas, and well-differentiated endometrial adenocarcinomas. The diagnostic uses can be applied, not only in genetic testing, but also in monitoring a treatment modality. Accordingly, where treatment is ultimately aimed at correcting expression level or the presence of aberrant sequence and aberrant tissue distribution or developmental expression, antibodies directed against the protein or relevant fragments can be used to monitor therapeutic efficacy.

Additionally, antibodies are useful in pharmacogenomic analysis. Thus, antibodies prepared against polymorphic proteins can be used to identify individuals that require modified treatment modalities. The antibodies are also useful as diagnostic tools as an immunological marker for aberrant protein analyzed by electrophoretic mobility, isoelectric point, tryptic peptide digest, and other physical assays known to those in the art.

The antibodies are also useful for tissue typing. Independent lines of evidence show expression of splice form 1 in fetal tissues such as brain and kidney; differentiated tissues such as brain, pituitary gland, heart, leukocytes, kidney, liver, thyroid, lung, placenta, skeletal muscle, small intestine, prostate, testis, adrenal gland, bone marrow, and pancreas; and neoplastic tissues such as germ cell tumors, lung carcinoid tissue, brain anaplastic oligodendrogliomas, chronic lymphocytic leukemic B-cells, glioblastomas, and well-differentiated endometrial adenocarcinomas. Thus, where a specific protein has been correlated with expression in a specific tissue, antibodies that are specific for this protein can be used to identify a tissue type.

The antibodies are also useful for inhibiting protein function, for example, blocking the binding of the transporter peptide to a binding partner such as a ligand or protein binding partner. These uses can also be applied in a therapeutic context in which treatment involves inhibiting the protein's function. An antibody can be used, for example, to block binding, thus modulating (agonizing or antagonizing) the peptides activity. Antibodies can be prepared against specific fragments containing sites required for function or against intact protein that is associated with a cell or cell membrane. See Figure 2 for structural information relating to the proteins of the present invention.

The invention also encompasses kits for using antibodies to detect the presence of a protein in a biological sample. The kit can comprise antibodies such as a labeled or labelable antibody and a compound or agent for detecting protein in a biological sample; means for determining the amount

of protein in the sample; means for comparing the amount of protein in the sample with a standard; and instructions for use. Such a kit can be supplied to detect a single protein or epitope or can be configured to detect one of a multitude of epitopes, such as in an antibody detection array. Arrays are described in detail below for nucleic acid arrays and similar methods have been developed for antibody arrays.

Nucleic Acid Molecules

The present invention further provides isolated nucleic acid molecules that encode a transporter peptide or protein of the present invention (cDNA, transcript and genomic sequence). Such nucleic acid molecules will consist of, consist essentially of, or comprise a nucleotide sequence that encodes one of the transporter peptides of the present invention, an allelic variant thereof, or an ortholog or paralog thereof.

As used herein, an "isolated" nucleic acid molecule is one that is separated from other nucleic acid present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences that naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. However, there can be some flanking nucleotide sequences, for example up to about 5KB, 4KB, 3KB, 2KB, or 1KB or less, particularly contiguous peptide encoding sequences and peptide encoding sequences within the same gene but separated by introns in the genomic sequence. The important point is that the nucleic acid is isolated from remote and unimportant flanking sequences such that it can be subjected to the specific manipulations described herein such as recombinant expression, preparation of probes and primers, and other uses specific to the nucleic acid sequences.

Moreover, an "isolated" nucleic acid molecule, such as a transcript/cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. However, the nucleic acid molecule can be fused to other coding or regulatory sequences and still be considered isolated.

For example, recombinant DNA molecules contained in a vector are considered isolated. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include *in vivo* or *in vitro* RNA transcripts of the isolated DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically.

Accordingly, the present invention provides nucleic acid molecules that consist of the nucleotide sequence shown in Figure 1 or 3 (SEQ ID NOS:1 and 4, cDNA/transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in Figure 2, SEQ ID NOS:2 and 5. A nucleic acid molecule consists of a nucleotide sequence when the nucleotide sequence is the complete nucleotide sequence of the nucleic acid molecule.

The present invention further provides nucleic acid molecules that consist essentially of the nucleotide sequence shown in Figure 1 or 3 (SEQ ID NOS:1 and 4, cDNA/transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in Figure 2, SEQ ID NOS:2 and 5. A nucleic acid molecule consists essentially of a nucleotide sequence when such a nucleotide sequence is present with only a few additional nucleic acid residues in the final nucleic acid molecule.

The present invention further provides nucleic acid molecules that comprise the nucleotide sequences shown in Figure 1 or 3 (SEQ ID NOS:1 and 4, cDNA/transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in Figure 2, SEQ ID NOS:2 and 5. A nucleic acid molecule comprises a nucleotide sequence when the nucleotide sequence is at least part of the final nucleotide sequence of the nucleic acid molecule. In such a fashion, the nucleic acid molecule can be only the nucleotide sequence or have additional nucleic acid residues, such as nucleic acid residues that are naturally associated with it or heterologous nucleotide sequences. Such a nucleic acid molecule can have a few additional nucleotides or can comprise several hundred or more additional nucleotides. A brief description of how various types of these nucleic acid molecules can be readily made/isolated is provided below.

In Figures 1 and 3, both coding and non-coding sequences are provided. Because of the source of the present invention, humans genomic sequence (Figure 3) and cDNA/transcript sequences (Figure 1), the nucleic acid molecules in the Figures will contain genomic intronic sequences, 5' and 3' non-coding sequences, gene regulatory regions and non-coding intergenic sequences. In general such sequence features are either noted in Figures 1 and 3 or can readily be identified using computational tools known in the art. As discussed below, some of the non-coding regions, particularly gene regulatory elements such as promoters, are useful for a variety of purposes, e.g. control of heterologous gene expression, target for identifying gene activity modulating compounds, and are particularly claimed as fragments of the genomic sequence provided herein.

The isolated nucleic acid molecules can encode the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature peptide (when the mature form

has more than one peptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, facilitate protein trafficking, prolong or shorten protein half-life or facilitate manipulation of a protein for assay or production, among other things. As generally is the case *in situ*, the additional amino acids may be processed away from the mature protein by cellular enzymes.

As mentioned above, the isolated nucleic acid molecules include, but are not limited to, the sequence encoding the transporter peptide alone, the sequence encoding the mature peptide and additional coding sequences, such as a leader or secretory sequence (e.g., a pre-pro or pro-protein sequence), the sequence encoding the mature peptide, with or without the additional coding sequences, plus additional non-coding sequences, for example introns and non-coding 5' and 3' sequences such as transcribed but non-translated sequences that play a role in transcription, mRNA processing (including splicing and polyadenylation signals), ribosome binding and stability of mRNA. In addition, the nucleic acid molecule may be fused to a marker sequence encoding, for example, a peptide that facilitates purification.

Isolated nucleic acid molecules can be in the form of RNA, such as mRNA, or in the form DNA, including cDNA and genomic DNA obtained by cloning or produced by chemical synthetic techniques or by a combination thereof. The nucleic acid, especially DNA, can be double-stranded or single-stranded. Single-stranded nucleic acid can be the coding strand (sense strand) or the non-coding strand (anti-sense strand).

The invention further provides nucleic acid molecules that encode fragments of the peptides of the present invention as well as nucleic acid molecules that encode obvious variants of the transporter proteins of the present invention that are described above. Such nucleic acid molecules may be naturally occurring, such as allelic variants (same locus), paralogs (different locus), and orthologs (different organism), or may be constructed by recombinant DNA methods or by chemical synthesis. Such non-naturally occurring variants may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells, or organisms. Accordingly, as discussed above, the variants can contain nucleotide substitutions, deletions, inversions and insertions. Variation can occur in either or both the coding and non-coding regions. The variations can produce both conservative and non-conservative amino acid substitutions.

The present invention further provides non-coding fragments of the nucleic acid molecules provided in Figures 1 and 3. Preferred non-coding fragments include, but are not limited to, promoter sequences, enhancer sequences, gene modulating sequences and gene termination sequences. Such fragments are useful in controlling heterologous gene expression and in

developing screens to identify gene-modulating agents. A promoter can readily be identified as being 5' to the ATG start site in the genomic sequence provided in Figure 3.

A fragment comprises a contiguous nucleotide sequence greater than 12 or more nucleotides. Further, a fragment could be at least 30, 40, 50, 100, 250 or 500 nucleotides in length. The length of the fragment will be based on its intended use. For example, the fragment can encode epitope bearing regions of the peptide, or can be useful as DNA probes and primers. Such fragments can be isolated using the known nucleotide sequence to synthesize an oligonucleotide probe. A labeled probe can then be used to screen a cDNA library, genomic DNA library, or mRNA to isolate nucleic acid corresponding to the coding region. Further, primers can be used in PCR reactions to clone specific regions of gene.

A probe/primer typically comprises substantially a purified oligonucleotide or oligonucleotide pair. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 20, 25, 40, 50 or more consecutive nucleotides.

Orthologs, homologs, and allelic variants can be identified using methods well known in the art. As described in the Peptide Section, these variants comprise a nucleotide sequence encoding a peptide that is typically 60-70%, 70-80%, 80-90%, and more typically at least about 90-95% or more homologous to the nucleotide sequence shown in the Figure sheets or a fragment of this sequence. Such nucleic acid molecules can readily be identified as being able to hybridize under moderate to stringent conditions, to the nucleotide sequence shown in the Figure sheets or a fragment of the sequence. Allelic variants can readily be determined by genetic locus of the encoding gene. RH panel mapping shows the gene encoding the transporter proteins of the present invention is found on chromosome 17 near markers SHGC-56719 and SHGC-58932 (LOD=15.9 and 15.68).

Figure 3 provides information on SNPs that have been found in the gene encoding the transporter proteins of the present invention. The following variations were seen: g30344a, a31170g, c16256t, a13376t, t12210c, g12072c, g11922t, -11903a, c10009g, c4519t, a4181g, a20952c, t20987c, g21620a, t21795c, a22753t, g22945a, g23032a, g23738a, t23952g, a24123g, c24527-, c24691t, g25015a, and g25191t.

As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences encoding a peptide at least 60-70% homologous to each other typically remain hybridized to each other. The conditions can be such that sequences at least about 60%, at least about 70%, or at least about 80% or more

homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. One example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65C. Examples of moderate to low stringency hybridization conditions are well known in the art.

Nucleic Acid Molecule Uses

The nucleic acid molecules of the present invention are useful for probes, primers, chemical intermediates, and in biological assays. The nucleic acid molecules are useful as a hybridization probe for messenger RNA, transcript/cDNA and genomic DNA to isolate full-length cDNA and genomic clones encoding the peptide described in Figure 2 and to isolate cDNA and genomic clones that correspond to variants (alleles, orthologs, etc.) producing the same or related peptides shown in Figure 2. As illustrated in Figure 3, identified SNP variations include g30344a, a31170g, c16256t, a13376t, t12210c, g12072c, g11922t, -11903a, c10009g, c4519t, a4181g, a20952c, t20987c, g21620a, t21795c, a22753t, g22945a, g23032a, g23738a, t23952g, a24123g, c24527-, c24691t, g25015a, and g25191t.

The probe can correspond to any sequence along the entire length of the nucleic acid molecules provided in the Figures. Accordingly, it could be derived from 5' noncoding regions, the coding region, and 3' noncoding regions. However, as discussed, fragments are not to be construed as encompassing fragments disclosed prior to the present invention.

The nucleic acid molecules are also useful as primers for PCR to amplify any given region of a nucleic acid molecule and are useful to synthesize antisense molecules of desired length and sequence.

The nucleic acid molecules are also useful for constructing recombinant vectors. Such vectors include expression vectors that express a portion of, or all of, the peptide sequences. Vectors also include insertion vectors, used to integrate into another nucleic acid molecule sequence, such as into the cellular genome, to alter *in situ* expression of a gene and/or gene product. For example, an endogenous coding sequence can be replaced via homologous recombination with all or part of the coding region containing one or more specifically introduced mutations.

The nucleic acid molecules are also useful for expressing antigenic portions of the proteins.

The nucleic acid molecules are also useful as probes for determining the chromosomal positions of the nucleic acid molecules by means of *in situ* hybridization methods. RH panel

mapping shows the gene encoding the transporter proteins of the present invention is found on chromosome 17 near markers SHGC-56719 and SHGC-58932 (LOD=15.9 and 15.68).

The nucleic acid molecules are also useful in making vectors containing the gene regulatory regions of the nucleic acid molecules of the present invention.

The nucleic acid molecules are also useful for designing ribozymes corresponding to all, or a part, of the mRNA produced from the nucleic acid molecules described herein.

The nucleic acid molecules are also useful for making vectors that express part, or all, of the peptides.

The nucleic acid molecules are also useful for constructing host cells expressing a part, or all, of the nucleic acid molecules and peptides.

The nucleic acid molecules are also useful for constructing transgenic animals expressing all, or a part, of the nucleic acid molecules and peptides.

The nucleic acid molecules are also useful as hybridization probes for determining the presence, level, form and distribution of nucleic acid expression. Screening of tissue specific cDNA libraries for cDNA retrieval showed expression of splice form 1 in fetal brain, brain, pituitary gland, heart, leukocytes, kidney, liver, thyroid, lung, placenta, skeletal muscle, fetal kidney, small intestine, prostate, testis, adrenal gland, bone marrow, and pancreas. Additionally, BLAST hits to ESTs derived from tissue specific libraries shows expression of splice form 1 in germ cell tumors, lung carcinoid tissue, brain anaplastic oligodendroglioma, chronic lymphocytic leukemia B-cells, infant brain (73 days post natal), placenta, glioblastoma, well-differentiated endometrial adenocarcinoma, and fetal liver and spleen.

Accordingly, the probes can be used to detect the presence of, or to determine levels of, a specific nucleic acid molecule in cells, tissues, and in organisms. The nucleic acid whose level is determined can be DNA or RNA. Accordingly, probes corresponding to the peptides described herein can be used to assess expression and/or gene copy number in a given cell, tissue, or organism. These uses are relevant for diagnosis of disorders involving an increase or decrease in transporter protein expression relative to normal results.

In vitro techniques for detection of mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detecting DNA include Southern hybridizations and *in situ* hybridization.

Probes can be used as a part of a diagnostic test kit for identifying cells or tissues that express a transporter protein, such as by measuring a level of a transporter-encoding nucleic acid in a sample of cells from a subject e.g., mRNA or genomic DNA, or determining if a transporter gene

has been mutated. Screening of tissue specific cDNA libraries for cDNA retrieval showed expression of splice form 1 in fetal brain, brain, pituitary gland, heart, leukocytes, kidney, liver, thyroid, lung, placenta, skeletal muscle, fetal kidney, small intestine, prostate, testis, adrenal gland, bone marrow, and pancreas. Additionally, BLAST hits to ESTs derived from tissue specific libraries shows expression of splice form 1 in germ cell tumors, lung carcinoid tissue, brain anaplastic oligodendroglioma, chronic lymphocytic leukemia B-cells, infant brain (73 days post natal), placenta, glioblastoma, well-differentiated endometrial adenocarcinoma, and fetal liver and spleen.

Nucleic acid expression assays are useful for drug screening to identify compounds that modulate transporter nucleic acid expression.

The invention thus provides a method for identifying a compound that can be used to treat a disorder associated with nucleic acid expression of the transporter gene, particularly biological and pathological processes that are mediated by the transporter in cells and tissues that express it. Independent lines of evidence show expression of splice form 1 in fetal tissues such as brain and kidney; differentiated tissues such as brain, pituitary gland, heart, leukocytes, kidney, liver, thyroid, lung, placenta, skeletal muscle, small intestine, prostate, testis, adrenal gland, bone marrow, and pancreas; and neoplastic tissues such as germ cell tumors, lung carcinoid tissue, brain anaplastic oligodendrogliomas, chronic lymphocytic leukemia B-cells, glioblastomas, and well-differentiated endometrial adenocarcinomas. The method typically includes assaying the ability of the compound to modulate the expression of the transporter nucleic acid and thus identifying a compound that can be used to treat a disorder characterized by undesired transporter nucleic acid expression. The assays can be performed in cell-based and cell-free systems. Cell-based assays include cells naturally expressing the transporter nucleic acid or recombinant cells genetically engineered to express specific nucleic acid sequences.

The assay for transporter nucleic acid expression can involve direct assay of nucleic acid levels, such as mRNA levels, or on collateral compounds involved in the signal pathway. Further, the expression of genes that are up- or down-regulated in response to the transporter protein signal pathway can also be assayed. In this embodiment the regulatory regions of these genes can be operably linked to a reporter gene such as luciferase.

Thus, modulators of transporter gene expression can be identified in a method wherein a cell is contacted with a candidate compound and the expression of mRNA determined. The level of expression of transporter mRNA in the presence of the candidate compound is compared to the level of expression of transporter mRNA in the absence of the candidate compound. The candidate

compound can then be identified as a modulator of nucleic acid expression based on this comparison and be used, for example to treat a disorder characterized by aberrant nucleic acid expression. When expression of mRNA is statistically significantly greater in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of nucleic acid expression. When nucleic acid expression is statistically significantly less in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of nucleic acid expression.

The invention further provides methods of treatment, with the nucleic acid as a target, using a compound identified through drug screening as a gene modulator to modulate transporter nucleic acid expression in cells and tissues that express the transporter. Screening of tissue specific cDNA libraries for cDNA retrieval showed expression of splice form 1 in fetal brain, brain, pituitary gland, heart, leukocytes, kidney, liver, thyroid, lung, placenta, skeletal muscle, fetal kidney, small intestine, prostate, testis, adrenal gland, bone marrow, and pancreas. Additionally, BLAST hits to ESTs derived from tissue specific libraries shows expression of splice form 1 in germ cell tumors, lung carcinoid tissue, brain anaplastic oligodendroglioma, chronic lymphocytic leukemia B-cells, infant brain (73 days post natal), placenta, glioblastoma, well-differentiated endometrial adenocarcinoma, and fetal liver and spleen. Modulation includes both up-regulation (i.e. activation or agonization) or down-regulation (suppression or antagonization) of nucleic acid expression.

Alternatively, a modulator for transporter nucleic acid expression can be a small molecule or drug identified using the screening assays described herein as long as the drug or small molecule inhibits the transporter nucleic acid expression in the cells and tissues that express the protein. Independent lines of evidence show expression of splice form 1 in fetal tissues such as brain and kidney; differentiated tissues such as brain, pituitary gland, heart, leukocytes, kidney, liver, thyroid, lung, placenta, skeletal muscle, small intestine, prostate, testis, adrenal gland, bone marrow, and pancreas; and neoplastic tissues such as germ cell tumors, lung carcinoid tissue, brain anaplastic oligodendrogliomas, chronic lymphocytic leukemic B-cells, glioblastomas, and well-differentiated endometrial adenocarcinomas.

The nucleic acid molecules are also useful for monitoring the effectiveness of modulating compounds on the expression or activity of the transporter gene in clinical trials or in a treatment regimen. Thus, the gene expression pattern can serve as a barometer for the continuing effectiveness of treatment with the compound, particularly with compounds to which a patient can develop resistance. The gene expression pattern can also serve as a marker indicative of a

physiological response of the affected cells to the compound. Accordingly, such monitoring would allow either increased administration of the compound or the administration of alternative compounds to which the patient has not become resistant. Similarly, if the level of nucleic acid expression falls below a desirable level, administration of the compound could be commensurately decreased.

The nucleic acid molecules are also useful in diagnostic assays for qualitative changes in transporter nucleic acid expression, and particularly in qualitative changes that lead to pathology. The nucleic acid molecules can be used to detect mutations in transporter genes and gene expression products such as mRNA. The nucleic acid molecules can be used as hybridization probes to detect naturally occurring genetic mutations in the transporter gene and thereby to determine whether a subject with the mutation is at risk for a disorder caused by the mutation. Mutations include deletion, addition, or substitution of one or more nucleotides in the gene, chromosomal rearrangement, such as inversion or transposition, modification of genomic DNA, such as aberrant methylation patterns or changes in gene copy number, such as amplification. Detection of a mutated form of the transporter gene associated with a dysfunction provides a diagnostic tool for an active disease or susceptibility to disease when the disease results from overexpression, underexpression, or altered expression of a transporter protein.

Individuals carrying mutations in the transporter gene can be detected at the nucleic acid level by a variety of techniques. Figure 3 provides information on SNPs that have been found in the gene encoding the transporter proteins of the present invention. The following variations were seen: g30344a, a31170g, c16256t, a13376t, t12210c, g12072c, g11922t, -11903a, c10009g, c4519t, a4181g, a20952c, t20987c, g21620a, t21795c, a22753t, g22945a, g23032a, g23738a, t23952g, a24123g, c24527-, c24691t, g25015a, and g25191t. RH panel mapping shows the gene encoding the transporter proteins of the present invention is found on chromosome 17 near markers SHGC-56719 and SHGC-58932 (LOD=15.9 and 15.68). Genomic DNA can be analyzed directly or can be amplified by using PCR prior to analysis. RNA or cDNA can be used in the same way. In some uses, detection of the mutation involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g. U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran *et al.*, *Science* 241:1077-1080 (1988); and Nakazawa *et al.*, *PNAS* 91:360-364 (1994)), the latter of which can be particularly useful for detecting point mutations in the gene (see Abravaya *et al.*, *Nucleic Acids Res.* 23:675-682 (1995)). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample,

contacting the nucleic acid sample with one or more primers which specifically hybridize to a gene under conditions such that hybridization and amplification of the gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. Deletions and insertions can be detected by a change in size of the amplified product compared to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to normal RNA or antisense DNA sequences.

Alternatively, mutations in a transporter gene can be directly identified, for example, by alterations in restriction enzyme digestion patterns determined by gel electrophoresis.

Further, sequence-specific ribozymes (U.S. Patent No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site. Perfectly matched sequences can be distinguished from mismatched sequences by nuclease cleavage digestion assays or by differences in melting temperature.

Sequence changes at specific locations can also be assessed by nuclease protection assays such as RNase and S1 protection or the chemical cleavage method. Furthermore, sequence differences between a mutant transporter gene and a wild-type gene can be determined by direct DNA sequencing. A variety of automated sequencing procedures can be utilized when performing the diagnostic assays (Naeve, C.W., (1995) *Biotechniques* 19:448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen *et al.*, *Adv. Chromatogr.* 36:127-162 (1996); and Griffin *et al.*, *Appl. Biochem. Biotechnol.* 38:147-159 (1993)).

Other methods for detecting mutations in the gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes (Myers *et al.*, *Science* 230:1242 (1985)); Cotton *et al.*, *PNAS* 85:4397 (1988); Saleeba *et al.*, *Meth. Enzymol.* 217:286-295 (1992)), electrophoretic mobility of mutant and wild type nucleic acid is compared (Orita *et al.*, *PNAS* 86:2766 (1989); Cotton *et al.*, *Mutat. Res.* 285:125-144 (1993); and Hayashi *et al.*, *Genet. Anal. Tech. Appl.* 9:73-79 (1992)), and movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (Myers *et al.*, *Nature* 313:495 (1985)). Examples of other techniques for detecting point mutations include selective oligonucleotide hybridization, selective amplification, and selective primer extension.

The nucleic acid molecules are also useful for testing an individual for a genotype that while not necessarily causing the disease, nevertheless affects the treatment modality. Thus, the nucleic acid molecules can be used to study the relationship between an individual's genotype and the

individual's response to a compound used for treatment (pharmacogenomic relationship).

Accordingly, the nucleic acid molecules described herein can be used to assess the mutation content of the transporter gene in an individual in order to select an appropriate compound or dosage regimen for treatment. Figure 3 provides information on SNPs that have been found in the gene encoding the transporter proteins of the present invention. The following variations were seen: g30344a, a31170g, c16256t, a13376t, t12210c, g12072c, g11922t, -11903a, c10009g, c4519t, a4181g, a20952c, t20987c, g21620a, t21795c, a22753t, g22945a, g23032a, g23738a, t23952g, a24123g, c24527-, c24691t, g25015a, and g25191t.

Thus nucleic acid molecules displaying genetic variations that affect treatment provide a diagnostic target that can be used to tailor treatment in an individual. Accordingly, the production of recombinant cells and animals containing these polymorphisms allow effective clinical design of treatment compounds and dosage regimens.

The nucleic acid molecules are thus useful as antisense constructs to control transporter gene expression in cells, tissues, and organisms. A DNA antisense nucleic acid molecule is designed to be complementary to a region of the gene involved in transcription, preventing transcription and hence production of transporter protein. An antisense RNA or DNA nucleic acid molecule would hybridize to the mRNA and thus block translation of mRNA into transporter protein.

Alternatively, a class of antisense molecules can be used to inactivate mRNA in order to decrease expression of transporter nucleic acid. Accordingly, these molecules can treat a disorder characterized by abnormal or undesired transporter nucleic acid expression. This technique involves cleavage by means of ribozymes containing nucleotide sequences complementary to one or more regions in the mRNA that attenuate the ability of the mRNA to be translated. Possible regions include coding regions and particularly coding regions corresponding to the catalytic and other functional activities of the transporter protein, such as ligand binding.

The nucleic acid molecules also provide vectors for gene therapy in patients containing cells that are aberrant in transporter gene expression. Thus, recombinant cells, which include the patient's cells that have been engineered *ex vivo* and returned to the patient, are introduced into an individual where the cells produce the desired transporter protein to treat the individual.

The invention also encompasses kits for detecting the presence of a transporter nucleic acid in a biological sample. Screening of tissue specific cDNA libraries for cDNA retrieval showed expression of splice form 1 in fetal brain, brain, pituitary gland, heart, leukocytes, kidney, liver, thyroid, lung, placenta, skeletal muscle, fetal kidney, small intestine, prostate, testis, adrenal gland, bone marrow, and pancreas. Additionally, BLAST hits to ESTs derived from tissue

specific libraries shows expression of splice form 1 in germ cell tumors, lung carcinoid tissue, brain anaplastic oligodendroglioma, chronic lymphocytic leukemia B-cells, infant brain (73 days post natal), placenta, glioblastoma, well-differentiated endometrial adenocarcinoma, and fetal liver and spleen. For example, the kit can comprise reagents such as a labeled or labelable nucleic acid or agent capable of detecting transporter nucleic acid in a biological sample; means for determining the amount of transporter nucleic acid in the sample; and means for comparing the amount of transporter nucleic acid in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect transporter protein mRNA or DNA.

Nucleic Acid Arrays

The present invention further provides nucleic acid detection kits, such as arrays or microarrays of nucleic acid molecules that are based on the sequence information provided in Figures 1 and 3 (SEQ ID NOS:1, 3, and 4).

As used herein "Arrays" or "Microarrays" refers to an array of distinct polynucleotides or oligonucleotides synthesized on a substrate, such as paper, nylon or other type of membrane, filter, chip, glass slide, or any other suitable solid support. In one embodiment, the microarray is prepared and used according to the methods described in US Patent 5,837,832, Chee *et al.*, PCT application W095/11995 (Chee *et al.*), Lockhart, D. J. *et al.* (1996; Nat. Biotech. 14: 1675-1680) and Schena, M. *et al.* (1996; Proc. Natl. Acad. Sci. 93: 10614-10619), all of which are incorporated herein in their entirety by reference. In other embodiments, such arrays are produced by the methods described by Brown *et al.*, US Patent No. 5,807,522.

The microarray or detection kit is preferably composed of a large number of unique, single-stranded nucleic acid sequences, usually either synthetic antisense oligonucleotides or fragments of cDNAs, fixed to a solid support. The oligonucleotides are preferably about 6-60 nucleotides in length, more preferably 15-30 nucleotides in length, and most preferably about 20-25 nucleotides in length. For a certain type of microarray or detection kit, it may be preferable to use oligonucleotides that are only 7-20 nucleotides in length. The microarray or detection kit may contain oligonucleotides that cover the known 5', or 3', sequence, sequential oligonucleotides that cover the full length sequence; or unique oligonucleotides selected from particular areas along the length of the sequence. Polynucleotides used in the microarray or detection kit may be oligonucleotides that are specific to a gene or genes of interest.

In order to produce oligonucleotides to a known sequence for a microarray or detection kit, the gene(s) of interest (or an ORF identified from the contigs of the present invention) is typically examined using a computer algorithm which starts at the 5' or at the 3' end of the nucleotide sequence. Typical algorithms will then identify oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that may interfere with hybridization. In certain situations it may be appropriate to use pairs of oligonucleotides on a microarray or detection kit. The "pairs" will be identical, except for one nucleotide that preferably is located in the center of the sequence. The second oligonucleotide in the pair (mismatched by one) serves as a control. The number of oligonucleotide pairs may range from two to one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support.

In another aspect, an oligonucleotide may be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application W095/251116 (Baldeschweiler *et al.*) which is incorporated herein in its entirety by reference. In another aspect, a "gridded" array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536, 6144 or more oligonucleotides, or any other number between two and one million which lends itself to the efficient use of commercially available instrumentation.

In order to conduct sample analysis using a microarray or detection kit, the RNA or DNA from a biological sample is made into hybridization probes. The mRNA is isolated, and cDNA is produced and used as a template to make antisense RNA (aRNA). The aRNA is amplified in the presence of fluorescent nucleotides, and labeled probes are incubated with the microarray or detection kit so that the probe sequences hybridize to complementary oligonucleotides of the microarray or detection kit. Incubation conditions are adjusted so that hybridization occurs with precise complementary matches or with various degrees of less complementarity. After removal of nonhybridized probes, a scanner is used to determine the levels and patterns of fluorescence. The scanned images are examined to determine degree of complementarity and the relative

abundance of each oligonucleotide sequence on the microarray or detection kit. The biological samples may be obtained from any bodily fluids (such as blood, urine, saliva, phlegm, gastric juices, etc.), cultured cells, biopsies, or other tissue preparations. A detection system may be used to measure the absence, presence, and amount of hybridization for all of the distinct sequences simultaneously. This data may be used for large-scale correlation studies on the sequences, expression patterns, mutations, variants, or polymorphisms among samples.

Using such arrays, the present invention provides methods to identify the expression of the transporter proteins/peptides of the present invention. In detail, such methods comprise incubating a test sample with one or more nucleic acid molecules and assaying for binding of the nucleic acid molecule with components within the test sample. Such assays will typically involve arrays comprising many genes, at least one of which is a gene of the present invention and or alleles of the transporter gene of the present invention. Figure 3 provides information on SNPs that have been found in the gene encoding the transporter proteins of the present invention. The following variations were seen: g30344a, a31170g, c16256t, a13376t, t12210c, g12072c, g11922t, -11903a, c10009g, c4519t, a4181g, a20952c, t20987c, g21620a, t21795c, a22753t, g22945a, g23032a, g23738a, t23952g, a24123g, c24527-, c24691t, g25015a, and g25191t.

Conditions for incubating a nucleic acid molecule with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the nucleic acid molecule used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification or array assay formats can readily be adapted to employ the novel fragments of the Human genome disclosed herein. Examples of such assays can be found in Chard, T, *An Introduction to Radioimmunoassay and Related Techniques*, Elsevier Science Publishers, Amsterdam, The Netherlands (1986); Bullock, G. R. *et al.*, *Techniques in Immunocytochemistry*, Academic Press, Orlando, FL Vol. 1 (1982), Vol. 2 (1983), Vol. 3 (1985); Tijssen, P., *Practice and Theory of Enzyme Immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology*, Elsevier Science Publishers, Amsterdam, The Netherlands (1985).

The test samples of the present invention include cells, protein or membrane extracts of cells. The test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing nucleic acid extracts or of cells are well known in the art and can be readily be adapted in order to obtain a sample that is compatible with the system utilized.

In another embodiment of the present invention, kits are provided which contain the necessary reagents to carry out the assays of the present invention.

Specifically, the invention provides a compartmentalized kit to receive, in close confinement, one or more containers which comprises: (a) a first container comprising one of the nucleic acid molecules that can bind to a fragment of the Human genome disclosed herein; and (b) one or more other containers comprising one or more of the following: wash reagents, reagents capable of detecting presence of a bound nucleic acid.

In detail, a compartmentalized kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers, strips of plastic, glass or paper, or arraying material such as silica. Such containers allows one to efficiently transfer reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which contains the nucleic acid probe, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and containers which contain the reagents used to detect the bound probe. One skilled in the art will readily recognize that the previously unidentified transporter gene of the present invention can be routinely identified using the sequence information disclosed herein can be readily incorporated into one of the established kit formats which are well known in the art, particularly expression arrays.

Vectors/host cells

The invention also provides vectors containing the nucleic acid molecules described herein. The term "vector" refers to a vehicle, preferably a nucleic acid molecule, which can transport the nucleic acid molecules. When the vector is a nucleic acid molecule, the nucleic acid molecules are covalently linked to the vector nucleic acid. With this aspect of the invention, the vector includes a plasmid, single or double stranded phage, a single or double stranded RNA or DNA viral vector, or artificial chromosome, such as a BAC, PAC, YAC, OR MAC.

A vector can be maintained in the host cell as an extrachromosomal element where it replicates and produces additional copies of the nucleic acid molecules. Alternatively, the vector may integrate into the host cell genome and produce additional copies of the nucleic acid molecules when the host cell replicates.

The invention provides vectors for the maintenance (cloning vectors) or vectors for expression (expression vectors) of the nucleic acid molecules. The vectors can function in procaryotic or eukaryotic cells or in both (shuttle vectors).

Expression vectors contain cis-acting regulatory regions that are operably linked in the vector to the nucleic acid molecules such that transcription of the nucleic acid molecules is allowed in a host cell. The nucleic acid molecules can be introduced into the host cell with a separate nucleic acid molecule capable of affecting transcription. Thus, the second nucleic acid molecule may provide a trans-acting factor interacting with the cis-regulatory control region to allow transcription of the nucleic acid molecules from the vector. Alternatively, a trans-acting factor may be supplied by the host cell. Finally, a trans-acting factor can be produced from the vector itself. It is understood, however, that in some embodiments, transcription and/or translation of the nucleic acid molecules can occur in a cell-free system.

The regulatory sequence to which the nucleic acid molecules described herein can be operably linked include promoters for directing mRNA transcription. These include, but are not limited to, the left promoter from bacteriophage λ , the lac, TRP, and TAC promoters from *E. coli*, the early and late promoters from SV40, the CMV immediate early promoter, the adenovirus early and late promoters, and retrovirus long-terminal repeats.

In addition to control regions that promote transcription, expression vectors may also include regions that modulate transcription, such as repressor binding sites and enhancers. Examples include the SV40 enhancer, the cytomegalovirus immediate early enhancer, polyoma enhancer, adenovirus enhancers, and retrovirus LTR enhancers.

In addition to containing sites for transcription initiation and control, expression vectors can also contain sequences necessary for transcription termination and, in the transcribed region a ribosome binding site for translation. Other regulatory control elements for expression include initiation and termination codons as well as polyadenylation signals. The person of ordinary skill in the art would be aware of the numerous regulatory sequences that are useful in expression vectors. Such regulatory sequences are described, for example, in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989).

A variety of expression vectors can be used to express a nucleic acid molecule. Such vectors include chromosomal, episomal, and virus-derived vectors, for example vectors derived from bacterial plasmids, from bacteriophage, from yeast episomes, from yeast chromosomal elements, including yeast artificial chromosomes, from viruses such as baculoviruses,

papovaviruses such as SV40, Vaccinia viruses, adenoviruses, poxviruses, pseudorabies viruses, and retroviruses. Vectors may also be derived from combinations of these sources such as those derived from plasmid and bacteriophage genetic elements, e.g. cosmids and phagemids. Appropriate cloning and expression vectors for prokaryotic and eukaryotic hosts are described in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*. 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989).

The regulatory sequence may provide constitutive expression in one or more host cells (i.e. tissue specific) or may provide for inducible expression in one or more cell types such as by temperature, nutrient additive, or exogenous factor such as a hormone or other ligand. A variety of vectors providing for constitutive and inducible expression in prokaryotic and eukaryotic hosts are well known to those of ordinary skill in the art.

The nucleic acid molecules can be inserted into the vector nucleic acid by well-known methodology. Generally, the DNA sequence that will ultimately be expressed is joined to an expression vector by cleaving the DNA sequence and the expression vector with one or more restriction enzymes and then ligating the fragments together. Procedures for restriction enzyme digestion and ligation are well known to those of ordinary skill in the art.

The vector containing the appropriate nucleic acid molecule can be introduced into an appropriate host cell for propagation or expression using well-known techniques. Bacterial cells include, but are not limited to, *E. coli*, *Streptomyces*, and *Salmonella typhimurium*. Eukaryotic cells include, but are not limited to, yeast, insect cells such as *Drosophila*, animal cells such as COS and CHO cells, and plant cells.

As described herein, it may be desirable to express the peptide as a fusion protein. Accordingly, the invention provides fusion vectors that allow for the production of the peptides. Fusion vectors can increase the expression of a recombinant protein, increase the solubility of the recombinant protein, and aid in the purification of the protein by acting for example as a ligand for affinity purification. A proteolytic cleavage site may be introduced at the junction of the fusion moiety so that the desired peptide can ultimately be separated from the fusion moiety. Proteolytic enzymes include, but are not limited to, factor Xa, thrombin, and enterotransporter. Typical fusion expression vectors include pGEX (Smith *et al.*, *Gene* 67:31-40 (1988)), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann

et al., *Gene* 69:301-315 (1988)) and pET 11d (Studier *et al.*, *Gene Expression Technology: Methods in Enzymology* 185:60-89 (1990)).

Recombinant protein expression can be maximized in host bacteria by providing a genetic background wherein the host cell has an impaired capacity to proteolytically cleave the recombinant protein. (Gottesman, S., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 119-128). Alternatively, the sequence of the nucleic acid molecule of interest can be altered to provide preferential codon usage for a specific host cell, for example *E. coli*. (Wada *et al.*, *Nucleic Acids Res.* 20:2111-2118 (1992)).

The nucleic acid molecules can also be expressed by expression vectors that are operative in yeast. Examples of vectors for expression in yeast e.g., *S. cerevisiae* include pYepSec1 (Baldari, *et al.*, *EMBO J.* 6:229-234 (1987)), pMFa (Kurjan *et al.*, *Cell* 30:933-943(1982)), pJRY88 (Schultz *et al.*, *Gene* 54:113-123 (1987)), and pYES2 (Invitrogen Corporation, San Diego, CA).

The nucleic acid molecules can also be expressed in insect cells using, for example, baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith *et al.*, *Mol. Cell Biol.* 3:2156-2165 (1983)) and the pVL series (Lucklow *et al.*, *Virology* 170:31-39 (1989)).

In certain embodiments of the invention, the nucleic acid molecules described herein are expressed in mammalian cells using mammalian expression vectors. Examples of mammalian expression vectors include pCDM8 (Seed, B. *Nature* 329:840(1987)) and pMT2PC (Kaufman *et al.*, *EMBO J.* 6:187-195 (1987)).

The expression vectors listed herein are provided by way of example only of the well-known vectors available to those of ordinary skill in the art that would be useful to express the nucleic acid molecules. The person of ordinary skill in the art would be aware of other vectors suitable for maintenance propagation or expression of the nucleic acid molecules described herein. These are found for example in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

The invention also encompasses vectors in which the nucleic acid sequences described herein are cloned into the vector in reverse orientation, but operably linked to a regulatory sequence that permits transcription of antisense RNA. Thus, an antisense transcript can be produced to all, or to a portion, of the nucleic acid molecule sequences described herein, including both coding and non-coding regions. Expression of this antisense RNA is subject to each of the parameters

described above in relation to expression of the sense RNA (regulatory sequences, constitutive or inducible expression, tissue-specific expression).

The invention also relates to recombinant host cells containing the vectors described herein. Host cells therefore include prokaryotic cells, lower eukaryotic cells such as yeast, other eukaryotic cells such as insect cells, and higher eukaryotic cells such as mammalian cells.

The recombinant host cells are prepared by introducing the vector constructs described herein into the cells by techniques readily available to the person of ordinary skill in the art. These include, but are not limited to, calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, lipofection, and other techniques such as those found in Sambrook, *et al.* (*Molecular Cloning: A Laboratory Manual*, 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

Host cells can contain more than one vector. Thus, different nucleotide sequences can be introduced on different vectors of the same cell. Similarly, the nucleic acid molecules can be introduced either alone or with other nucleic acid molecules that are not related to the nucleic acid molecules such as those providing trans-acting factors for expression vectors. When more than one vector is introduced into a cell, the vectors can be introduced independently, co-introduced or joined to the nucleic acid molecule vector.

In the case of bacteriophage and viral vectors, these can be introduced into cells as packaged or encapsulated virus by standard procedures for infection and transduction. Viral vectors can be replication-competent or replication-defective. In the case in which viral replication is defective, replication will occur in host cells providing functions that complement the defects.

Vectors generally include selectable markers that enable the selection of the subpopulation of cells that contain the recombinant vector constructs. The marker can be contained in the same vector that contains the nucleic acid molecules described herein or may be on a separate vector. Markers include tetracycline or ampicillin-resistance genes for prokaryotic host cells and dihydrofolate reductase or neomycin resistance for eukaryotic host cells. However, any marker that provides selection for a phenotypic trait will be effective.

While the mature proteins can be produced in bacteria, yeast, mammalian cells, and other cells under the control of the appropriate regulatory sequences, cell-free transcription and translation systems can also be used to produce these proteins using RNA derived from the DNA constructs described herein.

Where secretion of the peptide is desired, which is difficult to achieve with multi-transmembrane domain containing proteins such as transporters, appropriate secretion signals are incorporated into the vector. The signal sequence can be endogenous to the peptides or heterologous to these peptides.

Where the peptide is not secreted into the medium, which is typically the case with transporters, the protein can be isolated from the host cell by standard disruption procedures, including freeze thaw, sonication, mechanical disruption, use of lysing agents and the like. The peptide can then be recovered and purified by well-known purification methods including ammonium sulfate precipitation, acid extraction, anion or cationic exchange chromatography, phosphocellulose chromatography, hydrophobic-interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography, or high performance liquid chromatography.

It is also understood that depending upon the host cell in recombinant production of the peptides described herein, the peptides can have various glycosylation patterns, depending upon the cell, or maybe non-glycosylated as when produced in bacteria. In addition, the peptides may include an initial modified methionine in some cases as a result of a host-mediated process.

Uses of vectors and host cells

The recombinant host cells expressing the peptides described herein have a variety of uses. First, the cells are useful for producing a transporter protein or peptide that can be further purified to produce desired amounts of transporter protein or fragments. Thus, host cells containing expression vectors are useful for peptide production.

Host cells are also useful for conducting cell-based assays involving the transporter protein or transporter protein fragments, such as those described above as well as other formats known in the art. Thus, a recombinant host cell expressing a native transporter protein is useful for assaying compounds that stimulate or inhibit transporter protein function.

Host cells are also useful for identifying transporter protein mutants in which these functions are affected. If the mutants naturally occur and give rise to a pathology, host cells containing the mutations are useful to assay compounds that have a desired effect on the mutant transporter protein (for example, stimulating or inhibiting function) which may not be indicated by their effect on the native transporter protein.

Genetically engineered host cells can be further used to produce non-human transgenic animals. A transgenic animal is preferably a mammal, for example a rodent, such as a rat or mouse,

in which one or more of the cells of the animal include a transgene. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal in one or more cell types or tissues of the transgenic animal. These animals are useful for studying the function of a transporter protein and identifying and evaluating modulators of transporter protein activity. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, and amphibians.

A transgenic animal can be produced by introducing nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. Any of the transporter protein nucleotide sequences can be introduced as a transgene into the genome of a non-human animal, such as a mouse.

Any of the regulatory or other sequences useful in expression vectors can form part of the transgenic sequence. This includes intronic sequences and polyadenylation signals, if not already included. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of the transporter protein to particular cells.

Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, both by Leder *et al.*, U.S. Patent No. 4,873,191 by Wagner *et al.* and in Hogan, B., *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of transgenic mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene can further be bred to other transgenic animals carrying other transgenes. A transgenic animal also includes animals in which the entire animal or tissues in the animal have been produced using the homologously recombinant host cells described herein.

In another embodiment, transgenic non-human animals can be produced which contain selected systems that allow for regulated expression of the transgene. One example of such a system is the *cre/loxP* recombinase system of bacteriophage P1. For a description of the *cre/loxP* recombinase system, see, e.g., Lakso *et al. PNAS* 89:6232-6236 (1992). Another example of a recombinase system is the FLP recombinase system of *S. cerevisiae* (O'Gorman *et al. Science* 251:1351-1355 (1991)). If a *cre/loxP* recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the *Cre* recombinase and a selected protein

is required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, I. *et al. Nature* 385:810-813 (1997) and PCT International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀ phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then transferred to pseudopregnant female foster animal. The offspring born of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.

Transgenic animals containing recombinant cells that express the peptides described herein are useful to conduct the assays described herein in an *in vivo* context. Accordingly, the various physiological factors that are present *in vivo* and that could effect ligand binding, transporter protein activation, and signal transduction, may not be evident from *in vitro* cell-free or cell-based assays. Accordingly, it is useful to provide non-human transgenic animals to assay *in vivo* transporter protein function, including ligand interaction, the effect of specific mutant transporter proteins on transporter protein function and ligand interaction, and the effect of chimeric transporter proteins. It is also possible to assess the effect of null mutations, that is mutations that substantially or completely eliminate one or more transporter protein functions.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

Claims

That which is claimed is:

1. An isolated peptide consisting of an amino acid sequence selected from the group consisting of:
 - (a) an amino acid sequence selected from the group consisting of SEQ ID NOS:2 and 5;
 - (b) an amino acid sequence of an allelic variant of an amino acid sequence selected from the group consisting of SEQ ID NOS:2 and 5, wherein said allelic variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule selected from the group consisting of SEQ ID NOS:1, 3, and 4;
 - (c) an amino acid sequence of an ortholog of an amino acid sequence selected from the group consisting of SEQ ID NOS:2 and 5, wherein said ortholog is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule selected from the group consisting of SEQ ID NOS:1, 3, and 4; and
 - (d) a fragment of an amino acid sequence selected from the group consisting of SEQ ID NOS:2 and 5, wherein said fragment comprises at least 10 contiguous amino acids.

2. An isolated peptide comprising an amino acid sequence selected from the group consisting of:
 - (a) an amino acid sequence selected from the group consisting of SEQ ID NOS:2 and 5;
 - (b) an amino acid sequence of an allelic variant of an amino acid sequence selected from the group consisting of SEQ ID NOS:2 and 5, wherein said allelic variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule selected from the group consisting of SEQ ID NOS:1, 3, and 4;
 - (c) an amino acid sequence of an ortholog of an amino acid sequence selected from the group consisting of SEQ ID NOS:2 and 5, wherein said ortholog is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule selected from the group consisting of SEQ ID NOS:1, 3, and 4; and
 - (d) a fragment of an amino acid sequence selected from the group consisting of SEQ ID NOS:2 and 5, wherein said fragment comprises at least 10 contiguous amino acids.

3. An isolated antibody that selectively binds to a peptide of claim 2.
4. An isolated nucleic acid molecule consisting of a nucleotide sequence selected from the group consisting of:
 - (a) a nucleotide sequence that encodes an amino acid sequence selected from the group consisting of SEQ ID NOS:2 and 5;
 - (b) a nucleotide sequence that encodes of an allelic variant of an amino acid sequence selected from the group consisting of SEQ ID NOS:2 and 5, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule selected from the group consisting of SEQ ID NOS:1, 3, and 4;
 - (c) a nucleotide sequence that encodes an ortholog of an amino acid sequence selected from the group consisting of SEQ ID NOS:2 and 5, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule selected from the group consisting of SEQ ID NOS:1, 3, and 4;
 - (d) a nucleotide sequence that encodes a fragment of an amino acid sequence selected from the group consisting of SEQ ID NOS:2 and 5, wherein said fragment comprises at least 10 contiguous amino acids; and
 - (e) a nucleotide sequence that is the complement of a nucleotide sequence of (a)-(d).
5. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:
 - (a) a nucleotide sequence that encodes an amino acid sequence selected from the group consisting of SEQ ID NOS:2 and 5;
 - (b) a nucleotide sequence that encodes an allelic variant of an amino acid sequence selected from the group consisting of SEQ ID NOS:2 and 5, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule selected from the group consisting of SEQ ID NOS:1, 3, and 4;
 - (c) a nucleotide sequence that encodes an ortholog of an amino acid sequence selected from the group consisting of SEQ ID NOS:2 and 5, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule selected from the group consisting of SEQ ID NOS:1, 3, and 4;

(d) a nucleotide sequence that encodes a fragment of an amino acid sequence selected from the group consisting of SEQ ID NOS:2 and 5, wherein said fragment comprises at least 10 contiguous amino acids; and

(e) a nucleotide sequence that is the complement of a nucleotide sequence of (a)-(d).

6. A gene chip comprising a nucleic acid molecule of claim 5.
7. A transgenic non-human animal comprising a nucleic acid molecule of claim 5.
8. A nucleic acid vector comprising a nucleic acid molecule of claim 5.
9. A host cell containing the vector of claim 8.
10. A method for producing any of the peptides of claim 1 comprising introducing a nucleotide sequence encoding any of the amino acid sequences in (a)-(d) into a host cell, and culturing the host cell under conditions in which the peptides are expressed from the nucleotide sequence.
11. A method for producing any of the peptides of claim 2 comprising introducing a nucleotide sequence encoding any of the amino acid sequences in (a)-(d) into a host cell, and culturing the host cell under conditions in which the peptides are expressed from the nucleotide sequence.
12. A method for detecting the presence of any of the peptides of claim 2 in a sample, said method comprising contacting said sample with a detection agent that specifically allows detection of the presence of the peptide in the sample and then detecting the presence of the peptide.
13. A method for detecting the presence of a nucleic acid molecule of claim 5 in a sample, said method comprising contacting the sample with an oligonucleotide that hybridizes to said nucleic acid molecule under stringent conditions and determining whether the oligonucleotide binds to said nucleic acid molecule in the sample.

14. A method for identifying a modulator of a peptide of claim 2, said method comprising contacting said peptide with an agent and determining if said agent has modulated the function or activity of said peptide.
15. The method of claim 14, wherein said agent is administered to a host cell comprising an expression vector that expresses said peptide.
16. A method for identifying an agent that binds to any of the peptides of claim 2, said method comprising contacting the peptide with an agent and assaying the contacted mixture to determine whether a complex is formed with the agent bound to the peptide.
17. A pharmaceutical composition comprising an agent identified by the method of claim 16 and a pharmaceutically acceptable carrier therefor.
18. A method for treating a disease or condition mediated by a human transporter protein, said method comprising administering to a patient a pharmaceutically effective amount of an agent identified by the method of claim 16.
19. A method for identifying a modulator of the expression of a peptide of claim 2, said method comprising contacting a cell expressing said peptide with an agent, and determining if said agent has modulated the expression of said peptide.

20. An isolated human transporter peptide having an amino acid sequence that shares at least 70% homology with an amino acid sequence selected from the group consisting of SEQ ID NOS:2 and 5.

21. A peptide according to claim 20 that shares at least 90 percent homology with an amino acid sequence selected from the group consisting of SEQ ID NOS:2 and 5.

22. An isolated nucleic acid molecule encoding a human transporter peptide, said nucleic acid molecule sharing at least 80 percent homology with a nucleic acid molecule selected from the group consisting of SEQ ID NOS:1, 3, and 4.

23. A nucleic acid molecule according to claim 22 that shares at least 90 percent homology with a nucleic acid molecule selected from the group consisting of SEQ ID NOS:1, 3, and 4.

SPLICE FORM 1:

```

1 AACAGCACGA GGGCGGACCC AGCTGTGGCG ACGCCAGGAG ACCCCAAGCT
51 GCATCGCCGA GTGGAAGCAA CTAGAACTCC AGGGCTGTGA AAGCCACAGG
101 TGGGGGCTGA GCGAGGCGTG GCCTCAGGAG CGGAGGACCC CCCCACTCTC
151 CCTCGAGCGC CGCAGTCCAC CGTAGCGGET GGAGCCCGCC TTGGTGCACA
201 GTTGGAAAAC CTCGGAGCCC CGCTGGATCT CCTGGCTGCC ACCCGCACCC
251 CCCGCCAGCC TACGCCCCAC CGTAGAGATG CCTTCTTCGG TGACGGCGCT
301 GGGTCAGGCC AGGTCTCTCTG GCCCCGGGAT GGGCCCGAGC GCCTGTCTGT
351 GCTCCCCTGC GGCCTGTCAG AGGAGGCTGC CCATCCTGGC GTGGCTGCC
401 AGCTACTCCC TGCAGTGGCT GAAGATGGAT TTCGTGCGCG GCCTCTCAGT
451 TGGCTCACT GCCATTCCCC AGGCGCTGGC CTATGCTGAA GTGGCTGGAC
501 TCCCGCCCCA GTATGGCCTC TACTCTGCCT TCATGGGCTG CTTGCTGTAT
551 TTCTTCTCTG GCACCTCCCG GGATGTGACT CTGGGCCCCA CCGCCATTAT
601 GTCCCTCTCTG GTCTCCTTCT ACACCTTCCA TGAGCCCGCC TACGCTGTGC
651 TGCTGGCCTT CCTGTCCGGC TGCATCCAGC TGGCCATGGG GGTCTCTCGT
701 TTGGGGTTCC TGCTGGACTT CATTTCCTAC CCCGTCATTA AAGGCTTCAC
751 CTCTGCTGCT GCCGTCACCA TCGGCTTTGG ACAGATCAAG AACCTGCTGG
801 GACTACAGAA CATCCCCAGG CCGTCTTCC TGCAGGTGTA CCACACCTTC
851 CTCAGGATTG CAGAGACCAG GGTAGGTGAC GCCGTCCTGG GGCTGGTCTG
901 CATGCTCTCTG CTGCTGGTGC TGAAGCTGAT GCGGGACCCAC GTGCCTCCCG
951 TCCACCCCGA GATGCCCCCT GGTGTGCGGC TCAGCCGTGG GCTGGTCTGG
1001 GCTGCCACGA CAGCTCGCAA CGCCTGGTG GTCTCCTTCG CAGCCCTGGT
1051 TGCGTACTCC TFCGAGGTGA CTGGATACCA GCCTTTCATC CTAACAGGGG
1101 AGACAGCTGA GGGGCTCCCT CCACTCCGA TCCCGCCCTT CTCAGTGACC
1151 ACAGCCAACG GGACGATCTC CTTACCCGAG ATGGTGACAG ACATGGGAGC
1201 CCGGCTGGCC GTGGTGCCCC TGATGGGCTT CCTGGAGAGC ATTGCGGTGG
1251 CCAAAGCCTT CGCATCTCAG AATAATTACC GCATCGATGC CAACCAGGAG
1301 CTGCTGGCCA TCGGTCTCAC CAACATGTTG GGCTCCCTCG TCTCCTCCTA
1351 CCCGGTCACA GGCAGCTTTG GACGGACAGC CGTGAACGCT CAGTCGGGGG
1401 TGTGCACCCC GCGGGGGGGC CTGCTGACGG GAGTGCTGGT GCTGCTGTCT
1451 CTGGACTACC TGACCTCACT GTTCTACTAC ATCCCCAAGT CTGCCCTGGC
1501 TGCCGTCATC ATCATGGCCG TGGCCCCGCT GTTCGACACC AAGATCTTCA
1551 GGACGCTCTG GCGTGTAAAG AGGCTGGACC TGCTGCCCTT GTGCGTGACC
1601 TTCCTGCTGT GCTTCTGGGA GGTGCAGTAC GGCATCCTGG CCGGGGCCCT
1651 GGTGTCTCTG CTCTGCTCC TGCACTCTGC AGCCAGGCCCT GAGACCAAGG
1701 TGTCAGAGGG GCCGGTCTCTG GTCCTGCAGC CGGCCAGCGG CCTGTCTTTC
1751 CCTGCCATGG AGGCTCTGCG GGAGGAGATC CTAAGCCGGG CCCTGGAAGT
1801 GTCCCCGCCA CGCTGCCTGG TCCTGGAGTG CACCCATGTC TGCAGCATCG
1851 ACTACACTGT GGTGCTGGGA CTCGGCGAGC TCCTCCAGGA CTTCCAGAAG
1901 CAGGGCGTCG CCTTGGCCTT TGTGGGCTG CAGGTCCCCG TTCTCCGTGT
1951 CCTGCTGTCC GCTGACCTGA AGGGGTTCCT GTACTTCTCT ACCCTGGAAG
2001 AAGCAGAGAA GCACCTGAGG CAGGAGCCAG GGACCCAGCC CTACAACATC
2051 AGAGAAGACT CCATTCTGGA CCAAAGGTT GCCCTGCTCA AGGCATAATG
2101 GGGCCACCCG TGGGCATCCA CAGTTTCAG GGTGTTCGG AAGGTTCCTG
2151 TCACTGTGAT TGGATGCTGG ATGCCGCTG ATAGACATGC TGGCCTGGCT
2201 GAGAAACCCC TGAGCAGGTA ACCCAGGGAA GAGAAGGAAG CCAGGCCTGG
2251 AGGTCCACGG CAGTGGGAGT GGGGCTCACT GGCTTCTGT GGGATGACTG
2301 GAAATGACC TCGCTGCTGT TCCCTGGCAT GACCTCTTT GGAAGAGTGG
2351 TTTGGAGAGA GCCTTCTAGA ATGACAGACT GTGCGAGGAA GCAGGGGCAG
2401 GGGTTTCCAG CCCGGGCTGT GCGAGGCATC CTGGGGCTGG CAGCACCTTC
2451 CCGGCTCACC AGTGCCACCT GCGGGGGAGG GACGGGGCAG GCAGGAGTCT
2501 GGGAGGCGGG TCCGCTCCTC TTGTCTGCGG CATCTGTGCT CTCCGAGAGA
2551 AAACCAAGGT GTGTCAAATG ACGTCAAGTC TCTATTATAA AATAATTTTG
2601 TGTTTTCTAA ATGGAAAAAG TGATAGCTTT GGTGATTTTG TAAAAGTCAT
2651 AAATGCTTAT TGTAAAAAAT ACAGGAAACC ACCCTCACC CTGTCCACTT
2701 GGGTGATCAT TCCAGACCCC TCCCCAAACA TGCATATGTA CCTGTCCGTC
2751 AGTGTGTGGA TGTATGTTTA CAGTTCTACA TAAATGGGAT CATTTTATAC
2801 ATGGTGCTCT GGAACCCACA TTTTTCATGC AGTCATTGTC AGTGAATTAT
2851 TTATTGTGAT AATAAATAGC ATTAGAATAC AAGAAAAAAA AAAAAAAA
2901 AAAAAAAA AAAAAAAA (SEQ ID NO:1)

```

FEATURES:

```

5' UTR: 1-277
Start: 278
Stop: 2096
3' UTR: 2096-2919

```


SPLICE FORM 2:

```

1   GCTGTGGCGA CGCCAGGAGA CCCCAGCTG CATCGCCGAG TGGAGCAAC
51  TAGAACTCCA GGGCTGTGAA AGCCACAGGT GGGGGCTGAG CGAGGCGTGG
101 CCTCAGGAGC GGAGGACCCC CCCACTCTCC CTCGAGCGCC GCAGTCCACC
151 GTAGCGGGTG GAGCCCGCCT TGGTGCGCAG TTGGAAAACC TCGGAGCCCC
201 GCTGGATCTC CTGGCTGCCA CCCGCACCCC CCGCCAGCCT ACGCCCCACC
251 GTAGAGATGC CTTCTTCGGT GACGGCGCTG GGTCAAGCCA GGTCTCTGCG
301 CCCCCGGATG GCCCCGAGCG CCTGCTGCTG CTCCCCTGCG GCCCTGCAGA
351 GGAGGCTGCC CATCCTGGCG TGGCTGCCCA GCTACTCCCT GCAGTGGCTG
401 AAGATGGATT TCGTCGCCGG CCTCTCAGTT GGCCTCACTG CCATTCCCCA
451 GGGCTGGGCC TATGCTGAAG TGGCTGGACT CCGCCCCAG TATGGCCTCT
501 ACTCTGCCTT CATGGGCTGC TTCGTGTATT TCTTCTTGGG CACCTCCCCG
551 GATGTGACTC TGGGCCCCAC CGCCATTATG TCCCTCCTGG TCTCCTTCTA
601 CACCTTCCAT GAGCCCGCCT ACGCTGTGCT GCTGGCCTTC CTGTCCGGCT
651 GCATCCAGCT GGCCATGGGG GTCCCTGCGT TGGCTCACAT CTCCCCTCAT
701 CCTCTGGGAC TGGGTGGAGC CGGGACCAGC TCGATGTCCC CTCTTGGCTG
751 GCCAGGGTTC CTGCTGGACT TCATTTCCTA CCCCCTCATT AAAGGCTTCA
801 CCTCTGCTGC TGCCGTCACC ATCGGCTTTG GACAGATCAA GAACCTGCTG
851 GGACTACAGA ACATCCCCAG GCCGTTCCTC CTGCAGGTGT ACCACACCTT
901 CCTCAGGATT GCAGAGACCA GGGTAGGTGA CGCCCTCCTG GGGCTGGTCT
951 GCATGCTGCT GCTGCTGGTG CTGAAGCTGA TGCGGGACCA CGTGCCTCCC
1001 GTCCACCCCG AGATGCCCCC TGGTGTGCGG CTCAGCCGTG GGCTGGTCTG
1051 GGCTGCCACG ACAGCTCGCA ACGCCCTGGT GGTCTCCTTC GCAGCCCTGG
1101 TTGCGTACTC CTTGAGGTG ACTGGATACC AGCCTTTCAT CCTAACAGGG
1151 GAGACAGCTG AGGGGCTCCC TCCAGTCCGG ATCCCGCCCT TCTCAGTGAC
1201 CACAGCCAAC GGGACGATCT CCTTACCAGA GATGGTGCAG GACATGGGAG
1251 CCGGGCTGGC CGTGGTGCCC CTGATGGGCC TCCTGGAGAG CATTGGGGTG
1301 GCCAAAGCCT TCGCATCTCA GAATAATTAC CGCATCGATG CCAACCAGGA
1351 GCTGCTGGCC ATCGGTCTCA CCAACATGTT GGGCTCCCTC GTCTCCTCCT
1401 ACCCGGTCAC AGGCAGCTTT GGACGGACAG CCGTGAACGC TCAGTCGGGG
1451 GTGTGCACCC CGGCGGGGGG CCTGGTGACG GGAGTGCTGG TGCTGCTGTC
1501 TCTGGACTAC CTGACCTCAC TGTTCCTACTA CATCCCCAAG TCTGCCCTGG
1551 CTGCCGTCAT CATCATGGCC GTGGCCCCGC TGTTCGACAC CAAGATCTTC
1601 AGGACGCTCT GCGGTGTAA GAGGCTGGAC CTGCTGCCCC TGTGGGTGAC
1651 CTTCTGCTG TGCTTCTGGG AGGTGCAGTA CGGCATCCTG GCCGGGGCCC
1701 TGGTGTCTCT GCTCATGCTC CTGCACTCTG CAGCCAGGCC TGAGACCAAG
1751 GTGTGAGAGG GGCCGGTTCT GGTCTGACAG CCGGCCAGCG GCCTGTCTCT
1801 CCCTGCCATG GAGGCTCTGC GGGAGGAGAT CCTAAGCCGG GCCCTGGAAG
1851 TGTCCCGGCC ACGCTGCCTG GTCCCTGGAGT GCACCCATGT CTGCAGCATC
1901 GACTACACTG TGGTGTGGG ACTCGGCGAG CTCCTCCAGG ACTTCCAGAA
1951 GCAGGGCGTC GCCCTGGCCT TTGTGGGCCT GCAGGTCCCC GTTCTCCGTG
2001 TCCTGCTGTC CGCTGACCTG AAGGGGTTCC AGTACTTCTC TACCCTGGAA
2051 GAAGCAGAGA AGCACCTGAG GCAGGAGCCA GGGACCCAGC CCTACAACAT
2101 CAGAGAAGAC TCCATTCTGG ACCAAAAGGT TGCCCTGCTC AAGGCATAAT
2151 GGGGCCACCC GTGGGCATCC ACAGTTTGCA GGGTGTTCGG GAAGGTTCTT
2201 GTCATGTGA TTGGATGCTG GATGCCGCCT GATAGACATG CTGGCCTGGC
2251 TGAGAAACCC CTGAGCAGGT AACCAGGGA AGAGAAGGAA GCCAGGCCCTG
2301 GAGGTCCACG GCAGTGGGAG TGGGGCTCAC TGGCTTCCTG TGGGATGACT
2351 GGAAAATGAC CTCGCTGCTG TTCCCTGGCA TGACCCCTTT TGAAGAGTG
2401 GTTTGGAGAG AGCCTTCTAG AATGACAGAC TGTGCGAGGA AGCAGGGGCA
2451 GGGGTTTCCA GCCCGGGCTG TGCAGGCAT CCTGGGGCTG GCAGCACCTT
2501 CCGGCTCAC CAGTGCCACC TCGGGGGGAG GGACGGGGCA GGCAGGAGTC
2551 TGGGAGGCGG GTCGCTCCT CTTGTCTGCG GCATCTGTGC TCTCCGAGAG
2601 AAAACCAAGG TGTGTCAAAT GACGTCAAGT CTCTATTTAA AAATAATTTT
2651 GTGTTTTCTA AATGGAAAAA GTGATAGCTT TGGTGATTTT GTAAAAGTCA
2701 TAAATGCTTA TTGTAAAAAA TACAGGAAC CACCCCTCAC CCTGTCCACT
2751 TGGGTGATCA TTCCAGACCC CTCCCCAAAC ATGCATATGT ACCTGTCCGT
2801 CAGTGTGTGG ATGTATGTTT ACAGTTCTAC ATAAATGGGA TCATTTTATA
2851 CATGGTGCTC TGGAAACCCAC ATTTTTCATG CAGTCATTG CAGTGAATTA
2901 TTTATTGTGA TAATAAATAG CATTAGAATA CAAAAAATAA AAAAAAATAA
2951 AAAAA (SEQ ID NO:2)

```

FEATURES:

5' UTR: 1-257

Start: 257

Stop: 2147
3' UTR: 2150-2955

HOMOLOGOUS PROTEINS:**Top BLAST Hits:**

	Score	E
SPLICE FORM 1:		
gi 7302719 gb AAF57797.1 (AE003802) CG5002 gene product [Droso...	418	e-116
gi 7301881 gb AAF56989.1 (AE003772) CG7912 gene product [Droso...	408	e-113
gi 5834394 gb AAD53951.1 (AF180728) sulfate transporter [Droso...	388	e-107
gi 7301216 gb AAF56347.1 (AE003749) Esp gene product [Drosophi...	387	e-106
gi 7301962 gb AAF57068.1 (AE003774) CG9702 gene product [Droso...	351	8e-96
gi 7294633 gb AAF49971.1 (AE003543) CG6928 gene product [Droso...	347	2e-94
gi 7300023 gb AAF55195.1 (AE003708) CG6125 gene product [Droso...	330	3e-89
gi 7493011 pir T39116 probable sulfate permease - fission yeas...	267	2e-70
gi 6094367 sp O74377 SULH SCHPO PROBABLE SULFATE PERMEASE SPBC3...	266	4e-70
gi 2626753 dbj BAA23424.1 (AB008782) sulfate transporter [Arab...	266	4e-70

SPLICE FORM 2:

gi 7302719 gb AAF57797.1 (AE003802) CG5002 gene product [Droso...	404	e-111
gi 7301881 gb AAF56989.1 (AE003772) CG7912 gene product [Droso...	394	e-108
gi 5834394 gb AAD53951.1 (AF180728) sulfate transporter [Droso...	374	e-102
gi 7301216 gb AAF56347.1 (AE003749) Esp gene product [Drosophi...	373	e-102
gi 7301962 gb AAF57068.1 (AE003774) CG9702 gene product [Droso...	337	2e-91
gi 7294633 gb AAF49971.1 (AE003543) CG6928 gene product [Droso...	332	6e-90
gi 7300023 gb AAF55195.1 (AE003708) CG6125 gene product [Droso...	315	8e-85
gi 7493011 pir T39116 probable sulfate permease - fission yeas...	254	2e-66
gi 9955547 emb CAC05432.1 (AL391710) sulfate transporter [Arab...	254	2e-66
gi 2626753 dbj BAA23424.1 (AB008782) sulfate transporter [Arab...	253	4e-66
gi 6502994 gb AAF14540.1 AF163975_1 (AF163975) Suta [Penicilliu...	250	3e-65
gi 6094367 sp O74377 SULH SCHPO PROBABLE SULFATE PERMEASE SPBC3...	248	1e-64
gi 6502992 gb AAF14539.1 AF163974_1 (AF163974) sulfate permease...	244	2e-63
gi 10645530 gb AAG21641.1 AC069474_20 (AC069474) sulphate trans...	242	9e-63

BLAST to dbEST:**SPLICE FORM 1:**

gb AA582196.1 AA582196 nn44h12.s1 NCI_CGAP_GC5 Homo sapiens...	1027	0.0
gb AI690196.1 AI690196 tx33c05.x1 NCI_CGAP_Lu24 Homo sapien...	948	0.0
gb AI417381.1 AI417381 tg30c11.x1 NCI_CGAP_Brn25 Homo sapie...	902	0.0
gb AW207633.1 AW207633 UI-H-BI1-afl-c-10-0-UI.s1 NCI_CGAP_S...	890	0.0
gb AI494563.1 AI494563 qz16h03.x1 NCI_CGAP_CLL1 Homo sapien...	850	0.0
gb H15131.1 H15131 ym30b04.s1 Soares infant brain 1NIB Homo...	805	0.0
gb AI220943.1 AI220943 qg08c06.x1 Soares placenta 8to9weeks...	743	0.0
gb AW055140.1 AW055140 wz01c04.x1 NCI_CGAP_Brn23 Homo sapie...	718	0.0
gb AI963799.1 AI963799 wr67b09.x1 NCI_CGAP_Ut1 Homo sapiens...	718	0.0
gb N54913.1 N54913 yv34f02.s1 Soares fetal liver spleen 1NF...	710	0.0
gb AW008673.1 AW008673 ws71c02.x1 NCI_CGAP_Brn23 Homo sapie...	688	0.0
gb AI680222.1 AI680222 tw66e04.x1 NCI_CGAP_Ut3 Homo sapiens...	638	e-180
gb AA385773.1 AA385773 EST99540 Thyroid Homo sapiens cDNA 5...	636	e-180
gb H04038.1 H04038 yj45b06.r1 Soares placenta Nb2HP Homo sa...	626	e-177
gb AI000592.1 AI000592 os63b01.s1 NCI_CGAP_Brn2 Homo sapiens...	618	e-174

BLAST to CHGI:

TA_39934	NOT ASSIGNED [Homo sapiens]	1544	0.0
TA_44508	NOT ASSIGNED [Homo sapiens]	509	e-142
TA_102843	NOT ASSIGNED [Homo sapi...]	484	e-135
TA_82272	AAD14 [Homo sapiens]	44	0.018
TA_71453	ataxin SCA1 [Homo sapiens]	44	0.018
TA_74619	alkaline phosphatase, pl...	42	0.070
TA_52146	NOT ASSIGNED [Homo sapiens]	42	0.070
TA_237492	NOT ASSIGNED [Homo sapi...]	40	0.28
TA_158839	NOT ASSIGNED [Homo sapi...]	40	0.28

EXPRESSION INFORMATION FOR MODULATORY USE:**SPLICE FORM 1:**

Library source from BLAST dbEST hits:

AA582196 534 bp mRNA EST 05-SEP-1997	germ cell tumor
AI690196 486 bp mRNA EST 16-DEC-1999	carcinoid:lung
AI417381 470 bp mRNA EST 30-MAR-1999	anaplastic oligodendroglioma: brain
AW207633 511 bp mRNA EST 02-DEC-1999	unknown
AI494563 457 bp mRNA EST 17-MAR-1999	B-cell, chronic lymphocytic leukemia
H15131 508 bp mRNA EST 27-JUN-1995	infant brain, 73 days post natal
AI220943 375 bp mRNA EST 29-NOV-1998	two placentae: one from 8 weeks and another
from 9 weeks post conception	
AW055140 366 bp mRNA EST 09-MAR-2000	glioblastoma (pooled): brain
AI963799 377 bp mRNA EST 08-MAR-2000	well-differentiated endometrial
adenocarcinoma, 7 pooled tumors: uterus	
N54913 486 bp mRNA EST 28-JAN-1997	fetal liver and spleen
AW008673 369 bp mRNA EST 10-SEP-1999	glioblastoma (pooled): brain

Library source from cDNA retrieval:

Human Fetal Brain
Human Brain
Human Pituitary Gland
Human Heart
Human Leukocytes
Human Kidney
Human HeLa Cell
Human Liver
Human Thyroid
Human Lung
Human Placenta
Human Skeletal Muscle
Human Fetal Kidney
Human Small Intestine
Human Prostate
Human Testis
Human Adrenal Gland
Human Bone Marrow
Human Pancreas

SPLICE FORM 1:

```

1  MPSSVTALGQ ARSSGPGMAP SACCCSPAAL QRRLPILAWL PSYSLQWLKM
51 DFVAGLSVGL TAIPQALAYA EVAGLPPQYG LYSAFMGCFV YFFLGTSRDV
101 TLGPTAIMSL LVSFYTFHEP AYAVLLAFLS GCIQLAMGVL RLGFLLDFIS
151 YPVIKGF TSA AAVTIGFGQI KNLLGLQNI PPFPLQVYHT FLRIAETRVG
201 DAVLGLVCML LLLVLKLMRD HVPPVHPMP PGVRLSRGLV WAATTARNAL
251 VVSFAALVAY SFEVTGYQPF ILTGETAEG LPPVRIPEFSV TTANGTISET
301 EMVQDMGAGL AVVPLMGLLE SIATAKAFAS QNNYRIDANQ ELLAIGLTMN
351 LGSLVSSYPV TGSFGRTAVN AQSGVCTPAG GLVTGVLVLL SLDYLTSLFY
401 YIPKSALAAV IIMAVAPLFD TKIFRTLWRV KRLDLLPLCV TFLLCFWEVQ
451 YGILAGALVS LLMLLHSAAR PETKVSEGPV LVLQPASGLS FPAMEALREE
501 ILSRALEVSP PRCLVLECTH VCSIDYTVVL GLGELLQDFQ KQGVALLAEVG
551 LQVPVLRVLL SADLKGFQYF STLEEAEKHL RQEPGTQFYN IREDSILDQK
601 VALLKA (SEQ ID NO:3)

```

SPLICE FORM 2:

```

1  MPSSVTALGQ ARSSGPGMAP SACCCSPAAL QRRLPILAWL PSYSLQWLKM
51 DFVAGLSVGL TAIPQALAYA EVAGLPPQYG LYSAFMGCFV YFFLGTSRDV
101 TLGPTAIMSL LVSFYTFHEP AYAVLLAFLS GCIQLAMGVL RLHAISPHPL
151 GLGGAGTSSM SPLGWPGFLL DFISYPVIK FTSAAAVTIG FGQIKNLLGL
201 QNIPRPFFLQ VYHTFLRIAE TRVGDAVLGL VCMLLLLVLL LMRDHVPPVH
251 PEMPGVRLS RGLVWAATTA RNALVVSFAA LVAYSFEVTG YQPFILTGET
301 AEGLPPVRIP PFSVTTANGT ISFTMVQDM GAGLAVVPLM GLLESIATAK
351 AFASQNNYRI DANQELLAIG LTNMLGSLVS SYPVTGSFGR TAVNAQSGVC
401 TPAGGLVTGV LVLLSLDYLT SLFYIIPKSA LAAVIIMAVA PLFDTKIERT
451 LWRVKRLDLL PLWVTFLLCF WEVQYGILAG ALVSLMLLH SAARPETKVS
501 EGPVLVLQPA SGLSFPAMEA LREELSRAL EVSPPRCLVL ECTHVCSIDY
551 TVVLGLGELL QDFQKQGVALL AFVGLQVPVL RVLLSADLKGFQYFSTLEEA
601 EKHRLRQEPGT QPYNIREDSI LDQKVALLKA (SEQ ID NO:4)

```

FEATURES:

Functional domains and key regions:

SPLICE FORM 1:

[1] PDOC00001 PS00001 ASN_GLYCOSYLATION

N-glycosylation site

294-297 NGTI

[2] PDOC00005 PS00005 PKC_PHOSPHO_SITE

Protein kinase C phosphorylation site

Number of matches: 2

1 96-98 TSR

2 245-247 TAR

[3] PDOC00006 PS00006 CK2_PHOSPHO_SITE

Casein kinase II phosphorylation site

Number of matches: 6

1 96-99 TSRD

2 116-119 TFHE

3 298-301 SFTE

4 571-574 STLE

5 572-575 TLEE

6 595-598 SILD

[4] PDOC00008 PS00008 MYRISTYL

N-myristoylation site

Number of matches: 15

1	9-14	GQARSS
2	17-22	GMAPSA
3	55-60	GLSVGL
4	80-85	GLYSAF
5	168-173	GQIKNL
6	232-237	GVRLSR
7	238-243	GLVWAA
8	307-312	GAGLAV
9	317-322	GLLESI
10	352-357	GSLVSS
11	380-385	GGLVTG
12	381-386	GLVTGV
13	452-457	GILAGA
14	456-461	GALVSL
15	543-548	GVALAF

[5] PDOC00870 PS01130 SULFATE_TRANSP

Sulfate transporters signature

77-98 PQYGLYSAFMGCFVYFFLGTSR

Membrane spanning structure and domains:SPLICE FORM 1:

Helix	Begin	End	Score	Certainty
1	11	31	0.878	Putative
2	50	70	1.193	Certain
3	77	97	1.866	Certain
4	120	140	1.767	Certain
5	148	168	1.097	Certain
6	199	219	1.547	Certain
7	247	267	1.151	Certain
8	283	303	0.683	Putative
9	306	326	1.282	Certain
10	342	362	1.277	Certain
11	372	392	1.695	Certain
12	401	421	1.366	Certain
13	449	469	1.784	Certain
14	477	497	0.915	Putative
15	542	562	0.834	Putative

BLAST Alignment to Top Hit:

SPICE FORM 1:

gi|7302719|gb|AAF57797.1| (AE003802) CG5002 gene product [Droso... 418 e-116

Query: 25 CSPAALQRRRLPILAWLPSYSLOLWLMDFVAGLSVGLTAIPQALAYAEVAGLPPQYGLYSA 84
 C P+ + + P L WLP Y L+++ DF+AG +VGLT IPQA+AY VAGL PQYGLYSA
 Sbjct: 28 CRPSTVTNKFPIKWLPRYRLEYIMQDFIAGFTVGLTTIPQAIAYGVVAGLEFPQYGLYSA 87

Query: 85 FMGCFVYFFLGTSRDVTLGPTAIMSLLVSFYTFHEPAYAVLLAFLSGCIQLAMGVRLRGF 144
 FMGCF Y G+ +DVT+ TAIM+L+V+ Y P YAVL+ FL+GCI L +G+L +G
 Sbjct: 88 FMGCFTYIVFGSCKDVTIATTAIMALMVNQYATISPDYAVLVCFLAGCIVLLGLLNMGV 147

Query: 145 LLDFISYPVIKGFSAAAVTIGFGQIKNLLGLQNIIPRPFLLQVYHTFLRIAETRVGDAVL 204
 L+ FIS PVI GFT AAA TIG QI N++GL + + F + R+ DA+L
 Sbjct: 148 LVRFISIPVITGFTMAAATTIGSAQINNIVGLTSPSNDLLPAWKNNFFTHLTSIRLWDALL 207

Query: 205 GLVCMMLLLLVLKLMRDHVPPVHPMPGVRSLRGLVWA-ATTARNALVVSFAALVAYSFE 263
 G+ ++ LL++ ++D ++ + W +RNAL V F +AY
 Sbjct: 208 GVSSLVFLLMLTRVKD-----IKWGNRIFWKYLGLSRNALAVIFGTFLAYILS 255

Query: 264 VTGYQPFILTGETAEGLPVRIPPFSVTTANGTISFTEMVQDMGAGLAVVPLMGLLESIA 323
 G QPF +TG G+PF R+PPFS T +SF EM+ +GA L +PL+ +LE +A
 Sbjct: 256 RDGNQPFRTGNITAGVPPFRLPPFSTTVDGEYVSFGEMISTVGASLSIPLISILEIVA 315

Query: 324 VAKAFASQNNYRIDANQELLAIGLTNMLGSLVSSYPVTGSFGRRTAVNAQSGVCTPAGGLV 383
 ++KAF+ +DA+QE++A+G+ N++GS V S PVTGSF RTAVN SGV TP GG V
 Sbjct: 316 ISKAFS--KGKIVDASQEMVALGMCNIMGSFVLSMPVTGSFTRTAVNNASGVKTPGGAV 373

Query: 384 TGVLLVLLSLDYLTSLFYIIPKSALAAVIIMAVAPLEDTKIFRTLWRVKRLDLLPLCVTF 443
 TG LVL++L +LT FY+IPK LAA+II A+ L + + +W+ K+ DL P VT L
 Sbjct: 374 TGAFLVLMALAFLTQTFFYFIPKCTLAIIIAAMISLVELHKIKDMWKSKKKDLFFPVVTVL 433

Query: 444 LC-FWEVQYIGILAGALVSLMLLHSAARPET-----KVSEGPVLVLQPASGLSFPAMEAL 497
 C FW ++YGIL G +++ +L+S+ARP K++ V V+ L + + E L
 Sbjct: 434 TCMFWSLEYGILCGIGANMVYILYSSARPHVDIKLEKINGHEVSVVDVKQLDYASAEXL 493

Query: 498 REEILSRAL---EVSPPRCLVLECHVCSIDYTVVLGLGELLQDFQKQGVVALAFVGLQVPV 555
 +E+++ R L + + +V++ + SIDYTV + + + D + A+ +
 Sbjct: 494 KEKVV-RFLNNQNGETQLVVIKGEINSIDYTVAMNIVSMKGDLEALNCAMICWNWNIA 552

Query: 556 LRVL--LSADLKG-FQYFSTLEE 575
 V+ L+ DL+ F++ +LEE
 Sbjct: 553 AGVVCRLNNDLRPIKFDLSLEE 575 (SEQ ID NO :6)

SPICE FORM 2:

>gi|7302719|gb|AAF57797.1| (AE003802) CG5002 gene product

[Drosophila melanogaster]

Length = 595

Score = 404 bits (1026), Expect = e-111

Identities = 233/587 (39%), Positives = 340/587 (57%), Gaps = 51/587 (8%)

Query: 25 CSPAALQRRRLPILAWLPSYSLOLWLMDFVAGLSVGLTAIPQALAYAEVAGLPPQYGLYSA 84
 C P+ + + P L WLP Y L+++ DF+AG +VGLT IPQA+AY VAGL PQYGLYSA
 Sbjct: 28 CRPSTVTNKFPIKWLPRYRLEYIMQDFIAGFTVGLTTIPQAIAYGVVAGLEFPQYGLYSA 87

Query: 85 FMGCFVYFFLGTSRDVTLGPTAIMSLLVSFYTFHEPAYAVLLAFLSGCIQLAMGVRLRGF 144
 FMGCF Y G+ +DVT+ TAIM+L+V+ Y P YAVL+ FL+GCI L +G+L +
 Sbjct: 88 FMGCFTYIVFGSCKDVTIATTAIMALMVNQYATISPDYAVLVCFLAGCIVLLGLLNM-- 145

Query: 145 ISPHPLGLGGAGTSSMSPLGWPGLLDFISYPVIKGFSAAAVTIGFGQIKNLLGLQNIIP 204
 G L+ FIS PVI GFT AAA TIG QI N++GL +
 Sbjct: 146 -----GVLVRFISIPVITGFTMAAATTIGSAQINNIVGLTSPS 183

Query: 205 RPFLLQVYHTFLRIAETRVGDAVLGLVCMMLLLLVLKLMRDHVPPVHPMPGVRSLRGLV 264

```

      + F +   R+ DA+LG+ ++ LL++ ++D           ++ +
Sbjct: 184 NDLLPAWKNFTHLTSIRLWDALLGVSSSLVFLLLMTRVKD-----IKWGNRIF 231
Query: 265 WA-ATTARNALVVSFAALVAYSFEVTGYQPFILTGETAEGLPVRIPPFSVTTANGTISF 323
      W      +RNAL V F   +AY      G QPF +TG      G+PP R+PPFS T      +SF
Sbjct: 232 WKYLGLSRNALAVIFGTFLAYILSRDGNQPFRTVGNITAGVPPFRLPPFSTTVDGEYVSF 291
Query: 324 TEMVQDMGAGLAVVPLMGLLESIAVAKAFASQNNYRIDANQELLAIGLTNMLGSLVSSYP 383
      EM+ +GA L +PL+ +LE +A++KAF+      +DA+QE++A+G+ N++GS V S P
Sbjct: 292 GEMISTVGASLGSIPILISILEIVATSKAFS--KGKIVDASQEMVALGMCNIMGSFVLSMP 349
Query: 384 VTGSFGRRTAVNAQSGVCTPAGGLVTGVLVLLSLDYLTSLFYIIPKSALAAVIIMAVAPLF 443
      VTGSF RTAVN  SGV TP GG VTG LVL++L +LT  FY+IPK  LAA+II A+  L
Sbjct: 350 VTGSFTRTAVNNASGVKTPLGGAVTGALVLMALAFLTQTFYFIPKCTLAATIIAAMISLV 409
Query: 444 DTKIFRTLWRVKRLDLLPLWVTFLLC-FWEVOYGILAGALVSLMLLHSAARPET----- 497
      +      + +W+ K+ DL P  VT L C FW ++YGIL G      +++ +L+S+ARP
Sbjct: 410 ELHKIKDMWKSKKKDLFPFVTVLTCMFWSLEYGILCGIGANMVYILYSSARPHVDIKLE 469
Query: 498 KVSEGPVLVLQPASGLSFPAMEALREEILSRAL--EVSPPRCLVLECTHVCSIDYTVVLG 555
      K++  V V+      L + + E L+E+++ R L  +      + +V++  + SIDYTV +
Sbjct: 470 KINGHEVSVDVKQKLDYASAEYLKEKVV-RFLNNQNGETQLVVIKGEINSIDYTVAMN 528
Query: 556 LGELLQDFQKQGVALAFVGLQVPVLRVL--LSADLKG-FQYFSTLEE 599
      + + D +      A+      +      V+ L+ DL+ F++ +LEE
Sbjct: 529 IVSMKGDLEALNCAMICWNWNINIASAGVVCRLNNDLRPIKFDLSLEE 575 (SEQ ID NO :7)

```

Multiple sequence alignment of both splice forms and the top blast hit:

```

Splice Form 1 ~~~~~~ ~MPSSVTAL GQARSSGPGM APSACCCSPA ALQRRLPILA
Splice Form 2 ~~~~~~ ~MPSSVTAL GQARSSGPGM APSACCCSPA ALQRRLPILA
gi7302719_pe MRAEDNLYR EQLPNVSTLI ...RDGGRKL .....CRPS TVTNKFILK

      51                                     100
Splice Form 1 WLPSYSLQWL KMDFVAGLSV GLTAIPQALA YAEVAGLPPQ YGLYSAFMGC
Splice Form 2 WLPSYSLQWL KMDFVAGLSV GLTAIPQALA YAEVAGLPPQ YGLYSAFMGC
gi7302719_pe WLFRYRLEYI MQDFIAGFTV GLTTIPQAI A YGVVAGLEPQ YGLYSAFMGC

      101                                     150
Splice Form 1 FVYFFLGTSR DVTLGPTAIM SLLVSFYTFH EPAYAVLLAF LSGCIQLAMG
Splice Form 2 FVYFFLGTSR DVTLGPTAIM SLLVSFYTFH EPAYAVLLAF LSGCIQLAMG
gi7302719_pe FTYIVFGSCK DVTIATTAIM ALMVNQYATI SPDYAVLVCF LAGCIVLLLG

      151                                     200
Splice Form 1 VLRL.....GF LLDIFISYPVI KGFTSAAAVT
Splice Form 2 VLRLAHISPH PLGLGGAGTS SMSPLGWPGF LLDIFISYPVI KGFTSAAAVT
gi7302719_pe LLNM.....GV LVRFISIPVI TGFTMAAATT

      201                                     250
Splice Form 1 IGFGQIKNLL GLQNI PRPF LQVYHTFL.R IAETRVGDAV LGLVCMLLLL
Splice Form 2 IGFGQIKNLL GLQNI PRPF LQVYHTFL.R IAETRVGDAV LGLVCMLLLL
gi7302719_pe IGSAQINNIV GLTS.PSNDL LPAWKNFTH LTSIRLWDAL LGVSSSLVFL

      251                                     300
Splice Form 1 VLKLMRDHVP PVHPEMPPGV RLSRGLVWA. ATTARNALVV SFAALVAYSF
Splice Form 2 VLKLMRDHVP PVHPEMPPGV RLSRGLVWA. ATTARNALVV SFAALVAYSF
gi7302719_pe LMTRVKD... .....I KWGNRIFWKY LGLSRNALAV IFGTFLAYIL

```



```

301                                     350
Splice Form 1 EVTGYQPFIL TGETAEG LPP VRIPPF SVTT ANGTISFTEM VQDMGAGLAV
Splice Form 2 EVTGYQPFIL TGETAEG LPP VRIPPF SVTT ANGTISFTEM VQDMGAGLAV
gi7302719_pe SRDGNQPF RV TGNITAGV PP FRLPPF STTV DGEYVSFGEM ISTVGASLGS

351                                     400
Splice Form 1 VPLMGLLESI AVAKAFASQN NYRIDANQEL LAIGLTNMLG SLVSSYPVTG
Splice Form 2 VPLMGLLESI AVAKAFASQN NYRIDANQEL LAIGLTNMLG SLVSSYPVTG
gi7302719_pe IPLISILEIV AISKAFS..K GKIVDASQEM VALGMCNIMG SFVLSMPVTG

401                                     450
Splice Form 1 SFGRTAVNAQ SGVCTPAGGL VTGVLVLLSL DYLTSLFYIYI PKSALAAVII
Splice Form 2 SFGRTAVNAQ SGVCTPAGGL VTGVLVLLSL DYLTSLFYIYI PKSALAAVII
gi7302719_pe SFTRTAVNNA SGVKTP LGGA VTGALVLMAL AFLTQTFFYFI PKCTLAATII

451                                     500
Splice Form 1 MAVAPLFDTK IFRTLWRVKR LDLLPLCVTF LLC.FWEVQY GILAGALVSL
Splice Form 2 MAVAPLFDTK IFRTLWRVKR LDLLPLWVTF LLC.FWEVQY GILAGALVSL
gi7302719_pe AAMISLVELH KIKDMWKS RK KDLFPFVTV LTCMEWSLEY GILCGIGANM

501                                     550
Splice Form 1 LMLLHSAARP ET.....KVS EGPVLVLQPA SGLSFPAMEA LREEILSRAL
Splice Form 2 LMLLHSAARP ET.....KVS EGPVLVLQPA SGLSFPAMEA LREEILSRAL
gi7302719_pe VYILYSSARP HVDIKLEKIN GHEVSVVDVK QKLDYASA EY LKEKVV.RFL

551                                     600
Splice Form 1 ..EVSPPRCL VLECTHVCSI DYT VVLGLGE LLQDFQKQGV ALAFVGLQVP
Splice Form 2 ..EVSPPRCL VLECTHVCSI DYT VVLGLGE LLQDFQKQGV ALAFVGLQVP
gi7302719_pe NNQNGETQLV VIKGEEINSI DYT VAMNIVS MKGDLEALNC AMICWNWNIA

601                                     650
Splice Form 1 VLRVL..LSA DLKG.FQYFS TLEEA EKHLR QEPGTQPYNI REDSILDQKV
Splice Form 2 VLRVL..LSA DLKG.FQYFS TLEEA EKHLR QEPGTQPYNI REDSILDQKV
gi7302719_pe SAGVVCRLNN DLRPIFKFDL SLEEVVAGHF DSPSNTASTV TIEA~~~~~

651
Splice Form 1 ALLKA
Splice Form 2 ALLKA
gi7302719_pe ~~~~~

```

Hammer search results (Pfam):

Model	Seq-from	Seq-to	HMM-from	HMM-to	Score	E-value	Description
Sulfate_transp family	137	468	1	328	229.9	1.3e-66	Sulfate transporter

```

1   GGTCCCCGCG GCCCTCGGCC TTGCTCGGGG CCAAGGGACC GCGGACGGTC
51  AGGTGGCGCA GGGTCTCCTC CGGAGACCCC AGGATCCGGA GCCAGCGGCC
101 TTGTGGGCAG GGGCCGGGGG CAGGGGAGTG GATTTTGCCC GGAGCGGAGC
151 AGGCCGGGGG CAGTGGGGGG CTGGGGGTGA GGGTGGCTGG CTCTGCGCGC
201 GGGCGCCGGG GCCCTGGAAG ATGCTGCGCA CCTGAATTAA CCGGGCGCCT
251 CTGATGTCTT CCCAGAAGCA ACTAGAACTC CAGGGCTGTG AAAGCCACAG
301 GTGGGGGGCT AGCGAGGCTT GGCCTCAGGA GCGGAGGACC CCCCCCCCCC
351 CCCCCTCGAG CGCCGCGAGT CACCGTAGCG GGTGGAGCCC GCCTTGGTGC
401 GCAGTTGGAA AACCTCGGAA GCCCGCTGG ATCTCCTGGC TGCCACCCGC
451 ACCCCCCGCC AGCTACGGTG CGCCGCGGG CCCAGCTTCT CTCTGCGCTG
501 CTCCCCGTTA AATTCCCTGG GGAGACGGAA AAAAAGGCAA AGGAAGTCGG
551 TTCTCCAGGG GCCAGAAGTG TTGAGCCTAA TTAGTCTTCA GACTTCTCAA
601 TGAGGAATCG CTTATCAGTT TCTTATCTGG GAGAGTTGAG GATGGAGGGA
651 CAGAAGGCAC CCAGGATTTG CACGGGGGGG GATTCAGGCA GAGAGGGTGA
701 TGAGGGACGG GGTGGGCCTT CCAGTCTTGG CCCAGTCCCC ATCTTGACAA
751 CATTGTTGGC TTCTCTTAG AGCCGTTCGC CCCCCTGGGG AGGGGAGACC
801 CATAGTGACC TCTCTGACA CCCGCCGACC CTGACCAGTG TTGCCGGGTT
851 CTTCAAAGGC CACGCTCTGA CTGCTGGTCT GTGTCACCTG CACCCCCCAG
901 CCCCACCGTA GAGATGCCTT CTTGGGTGAC GCGCTGGGT CAGGCCAGGT
951 CCTCTGGCCC CGGATGGGCC CCGAGCGCCT GCTGCTGCTC CCCTGCGGCC
1001 CTGCAGAGGA GGCTGCCCAT CCTGGCGTGG CTGCCCAGCT ACTCCCTGCA
1051 GTGGCTGAAG ATGGATTTCT TCGCCGCGCT CTCAGTTGGC CTCACTGCCA
1101 TTCCCAGGC GCTGGCCTAT GCTGAAGTGG CTGGACTCCC GCCCCAGGTG
1151 AGGCGTCTGA CCCTGCTGCC AGCCATATCT CAGAAACAGT GCAGAATACA
1201 CAGTATCAAT CCCAGACACC ATCAGCGATT CCAGGTTTCC AGCCCCTGGG
1251 CCCCAGGAA CCTTTGGTTT ACAGTGTGTG ACGCAGATTG TCTCTGGGCC
1301 GACCCAGGCT CCTATGCCTG TTTGGTACAC ACAGACACTG AGCTGCTTAT
1351 GGAGGGGCCA GCGAGATGAC TCATGGAGGC CTCAGGAGTT CAAGACCAGC
1401 CCGACCAAAA TGGTGAACCC CCGTCTCCAC TAAAAATACA AAAATTAGGC
1451 TGGGTGCGGT GGCTCAAGCC TGTAATCCCA GCACCTTGGG AGGCCGAGGC
1501 AGGCGGATCG CAAGGTCAGG AGATGGAGAC CATCCTGGCT AACAGGGTGA
1551 ACCCCGCTCT CTACTAAAAA TACAAAAAAT TAGCCAGGTG TGGTGGCGGG
1601 TGCCTGTAGT CCCAGCTACC TGGGAGGCTG AGGCAGGAGA ATGGCGTGAA
1651 CCGGGGAGGC GGAGCTTGCA GTGAGCCGAG ACTGTGCCAC TGCCCTCCAG
1701 CTTGGGCGAC AGAGCGAGAC TCCATCTCAA AAAAAAATAA AAAAGAATGC
1751 TTCTCAGAC TTGGACACAG CACACGGGCC TGTACCGACC CCTCTGCCTG
1801 GCTGTCTGCA CCCTGAGGCC CCAGTTGAGT GCTGCTAAAA AAGTGGCCTC
1851 CTGATCACTG CAGGTCCACC CACAGGGCAG GGCGGTGCAC CTTTAACCTG
1901 GGCTGGACA CAGCTGACAC CCACACATCC CGAGCTTGGG CACGCACACT
1951 AGGGAGCTGG TGGATGGGCC TCGGCCTCCT GAGTGTCTAC CACCTCTCT
2001 CCCCACAGTA TGGCCTCTAC TCTGCCTTCA TGGGCTGCTT CGTGTATTTT
2051 TTCTTGGGCA CCTCCCGGGA TGTGACTCTG GGCCCCACCG CCATTATGTC
2101 CCTCTGGTCT TCCTTCTACA CCTTCCATGA GCCCGCTAC GCTGTGCTGC
2151 TGGCCTTCTT GTCCGGCTGC ATCCAGCTGG CCATGGGGGT CCTGCGTTTG
2201 GGTGAGGCTC TACCTTCTTG CCAAGGGGAT GCCCTCGACC TCAGCATTTG
2251 CTTGTTTGCA TTTCAAGTCT ATCCCCGTGT GCGTGTGTGT GCGTGTGTGT
2301 GGGGTGTGGG TATGTATGTG TGTGTGTGTA GGTGGGTGGG TGGTGGAGGG
2351 GGTGGGGCAC TTGGCTCCTT AGTCTACTAT TTTACTGATT AGAGGCCAGG
2401 ACATTGGAGA AAGTGACCTG TGGCTCAGAC CCCATATGCC CCNNNNNNNN
2451 NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNTTCATTTT
2501 CTACCCCGTC ATTAAGCTT CACCTCTGCT GCTGCCGTCA CCATCGGCTT
2551 TGGACAGATC AAGTAGGCA CGGCGCCAC CCAGGGCACT GCTCTTTGGC
2601 CACTGCTCGT TGGCAGAGG ATGGCGGGAG CAGGACTGAG GCCAGTCTTG
2651 ATCCCTGTGG CCAGTGGAGC TCTTGCTGTT TCAGATTGTC TTCCATGGGT
2701 CAAGAAGCAC CGGTGCTCT CATGGGTCCC CTGTTAATAA AATGACCCTC
2751 CTGGGAGGGA TGTCACGTGA TGGTTGGATT TCACAGCGGG TAACTTGGGG
2801 GCGGTAATT CCATCCCCCT GCTCTTGCCC GAGTTTCCGT GCCAGTGTGC
2851 TTGGCTGGCT CTGTGACGTG GCTCTGTTCT CCCTGCACTG GGCACACCCA
2901 GCAGGCCCCA CCAGTCATGA GCATGCTGCT AGAATTTCTA TAGGCAAATT
2951 ATTTCCCAT GCCAATTTAG TTAGATGGTT TTGTTTGTG CTTTTTTTTT
3001 TGGTTTCTGT TTAATATTTT TTAAATGCCA TGCCTTTAT ATTTTCTTTT
3051 AAAACATTTA TAATAAGTAC TAAATCAGT CATCAGCTGA GGGTGTAAAT
3101 TATTCTGTTT TTGCTGGGTT GTAAGTTCCT CGAGGGTAGG AACTGTCCTT
3151 CTCCCAGCCA TGGCCGCCCA GCATTGGGCT GGTGCAGTAG GGGGGTGTCT
3201 AGTGGGGTGT GTGTGGAGTG AAGTGAGCCC AGTCCACAG ATGGGACCAT
3251 GCGGCCCTCA TGGCAGACTA GGGTCACATG CTGCCTCTG ACCCTGTGTC

```

```

3301 ACTGCAGGTC ATCTTCCCCA AGCCAGGCCC TGTTCAGGC TGGCCTGAGA
3351 CAGTCTTCCC TGATGGAGGT ACCATGAGAA GACCAAGGAC AGGAGAGTGT
3401 GTGTGAGAGT GTGTATGAGT GTGTGTGTGT GTGAATGAGT GAGTGTGTGA
3451 GAGTGTGAGT GGGTTTGAGG GAGTGAGTGT GTGCGTGTGT GAGTGAGTGT
3501 GAGTGTGGGT GTGAGTGAGT GCGTGTGTGT GAGAGAGTGT GTGAGTGTGT
3551 ATGAGTGAGA GTGTGAGAGT GGGTGTGGGT GTTAGGGAGT GTGTGAGTGT
3601 GCGCGCGCGT GTGTGAGTGT ATGAGTGTGA GAGTGAGTGT GAGTGAGTGA
3651 GAGTGGGTGT GGGTGTGAGT GTGCGTGTGA GTGTGAGAGT GTGAGTGTGT
3701 GAGTGTGAGA ATAAAGTAGA CACTTTTTGC ACTCTTGCTA CGTGCGAGGC
3751 ACTGGGCAGG ACACTCTCCA TGTGTAATTC TCAACACACC CCGGGAGGTA
3801 GATTTATCAT TATTTCCATT TGAGAGAGGA GGGACCAACT TAGGTGTGGG
3851 TGAGCGTGAT TTGTACGTTA TCTACACGCA TCTCTCAGGG TTAGCTTGGC
3901 AAATGCTGTT TCAGGGCATG GTTGGTTCTT TAATCTGGAA ACATCATTTT
3951 TGGTGTCAAG AATGTTCTTT TGTAGGATCC CAGTGAGAGT GGAGAGCGGA
4001 GAGTGGAGAG TGGAAAGCAT CCCTTGTTCA TGCCTTCATA CTTGGCAACC
4051 CTAGCCCCGC CCAGGGACTC TGCAGCCATC TGGGGGGAGG GGCCTCCTCC
4101 TGACAGGCCC AGGACAGAAG ACCCTACCCC AACAGTCCCA GAGTCCGCCC
4151 CCCAGGATGT CCTAACCCCA CCCACCCTGT ACGCAGCAGT TTTAGGGCAG
4201 GGTCTTGGAG CCGTGTGGCA TGGGATCCAG GGCCTCAACT TTCCCCTCTG
4251 ACTCCTGTTG GGTCTCAGGC GATGTAAAGA ACTAAAGTGC AAGCTGTGCC
4301 TGCAGTGTGG ATCCCAGCTA CGTGGGAGGC CGAGGTGGGA GGATCACTGG
4351 AGCCCAGGAG TTCCAATCCA GCCTGGGCCA CAGAGCAAGC AAGACCCCCA
4401 CCCCCCAACC CCCCGCCGCT CTCTAAAGAA AAAAAACTA AACTAAACA
4451 CAGGATAGAG TGCTTCTCTC TGCCCAGGAC CTCAGAGCTG GTATCGTGGT
4501 GGGAGGCTCC TACTTTGCCG AGGATTCCCC AAGCTGGTTT CTTGAAGCCC
4551 CTCAGAGCCC TCCACATCTG CACACTACGA AGAGATTTTT CCTCCCGCAG
4601 CAGCGGAGCT GGGGGGTGGC GGGGCACCTA GTGAGGGAGA CATTCTCAAG
4651 CCAATGGCAG CAAGGGTCTA CACTGCAGGG GGCCTGGCTG CTGAGTGGCC
4701 TGGAGCCAAT GGGGGTGGGG CCAGGCAGCC CATGGCCCTT GGCCATCAAG
4751 CTGTAGAACC TGCTGCCTG CTGTGGGGTC ACCTACATTG TTTTTTATGA
4801 GAAAAGTAAT TTAGAGAAAA ACATATCACT GACCCAGTAA TTGTGAAGTA
4851 CTGTCTCCCA CGAGGGTAGC TTTGATCTCC TGCCCTAGGG GCGTGTGGGA
4901 GTGGGCAGGT GGACCCCTGA GCCCCTAAGA TGGGCCCCGG GAATAAGGGT
4951 TGGGAGCAGG GCCGGGGGAC ACTGTCTCAG CCTAGGGGA GGTGGGCGGG
5001 GAGCTGGGGA CAGATGGCCT TGGTTTGGGA GCATAGCCTC TGATCAGCAT
5051 CTCTGTGTTT GGACAGAACC TGCTGGGACT ACAGAACATC CCCAGGCCGT
5101 TCTTCTGCA GGTGTACCAC ACCTTCCCTA GGATTGCAGA GACCAGGTAC
5151 CCCGGGCTTT GTTCTCCCT CCTATAAGGA AGCTCCTTCT TCCACACCTC
5201 CTCTCCCGGC CCCACCTCA GTTCCCCAC CCCTGGTGAC TGCTCAAACA
5251 GGGGTCCCCA GAGCAGCCCC ATCAGCAGCA CCTGCAAGCT GGCAAGAAAT
5301 GAGACTCTCA GTCCTTTGCA GACCTGCCCT ATCGGAGCCA GAGGTTTAAAC
5351 AGGAGGCCGG TGCTCTGCGC GCAGGGGAGA GTTCAAGAAG CTCTGCTCTG
5401 GGGAGCTGGA GCAGGGCAAT GTTCTCTCT CCACAAAGCT TTCTTGGGGG
5451 ACAGGAATGG GGAGAGTCTG TGTAAGAAA AAGAAGGCAG TGTGTCTCCC
5501 CCAGGCTGTG ATTTGTAAAG GAGGAGAACA CAGGGCGTGG GGAGCTAACC
5551 CAGACAGAAC GCAGGTGGTG CAGGGACGGC AGGTGGAGCT GTGATGAGAG
5601 ATGAGGAGAC CCAAGCACTT CCCTCAGGTG GTTTAAAGAG CCTCTGATGG
5651 CCGGACACTG TGGCTCACAC CTGTAATCCC AGCACTTGG GAAGCCCAGG
5701 TGGGCAGATC ATCTTAGGTC AGGAGTTCAA GACCAGCCTG GTCACATGG
5751 TGAAACTCCG TCTCTACTAA AAATACAAAA ATTAGTCGGG TGTGATGGTG
5801 CGTGCCTGTA GTCCCAGCTG TTCAGGAGGC TGAGGCAGGA GGATTGCTTG
5851 AACCTGTGAG GCGGAGGTTG CAGTGAGCTG AGATCACGCC ACTGCACTCC
5901 AGCCCGGGTG ATAGAGTGAG ACTCCATCTC CGCCCTGCC TGCCCCCCCG
5951 AAAAGAAAAG CCTCTGATGA GGGGTACCTC CCTGCCAGAC CATCCAGCGG
6001 GAAGGCAGGA TGCTCTCTA CCTCTCTGGC TGGAAAGGGC TGGAGGAGGA
6051 AATGATCTAG GGGAGCTATA GAGATGGCTG CCCAGTGCTG TGGCCTGGAG
6101 GGAGTGGGGG CGATCCTGGA CCATCTTCCC CTCCCCTCTG ATCTGCTGCC
6151 GAAGCTTCCC AGCAGCTGAA CCCAGCTGGA AGCCAGTGG TTCTTTGCTC
6201 TTCAGAGGCA CCAGTGGGCA GGGGTGCGCC AGATGGGGGA GCAGTGATTA
6251 CGGAGCCTGA CCAGTCAGAG AGCGTCACGG GCTGTCTATG AAAAGGGGCC
6301 TTAGTGACCG TTTAGTCCTA AGCCTTCTAG AATGTCTAGA GCAGGGTGTC
6351 CAGTCTTTTG TCTTCCCTGG GCCACACAGG AAGAATTGTC TTAATAATACA
6401 CTAATGATAG CTGATGAGCT ACAAAAAAAT CATTGAAAGA ACTCATAATG
6451 TTTTAAGAAA GTTTACAAAT TTGTGTTGGG CCACATTCAA AGCCATCCCCA
6501 GGCTGCACAT GGCCACAGG CTGTGGGTTT GGCAGACTTG TTCTAGAGCC
6551 ACCTGCAGAG AGCATCAGCT GCTCAGGCTG GTCCCCATTC CCTGTGTTCA

```

6601 CTCACCAGAT CCTGTTCCAT AGACTTGAGT CCCAGAGAGC TACGGGAGTG
6651 AAAATGTGAG CACGTGCTC TGCCATCATC ATGACCCGGG CCTCTCCACT
6701 GCCTGTCTG CCCAAGCCTG TGTACTTACT GAAATTTGAA TTGAGTTTGT
6751 AAGTAGAACA GGGATGCATA TTGCTTAGGA GAAAACATCT CAGCCTAGTC
6801 TGTGTTTGGT CTTGCAGAGT AGCTTGCTAA AGTTCTGAG CTTTAGTTAA
6851 GTGTCTGTGA AATGGTGAAA ATATTGAAAA TGCTTTATTT CCTTGTGATA
6901 CTCACTGTGG TCTGGGACCA GCAGCCTGGG CATTTGGGCT CCCTGGGAGC
6951 TTCTTAGTGC CTCTCAGCTT AAGCAGCAGC AGGACGCTTG AGTCAGCAGT
7001 AGGCCTGGGC CGAGCTGGGT GGTGACCAGT CCTCTGCCTG TCCACAGGGT
7051 AGGTGACGCC GTCTGGGGC TGGTCTGCAT GCTGCTGCTG CTGGTGCTGA
7101 AGCTGATGCG GGACCACGTG CCTCCCGTCC ACCCCGAGAT GCCCCCTGGT
7151 GTGCGGCTCA GCCGTGGGCT GGTCTGGGCT GCCACGACAG GTGAGGGGCC
7201 TCTGGCTGAC ATCGTATGCA ACCTTGGCTG CAGGTTGGGG TCACTTGGGG
7251 AGTCTAGTGC CCACCTAGG GATTCTCAG TCATTGGTCT GGGTGTCACT
7301 TGAGCATTTGG GACATTTAAA ACACCACACC AAACCTCTGG ACATGTACTT
7351 TTTATTTAAT TAATTAATTA ATTATTTTTT GAGACAGAGT TTCGCTCTGT
7401 CGCCCAGGCT GGAGTACAGT GGTGTGATAT TGGCTCACTG CAACCTCCGC
7451 CTCCCAGGTT CATGTGATTC TCTGCTCA GCCTCCTGAG TAGCTGGGAT
7501 TACAGGCGCA TGCCACCACG CTCGACTGAT TTTTGTATTT ATAGTAGAGA
7551 CGGGGTTTCA CCATGTTGAC CATACTGGTC TCAAACCTCT GACCTCGAGT
7601 GATCTGCCCT CCTCGGCCTC CCGAAGTGCT GGGATTACAG GCATGAGCCA
7651 CCGCCCCGAC CCAAACCTCTA GAACATTTAA AACTCTGAGC CAAACCTCGT
7701 GGGTTCTGAT CGAGGGTCAG AGCTGAGAAC TGATGCATGG CCAGCTGTGG
7751 CCGTTCTCAA CCTGAAGCAG TTTTGCCCCC CTGGTGACAT GTGGCAATGT
7801 TGGGAACAT TTTTGGTGGG TACCACCGGG CGAGGCAGTT GCTGGCAACT
7851 AGCGAGGAGG GGCCAGGAAT GCCACTAAGC CCTGACGGC GCACAGCCTT
7901 CCACAGCAAA CAGTGATCCG GCCCAAATG TCGSCGGTGC CGAGGTGGAG
7951 AAACACAGTC TACTGGCAGG TCTGGGGAG ACAGAACAAA TTCGGGGAG
8001 ACCAACAGCG TCTGTTTGAA TTGTGCAGCT TTAGGGGGT ACAACTTCAG
8051 CTTCAGGCGC GGAGGCTGCA GGCTGAGCCA CAACCAACCA GGGGTCTTT
8101 GAGAAAGGGG TGGTGAGGGC TGGCTCGTGG AGGAGCAGGG CTGTCAAGCAG
8151 GTGAAGGACC ACCCTGGGGG AGGTGGAAGC CTCTCTCAG TGCATCCGGG
8201 ATGGGCATGG GTCCCCCTGG TGAGCACCGG GCAGGGATGC CCAGAGAAGA
8251 AGGCACACCC AGGAAAGTCA GGAAGCATAG GTGACTCCAA ACCTTCTCAG
8301 AGCCGAGGGG ACAGATTAAG CTCAGAATAA CCCGAGCTTG GTCTTGCTGT
8351 TTGGGGGCTG CAAAATCCAA CAGCCACAGA AGAGAGAGGG TGGCTGGATT
8401 TAGCTCTTGA GTCACCTCTG CTTGCCCAGG CTGGTCTGTT CTCTGTGGTC
8451 TCTCCCTGGA TCTGTTCAG CAGACTTGAG GCCGTGGTGA ACACTGAGAG
8501 TCTGGTGGGG TGCAGAGGAT GCTGGGTTTA GAGTGGAGAT GTCCAGCTTC
8551 CAGTCCCAGC CTGGCCTGGG TTAGACTTG CAAAGTAGCT TCCAAAGTTC
8601 CTGAGCTTTA GTTCAGTTGT CCGTGAAATA GTGAAAATGC TTTGTTATCT
8651 TTGTTATCTT TTGTTTTTTG TTTTTTTTTG GAGACGGTGT CTCACTCCTG
8701 TTGCCCAGGC TGGAGTGCAC TGGCCGTGAT CCTTGGCTCA CTGCAACCTG
8751 CCTCCTGGTT TTCAAGCAAT TATTCCTCCC TTAACCTCC CGSAGTAGCC
8801 TGGGATTTAC AGGCCGTGCA CCCACCACAC CCGGGCTAAT TTTTGTATT
8851 TTTGAGTTCA AGATGGGGGT TTCACCATTG TTGGCCCATG CTGGGTCTCG
8901 AAACCTCCCN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN
8951 NNNNNNNNCC CTAACCTGA AAGGCAGTGT CTCCGAGCC AGAAAGGTCT
9001 TTTAAGATGT TTAGACATCG GTAATGTCCA GAAACTTCAG AAACATTTTA
9051 CAGTGATAGG CTGCTGACTC CTTCTCCCC AGTGTGTGTA GCATTGTCTT
9101 AGGAAACTAC TTAATAAGCT TTTGATTCTT ATAACAGCTT TGAGAAATGAG
9151 TTTATTATTT TTTCCATTTT GTCAGTGAGG AAAGTGAGCC TATGAAAGAT
9201 GAAAAATAAA ACAGAACTTC TCAAGGCCAC ACGACTGGGA AGAGGCAGAA
9251 CAAGGACTTC ACCCGAGTGC TCTGTCTTTT TTTCTGAATG GTCTGTCTAG
9301 AAGTGTGTCA ATGTTATGAT CCTCTCAAAG AACCAGCTTT TGGTTTCATT
9351 GATCTCCCTT TTGCTTTGGT TTTCTAGTTC ATTGATTCTT GCTTGGGCTT
9401 TTATTATTTT CTTTCTTCTA TTTATTTTCA GTTAACCTTA TCCTTTTTTT
9451 TTTTTTTTTT AAAAAAAAT TTTTTTTTTT GAGACGGAGT TTCGCTCTTG
9501 TCCCCCAGGT TGGAGTGCAA TGGTGTGATC TCAGCTCACT GCAACCTCCG
9551 OCTCCCGGGT TCAAGTGATT CTCTGCCTC AGCCTCCCAA GTAGCTGGGA
9601 TTACAGGCGT ATGCCACCAT GCCTGGCTAA TTTTTTGTAT TTTTAATAGA
9651 GACGGGGTTT CACCATGTTG GCCAGGCTGG TCTCGAACTC CTGAACTCAG
9701 GTGATCCACC CGCCTCAGCC TCCCAAAGTG CTGGGATTAC AGGCGTGAGC
9751 CACTGTGCCC GGCCTTTTTT TTCAGATTCT TAAGGTGGAA GCCTGGGTCT
9801 TTGATTTGAG ACCTTCTTTC TTTCTAATA TGGTTGTTA AATGCTGTAA
9851 ATTTCACTCC TAGCATTACT TTAGCTGCAT CCCACAGTTT TTATATATAT

```

9901 GCTGTTCTTT AATTTTATT CGGTTCTAAA TACTTTGTGA TTTCCATTTT
9951 GACTTCTCCT TTGACCTGTG GATTATTTAG AAGTGGATTA TATGATTCT
10001 TCTGTGAAGC ATGGGAGTTA TTTAGTTTCC AAATAGTTGG GGGTTTCCCA
10051 ATTAGTACTT TGCCATTGAT TTCTAATTTA GTTCCATTGT GATAAGAAAA
10101 CGTACTTAGT GATTTAAATC TGTTCCTT TATTGAGAGT TGTATTATGG
10151 CCCTGAATAT GGTCTATCTT AGTGAATATT CTGTGTGTGC TTGAGAACAT
10201 GTTTTCTGCC ATTATTGGGT GGAATGTTCT GTAAATGTCA GTTAGGTCTG
10251 GTTGGTTATC TCAGGCTACT ATATTCTTGC TGATTTCTT TCTACTTGT
10301 CTGTTGATTA TAAAAGAAG AATGTTGAAA TAACCTCAGC TATAACCATG
10351 ACTTTGCTTA TTTTCCTTTC TTAACCTACCA GTTATGTTT CATATATTT
10401 GAAGCTCTGT TTTTAGTAT AAAACATAT AGAATTATA TTTTCTCTG
10451 GAATGATACT TTTTTTCTG GGCAATATTC TCTTCCCTGA AATCTACTT
10501 GATACTAAGA GAGCTACTCC AGCTTTCATT AGTGTAGCA TATCTTTCC
10551 CATCTTTTCT CTTTTTCTT TTTGAGACAG AATCTCTCT TGTTGCCAG
10601 GCTGGAGTGC AATGGCGTGA TCTTGGCTCA CTGCAACCTC CACCTCCAG
10651 GTTCAAGCAA TTGTTGTGCC TCAGCCTCCC AAGTAGCTGG AATTACAGGC
10701 TTGCACCACC AAGCCAGCT AATTTTGTG TTTTGTAGT CAATGAGGT
10751 TCACCATGTT GGCCAGCCTG GTCTCAAATT CTGGCCTCA AGTGATCCAC
10801 CTGCCTTGGC CTCCCAAAGT GCTGGGACAC CACACCAGC CTCCTATCTT
10851 TTTACTTTTA ACGTATTTAA TTGATTTGTG TTCTTGTGTT TAATGGTATG
10901 TTTTATGGGC AGCATATAGA TGGGATTTGT TTTTAACTCTC ATAATCTCTG
10951 CCTTTTAATT GGAATCTTAT GCCATTTATA TTTAATGTGA TTATTGGTCT
11001 CTTTGACTTT AGATCTACCA TGTGCTGTT TGTTTCTGT TTGCTCATT
11051 TGTTCTTTGT TCCCTTTTCC CCTCTCTCT ACCTCTACTG GATTATTTT
11101 TATGATTTCA TTTTACATCC TTTATTGGCT GATTAGCTGT AACGGCTATA
11151 TTTAGTTTTT GTTTGTTTGT TTCTAAGTGA CTGCTTTAAG GTTTGTGGTA
11201 AACATCTTTA TCTTGCTACA GTATACATTA AACTTCAACT TCATGTGATA
11251 TAAGAACCTT ATAACAGGCC AGGCGCAGTG GCTCACACCT ATAATCCTAG
11301 CACTTTGGGA GGCTGAGGGA GGCAGATTGT CTGAGCTCAG GAGCTAAGA
11351 CCAGCTGGG CAACATGGCG AAACCCCATC TCTACCAAAA ATACAAAAA
11401 TTAGCCAGGC ATGGTGGTGC ATGCCGTGA TCCCAGCTAC TGGGGAGGCT
11451 GAGGTGGGAG GATTGCTTGA ACCTGGAAGG CAGAGATTGC AGTGAGCCAA
11501 GATCCGTCAC TGAAGCTGCA AACTCCTGGG CTCAAGTAAT TCTCCTGCC
11551 CAGCCTCCTG AGTAGCTTGG TCTACAGGCA TGCACCACCA CATCTGGCTA
11601 ATTTTAAAAA TTTTAAAAA GAAACGGGCT ATGTTGCTCA GGCTGATCAA
11651 AGGTTCTTGG CCTCAAGTGA TGCTCCTGCC TCAGCCAACC AAAGTGCTGA
11701 GATTGCAGAT GTGAGCCACC ATTCCCTGCA GGAACAGTCT TAGATTTATC
11751 CACGTAGTCA CTGTTTCTGG TGCTCTTAAT TCCTTTGTAC AAATCCAGAT
11801 TTCCATCTGG TATAATTTT CTCTACCTG AAGGATGTTA TTTTCTCTC
11851 TGTGTCAGGC CTGTTGGTGA TTAACCTCTT CAGCATTTT TTTTTTTTTT
11901 TATTTGACAG GATTCACTCT GTCACCTCAG CTGGAATGCA GTGGTACAA
11951 TATAGTTCAC TGCAGCCTTG AACTCCTAGA CCAAGCAAT CCTCAGCCTC
12001 CTGAGTGGCT GGGACTATAG GCATGCATCA CCACGCTGG ATAATTTTTT
12051 ATTTTACTT TTTGTAGAGA TGGTGCTTTC CTACGTTGCC CAGGCTGGTC
12101 TCTTACTCCT GGGCTCAAGG GATCCTCCCA CGAGGGATCC TCCCACCTTG
12151 GCTTCCCAA TGTGGGATT ACAGGTGTGA GCCACTACTC CTGGTCTTCT
12201 TTCAACTTTT GACTTTTGTA TGTCTGAAAG TCTATTTTGC CTTTATTTT
12251 CAAAGATAGT TTTGCTGGTT ATAGAATTCT AGACTTTTTT TTTTCTTTCA
12301 GTACTTTTTA AAAAAAGTT ATTTATTATT TTTTTTATT TGAGACAGTG
12351 TCTCGCTGTG TCACCCAGGC TGGAGTGCAG TGGCACGATC TTGGCTCACT
12401 GCAATCTCTG CCTCCTGGGT TCAAGTGATT CTCTGTCTC AGCCTCCAG
12451 GTAGATGGAA TTACAGGCGC ATGCTACCAC GCCCGGCTAA TTTTGTACT
12501 TTTAGCAGAG ATGGGGTTTT GCCATGTTGG CCAGGCTGCT TTCGAACCTC
12551 CTGACCTCAG GGTGATCCGC CCTCCTTGGC CTCCCAAAGT GCTAGGATTA
12601 CAGGCGTGAG CCACTTTGCC TGGCCTCAGG ACTTTTAAAG ATGCTATTCT
12651 GCTGTCTTCT GGCCCACTTC GTTCAAGAA GTGTGCTGGC ATTCTTTGGT
12701 CCTCTGTATG TAACCTTTTT ATCCACCGCT TTTAAATAT TCTTTATCAC
12751 TGGTTTTAGG CAGTTTCATA ATGTGGCTTG ATGTAGTGT TTTTGTGTTG
12801 TTTGTTTTTT GTTTCTGTG TTTATGCTTG TGATTCATTG AACTTCTTAG
12851 ACATGTGGGT TTGCAGTTT ATCAAATTTG GAAAAATAAC ACCCATCTTT
12901 TCGTGAAATC TTTGTACTGT CCCCCTATGC GATTCCACAG ACTTCTTTG
12951 CAGAATCCCC TGTCTGTATT TCAGGCACCT CGAAGGTGTT CTCACAGCTC
13001 ACTTGGGATT TTCAGCCTTC TCCTTTGTGT GTTTCATTTT GGATAGTTTC
13051 TGCTGCTACA TTTTAGTCTT TTTTCTCTGT AATGTCTCAG CTGTTGTAAT
13101 TGCACCAAGT GCTTGTCCG TCTCAGACAC TGTGGTTTTC ATTTCTAGAA
13151 ATCCAGTTTG AATCTTTTTT TTTCTTTTTT TTTTTTTTTA AGATGGAGTT

```

13201 TCGCTCTGTT GTCCAGGCTG GAGTGCAATG GCGCGGTCTT GGCTCACTGT
13251 AACCTCTGCC TCCCGGCTTC AAGTGGTTTT CCTGCCTCAG CCTCCCAGGT
13301 AGCTGGGATT ATAGGCATCC ACCACCATGC CCAGCTAATT TTTGTATTTT
13351 TAGTAAAGAC AGAGCTTCAC TGTGTAGGCT GGGCCAGTCT CGAATTCCTG
13401 ACTTCAGGTG ATTCAGCTGC CTCGGCCTCC CAAAGTGCTG GGATTACAGG
13451 CGTGAGCTAC CGTGCCCAGC CTCAATTTGA ATCTTTTAAA ATGTATTTTC
13501 TACATCTTTA CTTAACAGTT GCAATCTTTC CTCTGTTTTT TTTTAAAGTA
13551 TATGGAATTT GGTTACAGTT ATTCTTTTAA TGTCCTATTA ACTAAATTAC
13601 ATTTGGTTAC AGTTACTCTT TTAAATGTCCT GTTAATTCCTG TCATCTTTAA
13651 CTATGTTACT TTTGGGTCTT TTTTATTTT TTTATTTTAA TTTTGTGAGA
13701 CAGGGTCTCA CTGTGTCACC CAGGCTAGAG TACAGTGGCA TGATCATGGT
13751 TCACTATAGC CTCAACCTCC CAGGCTCAAG TTATCATCTC ACCTCAGCCC
13801 CCCAAGTAGC TGGGACTATA GGCATATGCC ACCATGCTCA ACTAATTTTT
13851 TATTTTTTGT GGAGACAGTG TCTCACTAAT TTGCTCAGGC TGGCCTCAAA
13901 CTTCTGGGCT CAAGCAGTCC TCCTGTCTTG GCTTCCCAA GTGTTGGGAT
13951 TACAGGCTATG GGCCACTGCA CCCAGCCATA TTTTCTGCT TCTTTGCATG
14001 CCTAGTAATT TTTGTTTGGG TGGATGCTAG ACTTTGTGAG TTTGAGGTTA
14051 TTGCGTGCTG GATATTTTTG TATTCTATAA ATCTTCTTGA GCTTTGTTCT
14101 GGGATACAGT TAAGTTACTT AGGACAGTTC GATCCATTTA GGTCTTACTT
14151 TTAAGCTTTG TGAGCTGGAC CAGAGCAGTG TTCATTTCTAG GGCAAGCCTA
14201 ATTTGGCCCA CCACTTGATT TTGTAAATAA AGTTTTATTG GAAAATCACT
14251 CCCATTCAAT TACATGGTCA ATGTCAGGTT TTATGCAATA ATAACAGACT
14301 TGAGTAGTTG CGCCAGAGAC TTTATGGCCC ACAAAGCAAA AAGTTTTTAG
14351 TATTTTGGCC TTTACAGAAA ACATTTGCCA ACCCCAGGCC TTGGGCTAAT
14401 CTTCCCACT GCTGAGGTAA AACCTCTGG AGTCCCTGAT GCTCCATGAA
14451 TTATGAGGGT TTTTACTCTT GGTGTGAATC CTTGGGATTG TCCCTTGTA
14501 CCCTCTTTGT GACTCTTCCC CACTGTGGGT TTGGGTCATT TTCGCCCAGC
14551 TTTGCCTCGA CCACTTCTCT GCTGCACATC CGAGGGCACC TCTGCAGATC
14601 TCTGCAGCTC TGTCTCCGGC TGCCCTCTCT GCTCCTGTGA CCTTGCGGTC
14651 AGCTCCAGCT GCAGGCCTCC TCAGACTTCC TCCCAGCATT GCCCCCTGAA
14701 CTCAGGGAAA CCCCTGGGCT CTGCTAGGGG GTCCCTCCA TACACATGGG
14751 GACCATCGGG GGAACCGTA GGCAGCCGGC GGGGCAGTGA TAGACTCACC
14801 TCCCTTGT TT CCTGTGGCC GTCATGGCTG CTGTCCCGCG TCTTAGTGGC
14851 CATCATGTCC ACTGTCCCGC ATCTTGGAGG CCATTGTTTC TGTGTTTTGG
14901 GAAAGGGGGT AAATCTGGTT TCTTCTCTCT TTGTGCTTTG AGGTGGATGT
14951 GCCCTGGGCC ACCTGATTTT AGAGAGTCTT TGCCGCGGTG CACGATGTCC
15001 AGTCACCTGG AGCTTGGCAG CAGGTGGCAT GTGCACCTGT CCGCAGCCTG
15051 CAGCTCTGCC GTCCCACCTG CTTATGCTGC CACATAGCAT TTATGTCTGT
15101 GTTGTGTTTC CCAGAGTGCA GAGTGAGGAC TGTGGCCCGG TGGGGGCGTC
15151 TCCTGCCCTC GGGATGTCTG CCCAGTAAC CTGGAGGCAG CCGCGCTACC
15201 CCACACTCGC CGGGAGCAGG GTCFCGGACG CACCTCTCCT TCTCTCCTAG
15251 CTCGCAACGC CCTGGTGGTC TCCTTCGCAG CCCTGGTTGC GTACTCCTTC
15301 GAGGTGACTG GATACCAGCC TTTTATCCTA ACAGGGGAGA CAGCTGAGGG
15351 GCTCCCTCCA GTCCGGATCC CGCCCTTCTC AGTGACCACA GCCAACGGGA
15401 CGATCTCCTT CACCGAGATG GTGCAGGTGG GCGGAGCCGG GAGGCAGGAT
15451 GGCGTGGCTG AGGCTGCAGT GGCCCTGGC CTGGCTCCTA CCCTGATGTA
15501 TCTGCTGGGT GCCAGGGGGT CTGAGGTCAG TTAGGACAGC TGAGTCTCTA
15551 GGAACGGACA TCTCAGTTAT TAAAGAATCC CAGGTTGGAT GCAAACCTAG
15601 CGAGCTCAGG GATGTCACGT TTGTGTTTCT GGGCGCTTCT CCTGTTTTGG
15651 ACTCCAGCTG AGGATGAATT TACCGTGTTC CTCCCAGCAC CTGGCGCCTC
15701 TTCAGACAAG GAGGCGGATC CTGCAGCTGA CAAGCACTTG CTCCTGTTAC
15751 CTGTGGGGCG GGGTGGGTCC TTGCTGCTTT CATGGGTAC TGCTGGGTCC
15801 TACCCCTTAG GAAGGTCACT CACCATCCCT CTCTCCTCTC TCAGGACATG
15851 GGAGCCGGGC TGGCCGTGGT GCCCTGATG GGCCTCCTGG AGAGCATTCG
15901 GGTGGCCAAA GCCTTCGGTA AGACGCCTGT CACCCACACC CCAGGTCTCC
15951 CAGTGCGCCG GCTGGGCTAG GCCTGCCTGC TTTCTAGCTT GCCTTTATCC
16001 GTTACTAGTT TTAGAAATTT GAATTCATAT CCAAGTAATA CATGCTCATG
16051 ATAGATACAT ATGTATTGTG TATATATGAT AAAACTGGAT CTATAATGAG
16101 GCATGCCCTC CCACCCCATG GTGTGCTGGT GAGTGTGTGA ACAGCCTCTG
16151 CTGTTTGTGG AAATAAAGG TTTTGTCTCG TGGCCCTTGC CGATGTCCAC
16201 GGTGTAAACG CTGCTGTCTG ATTTTAAAGT AACGTCACTG AAAGGGGAGT
16251 TTGCACATGG AGCTGGGTTG AGATCTGCAT GAACAATCAT ATTCTATGGT
16301 GTCTCCACCA TGTAGATACA GTGGGTGCAA ATAACCTCAT CAGTAGTAGC
16351 CAAATGCCAA ATAAATTAGG AAGTGATGAG TTTTAAAGTAT TATCTTTGGG
16401 CCAGGCATGG TGGCCAGGC CTGTAATCCC AACACTTTGG GAGGCTGAGA
16451 CGGGAGGATC GCTTGAGCTC AGGAGTTTGA AACCCACCTA GGCAACGTAA

```

16501 CGAGACCTCG TTTCTATTAA AAATAAAAAAT TAGCTGGGCA TGGAGCACAC
16551 CTGTGGTACC AGCTTCTCAG AAGGCTGAGG CAGGAGGATC ACTTGAGCCC
16601 GGGAGGTCSA GGTGGCATTG AGCTGTGATA GTGCCACTGC ACTCCAGCCT
16651 GGGCAGCAGA ACAAGATCCT GTATTATCTG TTTAATTGAA AGTTTAAATT
16701 TAATTGGTAA TAATGGCTAT GTTTAGTAAT AGGCTCACAA AACTCCTAAA
16751 CATTACAGCA CATGCTTTAT TCAGCTGGCT CAGCCCATCG GCCAGCCCCT
16801 CCTCGCCCCC AGGGAGGCAG GGAACCCCTC GTCTCCTTCA GTGTCTGTTT
16851 TGAGTCAGCA TCTCTAGATT CCCCTCCTTG AGCTCCGTCC TTTACTCGCT
16901 CCACTCCTGC CAGCTTTGTA TTGTCTGTGC GGATGACACC TTCGTCTGT
16951 CTTGTACCCG TCATTTAGTC CTCTTGCGT TTGGGTTTAT GTTGATTCTA
17001 AAGGTTACAG CCCAGTTACC AGTGTATGTT ACTGTGACTG TGTAAATCGT
17051 GTTTACTGCC TAGCCAGGC TGTGCCAGG TAAAGTTCCT TCTCCAAAGT
17101 CCCAGTGCTC TAACCCCTTAC CCCCTTCAA GGAGTTTTTT TTGTTTTTTT
17151 TTTTTTTTTT TTTTGGAGA CAGAGTCTCA CTCTGTGGCC CAGGCTGGAG
17201 TGCAGTGGCA CGATCTCTGC TCACTGCAAC CTCCGCTTCC CAGGTTAAG
17251 CAATTCTCAT GCCTCAGTCT CCCAGGTAGC TGGGAATACA GGCATGCGCC
17301 ACCACGCCCA ACTAATATTC TATACTTTTA GTAGAGACAG GGTCTACTA
17351 TGTTGGCCAG GCTGGTCTCA AGTGATCTGC CCACCTGGGC CTCCCAGTAA
17401 TTTTTTTTTT TTTTTTTTTT GAGATAGTGT TTCCTCTTG TTGCCATGC
17451 TGGGTGCAAT GGTGTGATCT TGGCTCACCG CAACCTCCGC CCCCAGGTT
17501 CCAGCAATTA TCCTGCCTCA GCCTCCCAAG TAGCTGGGAT TACGGGTGTG
17551 CACCAACATG CCTGGCTAAT TTTGTATTTT TAGTAGAGAT GGGGTTCCTC
17601 CATGTTGATC AGACTGGTCT CAACTCCTG ACCTCAGGTA ATCCGCCAC
17651 CTCAGCTCC CAAAGTGCTG GGATTACAGG TGTAGCCAC CATGCTCAGC
17701 CCTCCAGTAA TTTCTTTTTT TTTTTTTTTT GAGACGGAGT CTCGCTCTGT
17751 CGCCCAGGCT GGAGTGCAGT GCGGTGATCT CGGCTCACTG CAAGCTCCGC
17801 CTCCTGGGTT CAGGCCATTC TCCTGCCTCA ACCTCCCGAG TAGCTGGGAC
17851 TACAGGCGTC CGCCACCACG CCCAGCTAAT TTTTGGATT TTTAGTAAAA
17901 ACGGGGGTTT CACCGGGGTT CTCGATCTCC TGACCTCGGG ATCTGCCCTG
17951 COTTAACCTC TCAAAGGCTC GGGATTACAG GCGGGAGCCC CTGGGCCCCG
18001 GCGTAATTT TTTAATGGAA AAACAAGGGC TCACTTTGGG GGCCAAGGCT
18051 GACCTCAAAC TCCTGAGTTC AAGGGATCCT CCTGCCTCGG GTTTNNNNNN
18101 NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNTGCTCT
18151 GGGCTAATTT TTGTTTTTTT GTAGAGAGAG TATTTGCCAT GTTGCCAGG
18201 CTGGTCTCGA ACTCCTGGGC TCAAGCGATC CTCCTGCCTT GGCTCTAAA
18251 AGTGCTGCGA TTATAGCTGT GAGCCACCAT ACCTGGCCTG ATTACATGGT
18301 ACTGTACCTC TTTCCACTCT GTGATACATT CAAGCACATG TTTACACGCA
18351 CATATATGTG AATATTTTAG GTGTGTATTC TTAGATTAC AAACTTATT
18401 GCGGTGTGTA GAAATTCATA ATCTGTGTTA CATTTTGTGA ATACTTTTG
18451 AGCGATGTTG AATATTACTG ACCAGGTCTT TACCGTTGGT TCCCTGTAGC
18501 ATCTCAGAA TATTACCGCA TCGATGCCAA CCAGGAGCTG CTGGCCATCG
18551 GTAAGACCCC AGCCGCGGGA AGGAAGACAC CAGCTGTGGG CCTCCAGGGT
18601 CCCAGGCCTG CCCCTCTGTG TCTCTGCAT TGTAGGAAGA CCATGATGGT
18651 GGTGATGAAC TGGGAGGGCA AAGGTGGCCC CAGATGGGAT CTTCTGGAAT
18701 ATTTAGTTTT GTTTGGGTT TTTGAGATGG AGTCTCACTC TGTGCCCAG
18751 GCAGGAGTGC AGTGGCACGA TCTCGGCTCA CTACAACCTC TGCCTCCTGG
18801 GTTCAAGTGA TTCTCCTGCC TCAGCCTCCC AAGTAGCTGG GATTAAAGGC
18851 ATATGCCACC ATGCATGGCT AATTTTGTGA TTTTGAGTAG AGATGGGGTT
18901 TCACCATGTT GGCCAGGCTG GTCTCGAACT CCTGACCTCA AGTGATCCGC
18951 CCGCCTCAGC CTCCCAAAGT GCTGAGATTA TAGGCGTGAG CCACTGCGCC
19001 TGGCCTATGC CTTGTTATCT TAAACCTTGA GACTCAGAGT GTGGCCTGGG
19051 ACCAGCAGCC TGGGCACTGG GCATCTCCTG GGAGCTTACT GGAAAGGCAG
19101 GATCTCAGGC CCCACCCAG ATCTCCGAAT CAGGATCTGT ATTCTTCAGG
19151 GCACGCCCAG GGGATTCATG GGGTCAGCTT AGAAGTCAA GTTTGGAAGC
19201 CGGGCATGGT GGCTCACGCC TGTAAATCCCA GCACTTTGGG AGGCCGAGGG
19251 AGGCAGATCA CCTGAGGTCA GGAGTTTGAA ACCAGCTTGG CCAAACCCCG
19301 TCTCTACTAA AAATACAAA ATTAGCTGGG TGTGGTGGTG TGTGCCGTG
19351 ATCCCAGCTA CTTGGGAGGT TGAGGCAGGA GAATCACTTG AACCCGGGTA
19401 GGCGGAGGTT ATAGTGAGCC AAGATTGCAC CACTGCACTC CAGCCTGGCA
19451 ACAGAGCGAG ACTCCTTCTC AAAAAAAGT CAAAGTTTGG
19501 GAAATGCTTA GAGACCCAT GTTTTTCAAA GACTTGTTTT GTATGACTTT
19551 ATGAGATGAT CAAGCAGGTT TGGCCACAAG GGGAGACAGC CAAAGGCTCA
19601 GGAAGATAAC CAGTTTTTTT TTACTCAAAG GTCCCTTAGT TACCAGGGAG
19651 GCCACAGCAT GCCTACTTAG GCCCATGTCA GAGGACACCA GGGGTGTCCC
19701 CGGAAGGATA AATCCCAATC TGTGATTTTA GGCCTCCGCC CTTTTTCGGG
19751 AATTTTCTTT GCTTAATGCT AATTTCAATA AAGGCCCCCG GCTTAAGACT

```

19801 TTTCATATGT TATTAATTTT AGGCGGGTTC TAACTCCTTA ATGAAGAAAT
19851 ATTCTCCCTT CCCTGGATTT CCGAATCACA CCATTCTTTC GAGAAACGCC
19901 TCCCACNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN
19951 NNNNNNGTTT TTTTTTTGGG CACCCGCCA TCATCTGGGG AGGCAGCATT
20001 AAGGCCCATC ACTTTGCCCT TCAATGTGAC TGTCTCTTTT TTACACGAAA
20051 AAGTTTTTTT GTGGAACCC GGTGGTGGC CCCATTACCT CCTGAGTGCC
20101 TAGGGTTTGT GTTCCGGGCC ATTTATCTCA GCTTTCACCC CCTCCTGGAT
20151 GGTAAGATGC TCCCTCTGT TCTGGTGGG GAAGCGGGT CCTGGTCCCA
20201 CAGGATAGAT TGGGTTCAA GTGTTTCTAGA GCTAGGATCT CTTCAGGCT
20251 CTCGTGGGTC ACTCCTGTTT CCCAGCACTT TGGGAGGGTA AGCCGAATGG
20301 GTCACCTAAG GTCAGGCATT TGAGACCAGA TTGGCCAGCA TGGCACACTC
20351 CCTGTGTGCT ACTAAAATA GAAAAATTAC ACTGGGTGTG GTGGCACATG
20401 CCCGTAGTCC CAGCACTTTG GCAGGTTCAA CCGGTGGAT CACTGAGGTC
20451 AGGAGTTTGA GACCAGCCTG GCCAACATGG CAAACTCTG TCTGTACTAA
20501 AAATACAGAA ATTAGCCAGG CGTGGTAGTG TGTGCTGTA ATCCCAGCTA
20551 CTCAGGAGGC TGAGGCAGGA GAATCGCTTG AACTGGGAGG CGGAGGCTGC
20601 AGTGAGCTGA GATCGCGCCA CTGCATTCCA GCCTGGGCAA CAAAGCCAGA
20651 CTCTGTCTCA AAAAAAAAAA AAAAAAAAAA AAAGGCTAGG CTTTACGTCT
20701 GCAAGATGT GGCCTGTTTT CTTCCTTCCC TGAAGGAGTG CGTAGGCCCA
20751 GGCCCCCAGG ATGATTCTCC CGAGCCCTGC CTTCCTGCTT CCTTCTGGG
20801 TTTTGTGCC CCTCCCATC TCCTTTCCCT CCATCCTGTG TGCCTTCCCT
20851 CCACGATCAG CCTGTCTTGC CTCCTCCCCA GGTCTCACC ACATGTTGGG
20901 CTCCCTCGTC TCCTCCTACC CGGTACAGG CAGCTTGGG CGGTGAGTGA
20951 CATGTCCGCC TCTTCTGTTT GCCCAGTTG GACGCTTAA CGTTGTTACG
21001 CTGACAAGGA GTCTGCCTGC CCTGACCCG GCGCCCGTC CTCCTACTGT
21051 AACGCTCCGT GGAGAGGCAG GGCCTGGGGT CACCCACTGT CCTCCAGGGT
21101 GTTCTCTGTT TCTTTATTCT CATAGATCGT CCTGCAGTTT CATACTAGAA
21151 AGTTCCACTG GGCATTGTGG TACACCCTTG TTATCCCAT TACTCTGGAG
21201 GCGGAAGCAG GAGAATCGCT TGAGCCAGC AGGATGAGGC TGCAGTGAAT
21251 TGTGACCGCA CCGCTGCACT CCAGCCTGGG CAACAGAGCG AGACCCTGTC
21301 TCTAAAATAA ATACTAGAAA GTTCCCAGCA CGCCAAAGCC CTCCTAGCTC
21351 CTGGTGCCAG AGTCAATTCC TGAAAGGACG TGGAGATAGG AAGGGCCTCG
21401 GCTCTGTCTT GAAGCAGCCG GGCATGAAGC TTAGCCAGA TGCCCTACGG
21451 CCCCTCCTCA GTCAGGACAA CAGGATGGAG GTGACCTGTG GCTTAAAGGA
21501 GAGAAGGAGG CGTCCCTGG CACTGCCAG TCCCCAGCT GGTGACCCTT
21551 GGCCTGCTGG GTATGGGGGC CCCACCTGGA TGGGGGCAGG AGACAGAGTC
21601 GGCAGGAACC TGAAAGGACA CGTGCTTCTT GAGCTTCTTC CTATAGTCAG
21651 GGTGGCCCAA GCGCGGCTGT CTGTGACTGC ACCCTAAGTC TCTTTGCCTC
21701 GGTCCCCTTG CAGTCCCCGC CTGCTTCCCA AGCCGTGCTG GGAGCTGACG
21751 TCCCCTCGGA AGATCAGCCA CAGGAGTGTG GACTGAGGTC TCCCTTTTCC
21801 CGGCCCTGG TGA CTGACGG TCTCTGTGTT GCCTTCCAGG ACAGCCGTGA
21851 ACGCTCAGTC GGGGTGTGTC ACCCGGCGG GGGGCTGGT GACGGGTAAG
21901 GCCCCCATC TTCCCCTTGT GCCCGCAGCC CTGAGAGTGG GAGAAAGGGA
21951 GGAGGGGGCC CACAGAGACG TCCCTTTGGC TCATGGGCGG TGCGCCCCGG
22001 GACTGCACAG GGACTTGGGG GGCCACACAG GAGTAGGGGG ACCACAGGAG
22051 ACTGAGCAGG GGCTGGGGGC CTTGGCAGTC GTCGCCCTAC CCCCACCCCT
22101 GTCCCCAGTG GGCTCTGCTG AACAGAGGC TGCTACGCTG CGTGCTGGGG
22151 GGACCCTGCA CTCGCCAGGT CACCTGTGTT CCCGTGCCCC GCAGGAGTGC
22201 TGGTGTGCT GTCTCTGGAC TACCTGACCT CACTGTTCTA CTACATCCCC
22251 AAGTCTGCCC TGGCTGCCGT CATCATCATG GCCGTGCCCC CGCTGTTTCCA
22301 CACCAAGATC TTCAGGACGC TCTGGCGTGT TAAGAGTACG TCCTTGTCTT
22351 ACAGGGGAGA GCGCTGTGAT GCGGTGTCTG AACCGGAGG GTGTCAATTA
22401 TGCTACCCCA TTTTCTCTGCA GCCCCTCTG TGGGGCTGGG ACTGGGAAGT
22451 TAGGGCAGTC CCGGAACAGA GAAGTGGATG GCCAGGAGAT GGCCCCAGAG
22501 ATGGTCCCGA GGCTCAGTGG GAAGAGCTGG AGCTCCTTGT CCTGACACCT
22551 GGGGTCTTGA GGCAGCACT GACCCGGGGG AGGGTCCCCCT CCTGATCCCC
22601 CTGCCCCCAT CCTACCCCTC CTTGCCACCC GCCTCCAGCC ACCACTCTGC
22651 CCGGCCCAGC TGGGGGGAGG GACAGGAGAC GTCCCTGGTG ACCAGCAGGG
22701 CCAGCGGAAC AGCCTTGCAC CCTGGCTCAG AATGGCAGTT CCTTTTTTTT
22751 TTATTATTAT TATTTTATT TTTTATTATT GATCATCTT GGGTGTCTCT
22801 TGCAGAGGGG GATTTGGCAG GGTCTATAGGA CAATATGGGG TTGGGGGTAA
22851 GGTACAGAT AACAGGATCC CAAGGCAGAG GAATTTTTCT TAGTGCAGAA
22901 CAAATGAAA AGTCTCCCAT GTCTACTTCT TTCTACACAG ACACAGCAAC
22951 CATCCGATTT CTCAATCTTT TCCCCACCTT TCCCCCTTT CTATTCCACA
23001 AAACCGCCAT TGTATCATG GCGCCTTCTC AGTGAGCTGT TGGGTACACC
23051 TCCAGACGG GGTGGTGGCC GGGCAGAGGG GCTCCTCACT TCCAGTAGG

23101 GGCGGCCGGG CAGAGGCGCC CCTCACCTCC CGGACGGGAG CAGTTCCTTT
 23151 AACTTAACAC ATTTTGTTTT GTTTGTGGAA GAAGCATGGA GTGGGTCAC
 23201 CTAGCTTACT TGGCATTTTC TGGTTAGCCC CAGCAAGTTG CCAGGTGAAA
 23251 GGATGGATAA TTTCTTGCA TGCCCGTCGC ATGCCAGGGC CTTTCGCGTG
 23301 CCAGTGCGCT GGGGCTTTAG AACAGCCCTG AAACGTGTTT ATGTGCCGGC
 23351 GTGGAATGGG ATGGCCGCTG CTGCTAGAAA CCAAGGCTCA GCCAGGGTGG
 23401 GGCAGGCCCTG ACCTATGCGT GCGGTGGAAT CCCCCACAGG GCTAAGCCCG
 23451 TGCACTTTGT CCCCAGGGCA CCTTCTCCTT GGCCAGGTCT CAAGGGCTCA
 23501 CGTGGTCCCT GCCCCACTCC TCAGGCCAGC TCTGTGCCCT GACAAGCCCC
 23551 TGCTGCTGCC CTCCCTGAGG TTGGAGGCCA GGGACCGGCC GGCAGGTCTC
 23601 ACCTGCGCTC AGCTCAGATG GGGAGGGCAT TTCTTTCTTT CGACTTGAAG
 23651 CATGGCCTGG TCAGCAGCTG CTGTCCCCAA GTCCTCAGGG GCTGCTTGGG
 23701 GTCCATGAGC ACCTTTACTC ATATGTGGGG GGCAGAAGGC TGTCCCGCTG
 23751 GTCAGCAGGG CCATGTTGGG GCCTCGGGCA GCTGCCGGGC ATTCTCAGC
 23801 TGTGCCCTTC TCCTAGGGCT GGACCTGCTG CCCCTGTGCG TGACCTTCCT
 23851 GCTGTGCTTC TGGGAGGTGC AGTACGGCAT CCTGGCCGGG GCCCTGGTGT
 23901 CTCTGCTCAT GCTCCTGCAC TCTGCAGCCA GGCCAGAGAC CAAGGTACCC
 23951 CTCCGTGGCC TCTGAGTGGG GAGTGTGCTG GGGGCAGGAT TCCTGGGCAT
 24001 GGTCTTATGT TTTGAGGGTC CGGGTGATT GTGGTCTGG GTGCTGCTGA
 24051 AGGGGACCGC TCGCTGGCAG GTGGGCAGTC ACCTTGCTAT AAACCATGGT
 24101 GTTCTCCAC TGTGTGGGGG CCGTGGGGGT CTCCCCTTAG CACCCCTCTC
 24151 CCGGTCCCTT GCAGCACGCT AGGTTGGGTG GGGGCTTCCC GCTTGGGACA
 24201 EGCCAAGCCT GGTGGAGGCC ACCCGGTCAG ACCCGCCTCC AGGACTCACT
 24251 CCTCCCCACA GGTGTCAGAG GGGCCGGTTC TGGTCTGCA GCCGGCCAGC
 24301 GGCCTGTCTT TCCCTGCCAT GGAGGCTCTG CGGGAGGAGA TCCTAAGCCG
 24351 GGCCCTGGAA GGTGCATGGG CGGGGGTCAA GGTGGTCTGA GGTCACTCCC
 24401 CTGTCTCTTG CCCCCACTC CCTGTGTGTC AGGACCCCAA GACCCTGTCC
 24451 CCGACGCTCT CCACTCCACA AGGATGCAGG CATCTCTGAG TGGGCTGGAC
 24501 CGTCTCTGT GGGCCTCAGC CAGTGGCTGC TGCAGCAAGG GTGGTGGCTC
 24551 CCCACATATC ACTCCTTCCC TGCCCCATAA GTCCGGTTCC TGTTCCTGGG
 24601 GGGTTGATTT TAGGGGAGCT AAGGGCCTGT GAGTCTTAGG AGGGAAACAG
 24651 CTGCTGCTGT CACCAAACAA TTGTCTCTGG TCCTGCCACC CGAATCCCCC
 24701 AACTGGGCGA CTCAGCCGCC ACGAGATGGA GCACTCTGGC CTCTCTGTCC
 24751 CCTGCCCCTG GCCAGAGCCT CCTTTGGCCT CTGCAGAGCA GCTTTGGGCT
 24801 GCTCTGGGTG GCCTGACCTG GCTCGGGCCT GTCTCCCCAG TGTCCCCGCC
 24851 ACGCTGCCTG GTCCTGGAGT GCACCCATGT CTGCAGCATC GACTACACTG
 24901 TGGTGCTGGG ACTCGGCGAG CTCCTCCAGG ACTTCCAGAA GCAGGGCGTC
 24951 GCCCTGGCCT TTGTGGGCCT GCAGGTGGGT GTGCACTGGG ATGCCTTAGG
 25001 GGTTAGCAGC TGCCGGAAGG CCTTCTGTG CCTGCCCTCC ATGGCGAATG
 25051 TGACATCTCT GGGCTGTGAT GCTGGACGGC CCTTCGGCCG GTGCTGGCTC
 25101 TGCTTCTGAT TTAAACAGTT CTTGTCCCCA TCTGGCCTTC CTCGTCCCTC
 25151 CCTGTGGAAG GGGGAGCGGT GGCCCCAGC CCTCCGAGGG GTCACGTTAT
 25201 GGCTTCTGGT CACTGCCACA CTGTCTTTG TGCTGGGGAC ACACAGTGAA
 25251 CGAGGGTCAG TCCCTGCTCT CAGGGGAATT GTATTTTAGG AAACAAAAAG
 25301 AGACAGGTGA GGCTAGGCGT GGTGGCACAC TCCTGGAATC CCAGCACTTT
 25351 GGGAGGCCAA GGCGGGCAGA TCACCTGAGG TCAGGAGTTC AAGACCAGCC
 25401 TGGCCAACAT GGTGAAACCC CGTCTCTACT AAAAATACAA AAAAACTAG
 25451 TCAGGTGTGG TGGCAGCGC CTGTAATTCC AGCTACATGG GAGGCTGGGA
 25501 GAATCGCTTG AACCTGGGAG GTGGAGGTTG CAGTAAGCCG AGATCCCACT
 25551 ACTGTACTCC AGCCTGGGCG ACAGAGTGGG ACTCCATCTC AAAAAACAAC
 25601 AAACGAAAAA AAACAGGTGC TCATAGAATT TCATGAAAAA CGTATTGTCA
 25651 GGGCTTCCAG AGGCTGAAGA CGGGTTCTA TGGAGGCCGT CCTGTTCAGA
 25701 GCCGCAGGTA AAGTGTAAAG GCTGGSTCCC AGGCCCTGCG TCTTAGGCCT
 25751 CACCTAGGAG CCTTCTGAGC ACTGCAGGGT CAACATCCCA GGGGTGTGGC
 25801 CAGTGTGTTG AGAGAGGCAG GGGTCTCTGT TGCTGTGGTT AAATGTGCGC
 25851 TCTCTGCCAA GTCCTAGATG GCAGAACGTG GGGGACTAGG GCGTGTCCCC
 25901 AGGCGCCCAG AGGAGACATT CATGAACTAG CCATGGAACA GGAGGCCAAG
 25951 TGACCCGTAT ACCCCAGGTG TGGACCACAG CCGACCCCTG TCAGAGTTTC
 26001 CTTCAATCCC AACCTGGCCC ACGAGGCTAG TGTATCTCTC ATCCCCATGT
 26051 CCAGAAGAGG TCACTGAGGC CCAGAGAAGC CAGGTAATCT GCCACGGTC
 26101 ACACAGGATG GTGGGCCAG CTTCAGATTT GGGCATGTGC CTTCAGAACT
 26151 TCGCTCATAA GTGTTACGTC CTGTGTCATA TTTGCAGAGC ACATGTCTTC
 26201 ATGGTCTTTG GAGATGATTC ACTTAAAAAA ATACTCTCTC GACCCAGACA
 26251 TGGTGGCTCA CACCTGTAAT CCCAGCACTT TGAGAGGCCG AGGCGGGAGG
 26301 TCAAGGGTTT GAGACCAGCC TGGCCAACAT AGTGAAACTC CGTCTCTACT
 26351 AAAAAATACAA AAATTAGACG GGCATGGTGG CGCACGCCCTG TAATCCCAGC

```

26401 TGCTCAGGGG GCTGAGGCAG GAGAATCGCT TGAACCCGGG AGGCAGAGGT
26451 TGCAGTGAGC CGAGATCGCG CCATTGCACT CCAGCCTGGG TAACAAGAGT
26501 GAAACTCCAT CTCAAAAACA AACAAACAAA CAAACAAAAA STCCTCTGGG
26551 CCAGGCGCTG TGGCTCACAC CTGTAATCCC AGCACTTTGG GAGGCCGAGG
26601 TAGGAGGATC ATTTGAGGCC AGGAGTTTGA GACCAGCCTG GGCAACATGA
26651 CGAAACCCCA TCAAAAAAAT AGGAAAAAAT AGCTGGACGT GGTGGTGTGC
26701 ACCTGTAGCT ACTCAGGAGG CTGAGGTGGG AGGATCACTT GAGTCTGGGA
26751 GGTTGAGGCT GCAGTGAGCC ATGATCGTGC CACTGCACTC CAGCCTGAGC
26801 AATGAGCAAG ACCCTGTCTC AAAAAACAAA AAATTTAAAA AAAAAAATC
26851 TTCCTCTGAC AGCATTCCCC TGGGGCTGCG TTTCTTCTCA CCATTCACTG
26901 GTATGGAGGT GAAGCCATAC CTCTCCGGGA GACTCTGAGA TGGCATGTCT
26951 ACCAGGCTGC CGACCCGTGT GCTACAGAGG AACATCCCTG CCCTGGCTAA
27001 AGTCTGTCTG TCTCTCAGGT CCCCGTTCTC CGTGTCTGCT TGTCGGCTGA
27051 CCTGAAGGGG TTCCAGTACT TCTCTACCTT GGAAGAAGCA GGTGGGCACA
27101 GTCAGACATC CTGTGGCTTT GGTGATTTTG TAAAAATCAT AAATGCTTAT
27151 TGTA AAAAAT ATGGGAAACC AGCTGGGCAC AGTGGCTCAT GCCTGTAATC
27201 CCAGCACTTT GGGAGGCCGA GGCAGGTGGA TCACCTGAGG TCAGGAGTTC
27251 GAGACCAGCC TGGCCAACAT GGTAAACCTT CATCAGTACT AAAAATACAA
27301 AATTAGCTG GGTGTGGTGG CATGCACCTC TAGTCCCAGC TATTCGGGAG
27351 GTGAAGCAG CAGAATCGCT TGAACCCAGG AGGCAGAGGT TGCAGTGC
27401 CGAGATTGTG CCTCTGCACT TCCAGAGTAG GGTGAGAGAG CTAGCCATGT
27451 TGTCCAGAAA ANNNNNNNNN NNNNNNNNN NNNNNNNNN NNNNNNNNN
27501 NNNNNNNNN NCCTGGTTGA GCAGGTATAA TCGCTTGCAA CCCAGGTAGC
27551 AGCAGTTGTA CTGAGTCCGA GAATTGTGCC ACTGCACTCC AGCCTGGGTG
27601 AGAGCAGCGA GTACTCTGTC TCAAAAAAAA AAAAAACAAA AAAAACAGGA
27651 AACCACCTCC ACCCCAGTCC ACTTTGGTGA TCACTCCATA CCCCTCCCCT
27701 AAACACGCAT ATGTACCTGC CTGTCAAGAT GTGGATATAT GTTTGCGGTT
27751 TTACGTAAAT GGGACCATTT CATACCTGGT GCTCTGGAAC CCACATTTT
27801 CATGCAGAAG GTTGAAGGA TGTCCTTCCA GCCGAAAGTC CACATCCCGG
27851 GGGATCAGGA CAGAGCAGGG CCGGCTCAGG AGATCCAGAA GCCCCGGGAC
27901 AGAAGGTACG GGAGGGACAG GAGCAGGGTG GCGGCTGACC CTTGAGACAG
27951 CAATCGCAGG AGTCTGAGC CGCAGCAGGT GTCAACAAGA GGATGGGCCA
28001 GAGATGCAGA GCATCCACCC CAGGCCACAC AGCAGTGGCC AGAGGGTCCC
28051 AGGCCCCAGT GCTAGGCCTC TTCCTCTTCC ACTGAGGTCA CAGCTGAAGC
28101 TGGGTCAAGT CCGTGAGAGT GAGGGGTGGC GGATGTTGTA CTGACTTCCT
28151 TGGCTCAATG TGACGTCAGG GAGATTCAAC CATGTTGTTG TAGAATCAGC
28201 TCAGATGCAG TGCACTGGAG GTGGATAAGC AGAATGTGGC CTGGCCGTGG
28251 GATGGGAGGG TACCCTGGAG CAGTAAGAAA GGGCCGTAG TCACCTGAAA
28301 AATACGCTTA CAGAGACTCA GGTGAGACCC TCATGGAGTT AGTGACACTG
28351 GCGTGGGTGG CCCACAGCTC CTTCCTGCAC ACCTTCCAGG ACTCTGGAAG
28401 GCCCTCCTTA ATCCCTTCCT GTGAAGTAC CCATCCTCAC TTCTGAGCTT
28451 TTAGTGCTTG AACATTTAT TGTATTTTCT GCAGAGAAGC ACCTGAGGCA
28501 GGAGCCAGGG ACCCAGCCCT ACAACATCAG AGAAGACTCC ATTCTGGACC
28551 AAAAGGTTGC CCGTCTCAAG GCATAATGGG GCCACCCGTG GGCATCCACA
28601 GTTTCAGGG GTTCCGGAA GGTTCCTGTC ACTGTGATTG GATGCTGGAT
28651 GCGCCTGAT AGACATGCTG GCCTGGCTGA GAAACCCCTG AGCAGGTAA
28701 CCAGGGAAGA GAAGGAAGCC AGGCCTGGAG GTCCACGGCA GTGGGGAGTG
28751 GGGCTCACTG GCTTCCTGTG GGATGACTGG AAAATGACCT CGCTGCTGTT
28801 CCCTGGCATG ACCCTCTTTG GAAGAGTGGT TTGGAGAGAG CCTTCTAGAA
28851 TGACAGACTG TCGAGGAAG CAGGGGCAGG GSTTTCCAGC CCGGGCTGTG
28901 CGAGGCATCC TGGGGCTGGC AGCACCTTCC CGGCTCACCA GTGCCACCTG
28951 CGGGGGAGGG ACGGGGCAGG CAGGAGTCTG GGAGGCGGGT CCGCTCCTCT
29001 TGTCTGCGGC ATCTGTGCTC TCCGAGAGAA AACCAAGGTG TGTCAAATGA
29051 CGTCAAGTCT CTATTTAAAA ATAATTTTGT GTTTTCTAAA TGGAAAAAGT
29101 GATAGCTTTG GTGATTTTGT AAAAGTCATA AATGCTTATT GTAAAAAATA
29151 CAGGAAACCA CCCTCACCC TGTCCACTTG GGTGATCATT CCAGACCCCT
29201 CCCCAAACAT GCATATGTAC CTGTCCGTCA GTGTGTGGAT GTATGTTTAC
29251 AGTTCTACAT AAATGGGATC ATTTTATACA TGGTGCTCTG GAACCCACAT
29301 TTTTCATGCA GTCATTTGCA GTGAATTATT TATTGTGATA ATAAATAGCA
29351 TTAGAATACA AGATTTTAA TGTCTGCGTG GTATTTTGGT CTATATATGC
29401 ATCATAATTG ACTTACCGAG CCCTCTGTTT AACGTGTGCG TGGGTTAGAG
29451 ACGGGATCGT GCCTCCTTTA GATGTGTCAG TTGAAGCCCT TGCCCTCTAT
29501 GTGACTGCGT TTGGAAACAG GGCTTTTAGG GGGTAACTAG GTTTAATGAA
29551 GGTCATAAAG GTGGGCCCTG AACCGATAGC TTTAGTGTCC TCGTGAGAAG
29601 AGACGCCAGA GAGCTCGTTC TCTGCACCC CACACCCAG GGAAGTCCAT
29651 GAGAGGACAC GGCAAAACCA GGCCATGCGC CCACCAGGAA GAAAGGCCCT

```

```

29701 ATGAGGACCC CAGCCTCCAA AACTGGGAGA AGATGAATCT CTGTGCTAGG
29751 CCCCAGCAGCC TGGGGTGATC TGTGACGGCG GCCTGAGCAG GTGAGGACTG
29801 CCTGCATGTT TGTATTTTAA TGAATGCTTT GATTGAGTCT GGGGGTAAAT
29851 CCCTGGAGGC CTGTGGCAGC CTCAGAGGTG TGTTCCTCCT GCACCTTCTT
29901 CAAGAAGAAT GTGGCCTGCC CTGCTGAGCC TCGTTCGCCC CGTTCGCCC
29951 GGGCAGTCCC GGCCAATGTC AGCGCAGCAA GGGGAGGGCC TCTGTAACCA
30001 GGGCTGCTGG CTGCGGGGCT CCCCACTGGA CACGGGAGCG GACATTGGAG
30051 TGTCTTTCAT CCGCGTCACT CTTCAGGTG CCTTGCTCC CATTTTCCTT
30101 CCTTCCTTCC TCTTCTTTC CTTCCTTCTT TCCTTCCCTT GCTCCCTTCC
30151 TTTTCTTTC TCTTCCGTT TTTCTTCTT TCTTCTTTC CTTTCTTTC
30201 TTCTTCCCG TTCTCCCTT CTTCCTCCT CCACCCCTT CTTCTCACTG
30251 TGTTCCTCAG GCTGGTCTT AACTCCTGG CTCAAGCAAT CCTCTTGCCT
30301 CAGCCTCTGG TGTGGCTGGG ACCACAGACA CATGCCACCG CGCCAGGCTA
30351 ATTTGTTAAT TTTTTTTATA GAGACAGGGT CTCACTTTGT TTCCAGGCTT
30401 CGTCTCAAAC TCCTGGGCTC AAGTGATACT CCAGCTTCAG CCTGAAGTGC
30451 TGGAATTAAG GTGTGAGCCA CCAATGCCTG CCTCTCTCA TTCACAAGTG
30501 AACCGTTCAC CCTGCGCTC CAATCCATGT CGTTTCTGAC CTCAGGCAGC
30551 TTCTCTTTC ACATAAAGTG AACCTGTCCC AAAGCTGTGC TCACTGGGCC
30601 CCCCTGCCAG GGCTGGAAGA GGCAGCAGTT CACATTGCGC TTGCACTCAC
30651 ATACCAAGGG CATCCATGCT TGAACCTAGA CATGGTTTCAT TCACAGGGAT
30701 GGGTGAAGGT AAACAGACTG TGGCGGGCAC TAGGCACTAT CAGTTTCATA
30751 AATCTGCATA CCACCTGTGA CTCAGCAGTT ATGCTTCTCG GAATCTACTC
30801 AAACATGCTT GAGTCAGCCT TCCAGGAAGC AGGCACAAGG ACGTTTGTGA
30851 CAACTTGGTC AGTAATTTTA AGAAGTAGGA AGAAACCTGA GTTTCCTCTGA
30901 ATTCGGTAAC ATCTTGACTG TAGGACACAC GAATAATGCC GTGGAATATT
30951 GTGCAGCAGT TAAAAGAAAT GAGGTGAAGG CCGGGTGTGG CAGCTCACGC
31001 CTGTTATCTC AGCACTTTGG GAGGCCGAGG CTGGTGGATC ACTTAAGGTC
31051 AGGAGTTTGA GACCAGTCTG GCCAACATGG CGAAACCTG TCTCTACTAA
31101 AAATACAAAA ATTAGCTGAC CTCTGTGACA GAGTGAGACT CTGCCTCAAA
31151 AAAAAAAAAA AAAAAAAAAA AAAAATGAGG TGAAGCTTTA AGTTGTAACA
31201 CTGATTTTGG GGTGCAATAA AGCAAGTTGC AGAATGATAC CCATGTTAAG
31251 ATGCTATTTG AGTGAACACA CGGACCAAAC AATTCTATGT TGGGTACAAA
31301 TTTAAGAAAG AGTTCTGGGC TGGGCACGGT GGCTCACAAC TGTAAATCCA
31351 GCACTCTGGG AGGGTGAATC GGATGGATCA GGAGGTGAGG ACTTCTAGAC
31401 TAGCCTGGCC AATATGGTGA AACCCTATCT CTACTAAAAA TACAAAAATT
31451 AGCCAGGCGT GTTGGCGCGT GTCTGGAGTC CCAGCTACTC AGGAGACTAA
31501 GGTAGGAGAA TCACCTGAAC CCGGGAGGCA GAGGTGAGC TGAGCTGAGA
31551 TCATGCCACT GCACTCTGGC CTGGGCAACA GAGCGAGACT CAAAAATAA
31601 ATAAATAAAT AAATAAAATA AATAAGAGTT TTCTGCACTT TGGGAGGCCT
31651 GTAGTCCCAG CTACTCTGGA GGCTGAGGCA AGAGGATCAC TTGAGCCTGG
31701 GGGGGTGCAG GCTGCAGTGA GTCCTGATTG TGTCAGTCAA ATCCAGCCTG
31751 GGCAACAGAG TGAGAC (SEQ ID NO: 5)

```

FEATURES:

```

Start:          914
Exon:           914-1147
Intron:         1148-2008
Exon:           2009-2286
Intron:         2287-2517
Exon:           2518-2563
Intron:         2564-5066
Exon:           5067-5146
Intron:         5147-7047
Exon:           7048-7190
Intron:         7191-15250
Exon:           15251-15426
Intron:         15427-15844
Exon:           15845-15917
Intron:         15918-18499
Exon:           18500-18550
Intron:         18551-20881
Exon:           20882-20942
Intron:         20943-21839
Exon:           21840-21895
Intron:         21896-22194
Exon:           22195-22335

```

Intron: 22336-23816
 Exon: 23817-23944
 Intron: 23945-24261
 Exon: 24262-24361
 Intron: 24362-24840
 Exon: 24841-24974
 Intron: 24975-27018
 Exon: 27019-27091
 Intron: 27092-28484
 Exon: 28485-28576
 Stop: 28574

CHROMOSOME MAP POSITION:

#	SHGCNAME	CHROM#	LOD_SCORE	DIST. (cRs)
1	SHGC-56719	17	15.9	14
2	SHGC-58932	17	15.68	14
3	SHGC-97	17	14.5	17
4	SHGC-53147	17	13.3	22
5	SHGC-33067	17	12.52	23

ALLELIC VARIANTS (SNPs):

POSITION	Major	Minor	Context
30344	g	a	aagcaatcctcttgcctcagcctctggtgtggctgggaccacagacacat [g/a]ccaccgcgccaggctaatttgttaatttttttatagagacagggtctca
31170	a	g	ctctgtgacagagtgtgagactctgcctcaaaaaaaaaaaaaaaaaaaaaa [a/g]aaaatgagggtgaagctttaagttgtaacactgattttgggggtgcaataaa
16256	c	t	aaacgctgctgtctgattttaaggtaacgtcactgaaaggggagtttgca [c/t]atggagctgggttgagatctgcataaacaatcatattctatggtgtctcc
13376	a	t	catgccagctaatttttgtatttttagtaaagacagagcttcactgtgt [a/t]ggctgggccagctctcgaattcctgacttcagggtgattcagctgcctcggc
12210	t	c	atgttgggattacaggtgtgagccactactcctggtcttctttcaacttt [t/c]gacttttgtatgtctgaaagtctattttgccttcatttttcaaagatagt
12072	g	c	catgcatcaccacgcctggataattttttatttttactttttgtagagat [g/c]gtgtcttctcactagttgcccaggctgggtctcttactcctgggctcaagggga
11922	g	t	taactctttcagcattttttttttttttttttttttttttttttttttttttt [g/t]tcactcaggctggaatgcagtggtacaattatagttcactgcagccttga
11903	-	a	ttgcaggcctgttggtgattaactctttcagcattttttttttttttttttt [-/a]tttgacaggattcactctgtcactcaggctggaatgcagtggtacaatta
10009	c	g	ctttgacctgtggattatttagaagtggtattatgatgttcttctgtgaa [c/g]catgggagttatttagtttccaaatagttgggggtttcccaatttagtact
4519	c	t	cctgccaggacctcagagctgggtatcgtggtgggaggctcctactttgc [c/t]gaggattccccaagctggtttcttgaagccctcagagccctccacatct
4181	a	g	aacagtcccagagtccgccccccaggatgtcctaaccaccaaccacctgt [a/g]cgcagcagtttttagggcagggtccttgagcctgtggccatgggatccagg

20952	a	c	tccctcgtctcctcctacccgggtcacaggcagctttggacggtgagtgac [a/c]tgccgcctctctctgtttgccacggttgacgccttaacggtgttacgct
20987	t	c	tggacggtgagtgacatgtccgcctctctgtttgccacggttgacgcc [t/c]taacggtgttacgctgacaaggagtgctgcctgacctgacccggcgcccc
21620	g	a	ccccacctggatgggggcaggagacagagtcggcaggaacctgaaaggac [g/a]cgtgcttcctgagcttcttcctatagtcagggtggcccaagcgcggtgt
21795	t	c	ctgacgtccctcgggaagatcagccacaggagtggtgactgaggtctccc [t/c]tttcccgccctggtgactgacggtctctgtgttgaccttcaggacagc
22753	a	t	agcggaaacagccttgacacctgggtcagaatggcagttccttttttttt [a/t]ttattattatt
22945	g	a	gcagaacaaaatgaaaagtctccatgtctacttctttctacacagacac [g/a]gcaaccatccgatttctcaatcttttccccacctttccccctttctatt
23032	g	a	ccccctttctattccacaaaaccgccattgtcatcatggcggttctca [g/a]tgagctgttggttacacctcccagacggggtggtggccgggcagaggggc
23738	g	a	ggggctgcttggtggtccatgagcacctttactcatatgtgggggcagaa [g/a]gctgtcccgctggtcagcagggccatgttggggcctcgggcagctgccgg
23952	t	g	tctgtcatgtctcctgcactctgcagccaggcctgagaccaaggtacccc [t/g]ccgtggcctctgagtgaggagtggtgtgtgggggcaggattcctgggcatgg
24123	a	g	gggcagtcaccttgctataaaccatggtgttctccactgtgtgggggcc [a/g]tgggggtctcccttagcacccctctcccggtccctgcagcacgctagg
24527	c	-	caggcatctctgagtgggctggaccgtcctctgtgggcctcagccagtgg [c/-]tgctgcagcaagggtggtggctccccacatatcactccttccctgccct
24691	c	t	agggaaacagctgctgctgtcaccaacaattgtctctggtcctgccacc [c/t]gaatcccccaactgggcgactcagccgccacgagatggagcactctggcc
25015	g	a	gggcctgcaggtgggtgtgcactgggatgccttaggggttagcagctgcc [g/a]gaaggccttccctgtgcctgcctcccatggcgaatgtgacatctctgggt
25191	g	t	ctcgtccctccctgtggaagggggagcgggtggcccccagccctccgaggg [g/t]tcacgttatggcttctggtcactgccacactgtcctttgtgctggggaca

POSITION	Major	Minor	
30344	g	a	Intron
31170	a	g	Intron

16256	c	t	Intron
13376	a	t	Intron
12210	t	c	Intron
12072	g	c	Intron
11922	g	t	Intron
11903	-	a	Intron
10009	c	g	Intron
4519	c	t	Intron
4181	a	g	Intron
20952	a	c	Intron
20987	t	c	Intron
21620	g	a	Intron
21795	t	c	Intron
22753	a	t	Intron
22945	g	a	Intron
23032	g	a	Intron
23738	g	a	Intron
23952	t	g	Intron

24123	a	g	Intron
24527	c	-	Intron
24691	c	t	Intron
25015	g	a	Intron
25191	g	t	Intron

Gene structure of Splice Form 2:

protein 1 MPSSVTALGQARSSGPGMAPSACCCSPAALQRRLPILAWLPSYSLQWLK
 MPSSVTALGQARSSGPGMAPSACCCSPAALQRRLPILAWLPSYSLQWLK
 MPSSVTALGQARSSGPGMAPSACCCSPAALQRRLPILAWLPSYSLQWLK
 genomic 687 acttgagcgcgattgcgagcagttttcgccaaccacgtccattcctca
 tcctcctgacgcgcgcgtccgcgggcccctaggtcttcgtcgactagta
 gttgggggtgcgctccggcgcgcccccctgcgggggcggggcccccggggg

protein 50 MDFVAGLSVGLTAIPQALAYAEVAGLPPQ
 MDFVAGLSVGLTAIPQALAYAEVAGLPPQ
 MDFVAGLSVGLTAIPQALAYAEVAGLPPQ
 genomic 834 agtgggctggcagaccgcgtgggggccccGTGAGGC Intron 1
 tattcgtctgtcctcactcacatcgcca<0-----[921 : 1781]
 gtcccccatcctctcgggcttagtacgcg

protein 79 YGLYSAFMGCFVYFFLGTSRDVTLGPTAIMSLLVSFYTFHEPAYAV
 YGLYSAFMGCFVYFFLGTSRDVTLGPTAIMSLLVSFYTFHEPAYAV
 YGLYSAFMGCFVYFFLGTSRDVTLGPTAIMSLLVSFYTFHEPAYAV
 genomic 1779 CAGTgcttgtagttgtttcgatcggacgcagaatccgtttatcgcggtg
 -0>agtaccttggttatttgcgatctgcccttctttctactaaccact
 tcctccgcgcgcgtccgcgcgtgtgccctgcgcgcgcgcctgcgcctg

protein 125 LLAFLSGCIQLAMGVRLRLAHISPHPLGLGGAGTSSMSPLGWPGFLDDEI
 LLAFLSGCIQLAMGVRL P G L L F
 LLAFLSGCIQLAMGVRLGEALPSCQG-----DALDLSICLFAPQ
 genomic 1920 ccgtctgtaccgaggcctgggccttgc ggcgcaatttgtc
 ttcttcggtatctgttgtgactccgag actatgtgttcta
 ggccgccccggcggcggtgtgtattcag tccccctcgtata

protein 174 SYPVIK FTSAAAVTIGFGQIK
 YP ++ FTSAAAVTIGFGQIK
 VYPRVR G:V[gtc] FTSAAAVTIGFGQIK
 genomic 2040 gtccgcGTGTGTGCG Intron 2 AAGCtatggggaagtgcaa
 tacgtg <2-----[2060 : 2347]-2> tccccctctgtgata
 ctctgt cctttccccctagcg

protein 196 NLLGLQNI PRPFFLQVYHTFLRIAET
 NLLGLQNI PRPFFLQVYHTFLRIAET
 NLLGLQNI PRPFFLQVYHTFLRIAET
 genomic 2394 GTAGGCA Intron 3 CAGaccgccaacacttccgtcatcaagga
 <0-----[2394 : 4901]-0>attgtaatcgctttataacttgtcac

cggaagcccgccggggcccccgtagc

protein 222 VGDAVLGLVCM L L L L L V L K L M R D H
VGDAVLGLVCM L L L L L V L K L M R D H
R:R[agg] VGDAVLGLVCM L L L L L V L K L M R D H

genomic 4980 AGGTACCCC Intron 4 CAGGgggggcgcggtaccccgcacacgc
<2-----[4982 : 6882]-2> tgacttgttgtttttttattgaa
atcccgggcccggggggggggggcc

protein 246 VPPVHPEMPPGVRLSRGLVWAATT
VPPVHPEMPPGVRLSRGLVWAATT
VPPVHPEMPPGVRLSRGLVWAATT A:A[gct]

genomic 6953 gccgccgaccggccacgcgtggaaGGTGAGGG Intron 5
tcctacatccgtgtgggttgcccc <1-----[7026 :10803]
gtccccggccttggcctggcgtcga

protein 270 RNALVVSFAALVAYSFEVTGYQPFILTGETAEG LPPVRIPPFSV
RNALVVSFAALVAYSFEVTGYQPFILTGETAEG LPPVRIPPFSV
RNALVVSFAALVAYSFEVTGYQPFILTGETAEG LPPVRIPPFSV

genomic 10801 TAGCTcagcggttggcggttggagtcctacaggagggcccgccaccttg
-1> gactttctccttcactatogaactttcgaccagtcctgtcctct
cccggccacgtgcccgtacgtccaaggatggctacgcgccag

protein 315 TTANGTISFTEMVQ DMGAGLAVVPLM
TTANGTISFTEMVQ DMGAGLAVVPLM
TTANGTISFTEMVQ DMGAGLAVVPLM

genomic 10938 aagagaattagagcGTGGGCG Intron 6 CAGgagggcgggcca
cccagctctcatta<0-----[10980:11397]-0>atgcgtcttctt
caccggccccgggg cgacggcgggcg

protein 341 GLLESIAVAKAF SQNNYRIDANQ
GLLESIAVAKAF SQNNYRIDANQ
GLLESIAVAKAF A:A[gca] SQNNYRIDANQ

genomic 11434 gccgaagggagtgGTAAGAC Intron 7 TAGCATcaatcaggac
gttagtctcact <1-----[11471:14777]-1> caaaagtacaa
ccggctggcacc tgttccctccg

protein 365 ELLAI LTNMLGSLVSSYPVTGSF
ELLAI LTNMLGSLVSSYPVTGSF
ELLAI G:G[ggg] LTNMLGSLVSSYPVTGSF

genomic 14813 gccgaGGTAAGAC Intron 8 CAGGTcaaatgtcgtttcgagat
attct <1-----[14829:15487]-1> tcattgcttccactcggg
gggcc cccggcccccccgccact

protein 389 G TAVNAQSGVCTPAGGLVT
G TAVNAQSGVCTPAGGLVT
G R:R[cgg] TAVNAQSGVCTPAGGLVT

genomic 15544 gCGGTGAGTG Intron 9 CAGGaggagctggtacgggcga
g <2-----[15549:16445]-2> cctacacgtgccccggttc
a acgctggggccggggcg

protein 409 VLVL LSLDYL TSLFYI PKSALA
VLVL LSLDYL TSLFYI PKSALA
G:G[gga] VLVL LSLDYL TSLFYI PKSALA

genomic 16501 GGTAAGGC Intron 10 CAGGAgcgccctcgatcatttaccatgcg
<1-----[16502:16800]-1> tttttctaataccttaatacacctc
gggggtgcccgcagccccgcgt

protein 433 AVIIMAVAPLFDTKIFRTLWRVK
AVIIMAVAPLFDTKIFRTLWRVK
AVIIMAVAPLFDTKIFRTLWRVK R:R[agg]

genomic 16872 ggaaagggcctgaaataactcgaAGTACGTC Intron 11 TAGGG
ctttctccttacattgctggta <1-----[16942:18422]-1>
ccccgcgcggccccgcgcggttg

protein 457 LDLLPLWVTFLLCFWEVQYGILAGALVSLMLLHSAARPETK
LDLLPL VTFLLCFWEVQYGILAGALVSLMLLHSAARPETK
LDLLPLCVTFLLCFWEVQYGILAGALVSLMLLHSAARPETK

genomic 18425 cgccctgatcccttggctgacgggcgtccaccctggacgaa
tattctgtcttggataagttcgcttcttttaccgcgaca
gcggcgcgccggcggggcccgcgcggtgcgcgctacgtgcg

protein 499 VSEGPVLVLQFASGLSFPAMEALREE
VSEGPVLVLQFASGLSFPAMEALREE
VSEGPVLVLQFASGLSFPAMEALREE

genomic 18551 GTACCCC Intron 12 CAGgtggcgcgcccagcttcgaggccgg
<0-----[18551:18867]-0>tcagctttaccggtctcctactgaa
gagggcgcgggcccgcctcggtgggg

protein 525 ILSRALE SPPRCLVLECTHVCSI
ILSRALE SPPRCLVLECTHVCSI
ILSRALE V:V[gtg] SPPRCLVLECTHVCSI

genomic 18946 acacgcgGGTGCATG Intron 13 CAGTGtccctcgcgtaacgtaa
ttggcta <1-----[18968:19446]-1> cccggttagcatggt
cacgcga cgaccgcggcctcccc

protein 549 DYTIVVLGLGELLQDFQKQGVAlAFVGLQ
DYTVVLGLGELLQDFQKQGVAlAFVGLQ
DYTVVLGLGELLQDFQKQGVAlAFVGLQ

genomic 19497 gtaggcgcggcccgtcacggcggtggccGTGGGTG Intron 14
aactttgtgattaataaagtctcttgta<0-----[19581:21620]
cctgggaccgcgcggggcccgcgtgcgg

protein 577 VPVLRVLLSADLKGfQYFSTLEEA
VPVLRVLLSADLKGfQYFSTLEEA
VPVLRVLLSADLKGfQYFSTLEEA E:E[gag]

genomic 21618 CAGgcgcgcctggcagtccttacggggGGTGGGCA Intron 15
-0>tcttgtttccatagtaatcctaac <1-----[21694:22916]
cctctcggtcgggcgcctcgaaa

protein 601 KHLRQEPGTQPYNIREDsILDQKVALlKA
KHLRQEPGTQPYNIREDsILDQKVALlKA
KHLRQEPGTQPYNIREDsILDQKVALlKA

genomic 22914 CAGAGaccacgcgacctaaggtacgcaggccag
-1> aatgaacgcacaatgaacttaaattcttac
gcggggagcgccccaacctgcagtcgcga

cds 687 920
intron 921 1781
cds 1782 2059
intron 2060 2347
cds 2348 2393
intron 2394 4901
cds 4902 4981
intron 4982 6882
cds 6883 7025

intron	7026	10803
cds	10804	10979
intron	10980	11397
cds	11398	11470
intron	11471	14777
cds	14778	14828
intron	14829	15487
cds	15488	15548
intron	15549	16445
cds	16446	16501
intron	16502	16800
cds	16801	16941
intron	16942	18422
cds	18423	18550
intron	18551	18867
cds	18868	18967
intron	18968	19446
cds	19447	19580
intron	19581	21620
cds	21621	21693
intron	21694	22916
cds	22917	23005

SEQUENCE LISTING

<110> APPLERA CORPORATION

<120> ISOLATED HUMAN TRANSPORTER PROTEINS,
NUCLEIC ACID MOLECULES ENCODING HUMAN TRANSPORTER PROTEINS,
AND USES THEREOF

<130> CL000746PCT

<140> TO BE ASSIGNED

<141> 2001-10-26

<150> 09/765,344

<15> 2001-01-22

<160> 7

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 2919

<212> DNA

<213> Human

<400> 1

aacagcacga gggcggaccc agctgtggcg acgccaggag accccaagct gcatcgccga 60
gtggaagcaa ctagaactcc agggctgtga aagccacagg tgggggctga gcgaggcgtg 120
gcctcaggag cggaggaccc cccactctc cctcgagcgc cgcagtcac cgtagcgggt 180
ggagcccgcc ttggtgcgca gttggaaaac ctggagccc cgctggatct cctggctgcc 240
accgcaccc ccgcccagcc tacgcccac cgtagagatg ccttcttcgg tgacggcgct 300
gggtcaggcc aggtcctctg gccccgggat ggcccagac gctgtgtgt gctccctgc 360
ggccctgcag aggaggctgc ccactctggc gtggctgcc agctactccc tgcagtggct 420
gaagatggat ttctgtgccg gctctcagt tggcctcact gccattcccc aggcgtggc 480
ctatgtgaa gtggtggac tccgccccca gtatggctc tactctgcct tcatgggctg 540
cttctgtat ttcttcttg gcaactccc ggaatgtgact ctgggcccc cgcattat 600
gtccctctg gtctcttct acacctcca tgagccgccc tacgtgtgc tctggcctt 660
cctgtccgc tgcattcagc tggccatgg ggtctgcgt ttggggttcc tctggactt 720
catttctac ccgctcatc aaggctcac ctctgtgtgt gccgtacca tcggctttg 780

acagatcaag aacctgctgg gactacagaa catccccagg ccgttcttcc tgcaggtgta 840
 ccacaccttc ctacaggattg cagagaccag ggtaggtgac gccgtccctgg ggctggtctg 900
 catgctgctg ctgctgggtgc tgaagctgat gcgggaccac gtgcctcccg tccaccccca 960
 gatgccccct ggtgtgcggc tcagccgtgg gctggtctgg gctgccacga cagctcgcaa 1020
 cgccctgggt gtctccttcg cagccctggt tgcgtactcc ttcgaggtga ctggatacca 1080
 gcccttcatc ctaacagggg agacagctga ggggctccct ccagtcogga tcccgccctt 1140
 ctacgtgacc acagccaacg ggacgatctc ctccaccgag atggtgcagg acatgggagc 1200
 cgggctggcc gtggtgcccc tgatgggcct cctggagagc attgcggtgg ccaaagcctt 1260
 cgcattctcag aataaattacc gcacgatgc caaccaggag ctgctggcca tcggtctcac 1320
 caacatgttg ggctccctcg tctcctcta cccgggcaca ggcagctttg gacggacagc 1380
 cgtgaacgct cagtcggggg tgtgcacccc ggccggggggc ctggtgacgg gagtgtggtt 1440
 gctgtgtct ctggactacc tgacctact gttctactac atccccaagt ctgccctggc 1500
 tgcctgcatc atcatggccg tggcccgct gttcgacacc aagatcttca ggacgtctg 1560
 gcgtgttaag aggtcggacc tctgccccct gtgcgtgacc ttctgtctgt gcttctggga 1620
 ggtgcagtac ggcattctgg ccggggccct ggtgtctctg ctcatgctcc tgcactctgc 1680
 agccaggcct gagaccaagg tgcagaggg gcgggttctg gtctgcagc cggccagcgg 1740
 cctgtcttc cctgccatgg aggtctctcg ggaggagatc ctaagccggg ccctggaagt 1800
 gtccccgcca cgctgcctgg tcttgagtg caccatgtc tgcagcatcg actacactgt 1860
 ggtgtctgga ctcggcgagc tctccagga ctccagaag cagggcgctg ccctggcctt 1920
 tgtgggcctg caggtccccg ttctcgtgt cctgtgtcc gctgacctga aggggttcca 1980
 gtacttctct acctggaag aagcagagaa gcacctgagg caggagccag ggaccagcc 2040
 ctacaacatc agagaagact ccattctgga ccaaaagggt gccctgtca aggcataatg 2100
 gggccacccg tgggcatcca cagtttcag ggtgtccgg aaggttctg tcactgtgat 2160
 tggatgtcgg atgccgcctg atagacatgc tggcctggct gagaaacccc tgagcaggta 2220
 acccaggga gagaggaag ccaggcctgg aggtccacgg cagtgggagt ggggctcact 2280
 ggcttctgt gggatgactg gaaaatgacc tcgtgtgtt tccctggcat gacctctt 2340
 ggaagagtgg ttgagagaga gccttctaga atgacagact gtgcgaggaa gcaggggcag 2400
 gggttccag cccgggctgt gcgaggcatc ctggggctgg cagcacctc ccggctcacc 2460
 agtgccacct gcgggggagg gacggggcag gcaggagtct gggaggcggg tccgtcttc 2520
 ttgtctcgg catctgtct ctccgagaga aaaccaaggt gtgtcaaatg acgtcaagtc 2580
 tctattaaa aataatttg tgtttctaa atggaaaaag tgatagcttt ggtgatttg 2640
 taaaagtcat aaatgcttat tgaataaat acaggaaacc acccctcacc ctgtccactt 2700
 ggggtgatcat tcagacccc tcccaaaca tcataatga cctgtccgtc agtgtgtgga 2760
 tgtatgtta cagttctaca taaatggat cttttatc atggtgtctt ggaaccaca 2820
 ttttcatgc agtcattgc agtgaattat ttattgtgat aataaatagc attagaatac 2880
 aagaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2919

<210> 2

<211> 2955

<212> DNA

<213> Human

<400> 2

gctgtggcga cgccaggaga cccaagctg catgccgag tggaagcaac tagaactcca 60
 gggctgtgaa agccacaggt gggggctgag cgaggcgtgg cctcaggagc ggaggacccc 120
 cccactctcc ctgagcgccc gcagtcacc gtagcgggtg gagcccgct tggcgcgag 180
 ttgaaaacc tcggagcccc gctggtctc ctggctgcca ccgcacccc ccgccagct 240
 acgccccacc gtagagatgc ctcttcggt gacggcgctg ggtcaggcca ggtcctctgg 300
 cccggggtg gccccgagcg cctgctgctg ctcccctgc gccctgcaga ggaggctgcc 360
 catctggcg tggctgcca gctactccct gcagtggctg aagatggatt tgcgcggg 420
 cctctcagtt ggctcactg ccatcccca ggcgctggcc tatgtgaag tggctggact 480
 ccgccccag tatggcctct actcgcctt catgggctgc ttcgtgtatt tcttctggg 540
 cacctccgg gatgtgactc tgggccccac cgccattat tccctctgg tctcttcta 600
 caccttcat gagcccgct acgctgtgt gctggccttc ctgtcgggt gcattcagct 660
 ggcatgggg gtctgtcgt ttgctacat ctccctcat cctctgggac tgggtggagc 720
 cgggaccagc tcgatgtccc ctctggctg gccagggttc ctgctggact tcatttcta 780
 cccgtcatt aaaggctca cctctgtgc tgcgtcacc atcggcttg gacagatcaa 840
 gaacctgctg ggactacaga acatccccag gccgttctc ctgcaggtgt accacacct 900
 cctcaggatt gcagagacca gggtaggtga cgccgtcctg gggctggtct gcattgctgt 960
 gctgtggtg ctgaagctga tgcgggacca cgtgcctccc gtccacccc agatgcccc 1020
 tgggtgcgg ctacgcgtg ggtgtgtct ggctgccacg acagctcga acgcctggt 1080
 ggtctcttc gcagccctg ttgcgtact ctctcagggt actggatacc agccttcat 1140
 cctaacagg gagacagct aggggctccc tccagtcgg atccgccct tctcagtac 1200
 cacagccaac gggacgatct cctcaccga gatggtgcag gacatgggag ccgggctggc 1260
 cgtgtgccc ctgatgggc tctggagag cattcggtg gccaaagct tcgcatctca 1320
 gaataattac cgcacgatg ccaaccagga gctgctggcc atcggctca ccaacatgt 1380
 gggctccctc gtctctct acccggtcac aggcagctt ggacggacag ccgtgaacgc 1440
 tcagtgggg gtgtgcacc cggcggggg cctggtgacg ggagtgtgg tctgctgtc 1500
 tctggactac ctgacctac tgttacta catcccaag tctgccctg ctccgtcat 1560
 catcatggcc gtggccccg tgtcgacac caagatctc aggaagctct ggctgttaa 1620
 gaggctggac ctgctcccc tgtgggtgac ctctctgtg tcttctggg aggtgcagta 1680
 cggcatctg gccggggccc tgggtctct gctcatgtc ctgcactct cagccaggcc 1740
 tgagaccaag gtgtcagagg gccgggtct ggtcctgcag ccggccagcg gcctgtcct 1800
 cctgccatg gaggctctg gggaggagat cctaagcgg gccctggaag tgtccccgc 1860
 acgtgcctg gtctggagt gcacctat ctgcagcct gactacact tggctgtgg 1920
 actcggcgag ctctccagg actccagaa gcaggcgct gccctggcct ttgtggcct 1980
 gcaggcccc gttctccgt tctgtctgc cgtgacctg aaggggttc agtactctc 2040
 tacctggaa gaagcagaga agcacctg gcaggagcca gggaccagc cctacaacat 2100
 cagagaagac tcattctg accaaaagt tgcctgtc aaggcataat ggggccacc 2160
 gtgggcacc acagttgca ggggttccg gaaggttct gtcactgtg ttgatgtg 2220

gatgcgcct gatagacatg ctggcctggc tgagaaaccc ctgagcaggt aaccagga 2280
 agagaaggaa gccaggcctg gaggtccacg gcagtgggag tggggctcac tggcttctg 2340
 tgggatgact ggaaaatgac ctgcctgctg ttccctggca tgacctctt tggaagagt 2400
 gtttgagag agccttctag aatgacagac tgtgcgagga agcaggggca ggggtttcca 2460
 gcccgggctg tgcgaggcat cctggggctg gcagcacctt cccggctcac cagtccacc 2520
 tgcgggggag ggacggggca ggcaggagtc tgggaggcgg gtccgctct ctgtctgcg 2580
 gcctctgtgc tctccgagag aaaaccaagg tgtgtcaaat gacgtcaagt ctctatttaa 2640
 aaataattt gtgtttcta aatggaaaaa gtgatagctt tggatattt gtaaaagtca 2700
 taaatgctta ttgtaaaaaa tacaggaaac caccctcac cctgtccact tgggtgatca 2760
 ttccagacc ctcccaaac atgcatatgt acctgtcgt cagtgtgtg atgtatgtt 2820
 acagtctac ataaatggga tcatttata catggtgctc tggaaaccac attttcatg 2880
 cagtcattg cagtgaatta ttattgtga taataaatag cattagaata caaaaaaaaa 2940
 aaaaaaaaa aaaaa 2955

<210> 3

<211> 606

<212> PRT

<213> Human

<400> 3

Met Pro Ser Ser Val Thr Ala Leu Gly Gln Ala Arg Ser Ser Gly Pro

1 5 10 15

Gly Met Ala Pro Ser Ala Cys Cys Cys Ser Pro Ala Ala Leu Gln Arg

20 25 30

Arg Leu Pro Ile Leu Ala Trp Leu Pro Ser Tyr Ser Leu Gln Trp Leu

35 40 45

Lys Met Asp Phe Val Ala Gly Leu Ser Val Gly Leu Thr Ala Ile Pro

50 55 60

Gln Ala Leu Ala Tyr Ala Glu Val Ala Gly Leu Pro Pro Gln Tyr Gly

65 70 75 80

Leu Tyr Ser Ala Phe Met Gly Cys Phe Val Tyr Phe Phe Leu Gly Thr

85 90 95

Ser Arg Asp Val Thr Leu Gly Pro Thr Ala Ile Met Ser Leu Leu Val

100 105 110

Ser Phe Tyr Thr Phe His Glu Pro Ala Tyr Ala Val Leu Leu Ala Phe

115 120 125

Leu Ser Gly Cys Ile Gln Leu Ala Met Gly Val Leu Arg Leu Gly Phe

130 135 140

Leu Leu Asp Phe Ile Ser Tyr Pro Val Ile Lys Gly Phe Thr Ser Ala

145 150 155 160

Ala Ala Val Thr Ile Gly Phe Gly Gln Ile Lys Asn Leu Leu Gly Leu
 165 170 175
 Gln Asn Ile Pro Arg Pro Phe Phe Leu Gln Val Tyr His Thr Phe Leu
 180 185 190
 Arg Ile Ala Glu Thr Arg Val Gly Asp Ala Val Leu Gly Leu Val Cys
 195 200 205
 Met Leu Leu Leu Leu Val Leu Lys Leu Met Arg Asp His Val Pro Pro
 210 215 220
 Val His Pro Glu Met Pro Pro Gly Val Arg Leu Ser Arg Gly Leu Val
 225 230 235 240
 Trp Ala Ala Thr Thr Ala Arg Asn Ala Leu Val Val Ser Phe Ala Ala
 245 250 255
 Leu Val Ala Tyr Ser Phe Glu Val Thr Gly Tyr Gln Pro Phe Ile Leu
 260 265 270
 Thr Gly Glu Thr Ala Glu Gly Leu Pro Pro Val Arg Ile Pro Pro Phe
 275 280 285
 Ser Val Thr Thr Ala Asn Gly Thr Ile Ser Phe Thr Glu Met Val Gln
 290 295 300
 Asp Met Gly Ala Gly Leu Ala Val Val Pro Leu Met Gly Leu Leu Glu
 305 310 315 320
 Ser Ile Ala Val Ala Lys Ala Phe Ala Ser Gln Asn Asn Tyr Arg Ile
 325 330 335
 Asp Ala Asn Gln Glu Leu Leu Ala Ile Gly Leu Thr Asn Met Leu Gly
 340 345 350
 Ser Leu Val Ser Ser Tyr Pro Val Thr Gly Ser Phe Gly Arg Thr Ala
 355 360 365
 Val Asn Ala Gln Ser Gly Val Cys Thr Pro Ala Gly Gly Leu Val Thr
 370 375 380
 Gly Val Leu Val Leu Leu Ser Leu Asp Tyr Leu Thr Ser Leu Phe Tyr
 385 390 395 400
 Tyr Ile Pro Lys Ser Ala Leu Ala Ala Val Ile Ile Met Ala Val Ala
 405 410 415
 Pro Leu Phe Asp Thr Lys Ile Phe Arg Thr Leu Trp Arg Val Lys Arg
 420 425 430
 Leu Asp Leu Leu Pro Leu Cys Val Thr Phe Leu Leu Cys Phe Trp Glu
 435 440 445
 Val Gln Tyr Gly Ile Leu Ala Gly Ala Leu Val Ser Leu Leu Met Leu
 450 455 460
 Leu His Ser Ala Ala Arg Pro Glu Thr Lys Val Ser Glu Gly Pro Val
 465 470 475 480

Leu Val Leu Gln Pro Ala Ser Gly Leu Ser Phe Pro Ala Met Glu Ala
 485 490 495
 Leu Arg Glu Glu Ile Leu Ser Arg Ala Leu Glu Val Ser Pro Pro Arg
 500 505 510
 Cys Leu Val Leu Glu Cys Thr His Val Cys Ser Ile Asp Tyr Thr Val
 515 520 525
 Val Leu Gly Leu Gly Glu Leu Leu Gln Asp Phe Gln Lys Gln Gly Val
 530 535 540
 Ala Leu Ala Phe Val Gly Leu Gln Val Pro Val Leu Arg Val Leu Leu
 545 550 555 560
 Ser Ala Asp Leu Lys Gly Phe Gln Tyr Phe Ser Thr Leu Glu Glu Ala
 565 570 575
 Glu Lys His Leu Arg Gln Glu Pro Gly Thr Gln Pro Tyr Asn Ile Arg
 580 585 590
 Glu Asp Ser Ile Leu Asp Gln Lys Val Ala Leu Leu Lys Ala
 595 600 605

<210> 4

<211> 630

<212> PRT

<213> Human

<400> 4

Met Pro Ser Ser Val Thr Ala Leu Gly Gln Ala Arg Ser Ser Gly Pro
 1 5 10 15
 Gly Met Ala Pro Ser Ala Cys Cys Cys Ser Pro Ala Ala Leu Gln Arg
 20 25 30
 Arg Leu Pro Ile Leu Ala Trp Leu Pro Ser Tyr Ser Leu Gln Trp Leu
 35 40 45
 Lys Met Asp Phe Val Ala Gly Leu Ser Val Gly Leu Thr Ala Ile Pro
 50 55 60
 Gln Ala Leu Ala Tyr Ala Glu Val Ala Gly Leu Pro Pro Gln Tyr Gly
 65 70 75 80
 Leu Tyr Ser Ala Phe Met Gly Cys Phe Val Tyr Phe Phe Leu Gly Thr
 85 90 95
 Ser Arg Asp Val Thr Leu Gly Pro Thr Ala Ile Met Ser Leu Leu Val
 100 105 110
 Ser Phe Tyr Thr Phe His Glu Pro Ala Tyr Ala Val Leu Leu Ala Phe
 115 120 125

Leu Ser Gly Cys Ile Gln Leu Ala Met Gly Val Leu Arg Leu Ala His
 130 135 140
 Ile Ser Pro His Pro Leu Gly Leu Gly Gly Ala Gly Thr Ser Ser Met
 145 150 155 160
 Ser Pro Leu Gly Trp Pro Gly Phe Leu Leu Asp Phe Ile Ser Tyr Pro
 165 170 175
 Val Ile Lys Gly Phe Thr Ser Ala Ala Ala Val Thr Ile Gly Phe Gly
 180 185 190
 Gln Ile Lys Asn Leu Leu Gly Leu Gln Asn Ile Pro Arg Pro Phe Phe
 195 200 205
 Leu Gln Val Tyr His Thr Phe Leu Arg Ile Ala Glu Thr Arg Val Gly
 210 215 220
 Asp Ala Val Leu Gly Leu Val Cys Met Leu Leu Leu Leu Val Leu Lys
 225 230 235 240
 Leu Met Arg Asp His Val Pro Pro Val His Pro Glu Met Pro Pro Gly
 245 250 255
 Val Arg Leu Ser Arg Gly Leu Val Trp Ala Ala Thr Thr Ala Arg Asn
 260 265 270
 Ala Leu Val Val Ser Phe Ala Ala Leu Val Ala Tyr Ser Phe Glu Val
 275 280 285
 Thr Gly Tyr Gln Pro Phe Ile Leu Thr Gly Glu Thr Ala Glu Gly Leu
 290 295 300
 Pro Pro Val Arg Ile Pro Pro Phe Ser Val Thr Thr Ala Asn Gly Thr
 305 310 315 320
 Ile Ser Phe Thr Glu Met Val Gln Asp Met Gly Ala Gly Leu Ala Val
 325 330 335
 Val Pro Leu Met Gly Leu Leu Glu Ser Ile Ala Val Ala Lys Ala Phe
 340 345 350
 Ala Ser Gln Asn Asn Tyr Arg Ile Asp Ala Asn Gln Glu Leu Leu Ala
 355 360 365
 Ile Gly Leu Thr Asn Met Leu Gly Ser Leu Val Ser Ser Tyr Pro Val
 370 375 380
 Thr Gly Ser Phe Gly Arg Thr Ala Val Asn Ala Gln Ser Gly Val Cys
 385 390 395 400
 Thr Pro Ala Gly Gly Leu Val Thr Gly Val Leu Val Leu Leu Ser Leu
 405 410 415
 Asp Tyr Leu Thr Ser Leu Phe Tyr Tyr Ile Pro Lys Ser Ala Leu Ala
 420 425 430
 Ala Val Ile Ile Met Ala Val Ala Pro Leu Phe Asp Thr Lys Ile Phe
 435 440 445

Arg Thr Leu Trp Arg Val Lys Arg Leu Asp Leu Leu Pro Leu Trp Val
 450 455 460
 Thr Phe Leu Leu Cys Phe Trp Glu Val Gln Tyr Gly Ile Leu Ala Gly
 465 470 475 480
 Ala Leu Val Ser Leu Leu Met Leu Leu His Ser Ala Ala Arg Pro Glu
 485 490 495
 Thr Lys Val Ser Glu Gly Pro Val Leu Val Leu Gln Pro Ala Ser Gly
 500 505 510
 Leu Ser Phe Pro Ala Met Glu Ala Leu Arg Glu Glu Ile Leu Ser Arg
 515 520 525
 Ala Leu Glu Val Ser Pro Pro Arg Cys Leu Val Leu Glu Cys Thr His
 530 535 540
 Val Cys Ser Ile Asp Tyr Thr Val Val Leu Gly Leu Gly Glu Leu Leu
 545 550 555 560
 Gln Asp Phe Gln Lys Gln Gly Val Ala Leu Ala Phe Val Gly Leu Gln
 565 570 575
 Val Pro Val Leu Arg Val Leu Leu Ser Ala Asp Leu Lys Gly Phe Gln
 580 585 590
 Tyr Phe Ser Thr Leu Glu Glu Ala Glu Lys His Leu Arg Gln Glu Pro
 595 600 605
 Gly Thr Gln Pro Tyr Asn Ile Arg Glu Asp Ser Ile Leu Asp Gln Lys
 610 615 620
 Val Ala Leu Leu Lys Ala
 625 630

<210> 5

<211> 31766

<212> DNA

<213> Human

<220>

<221> misc_feature

<222> (1)...(31766)

<223> n = A,T,C or G

<400> 5

ggccccgcg gccctcgcc ttgctcggg ccaagggacc gcgacggc aggtggcgca 60
 gggctcctc cgagacccc aggatccgga gccagcgcc ttgtgggcag gggccggggg 120
 caggggagtg gatttgccc ggagcggagc aggccggggg cagtgggggg ctgggggtga 180

ggggtggctgg ctctgcgcgc gggcgccggg gccctggaag atgctgcgca cctgaattaa 240
 ccggggcgct ctgatgtcct ccagaagca actagaactc cagggctgtg aaagccacag 300
 gtgggggctg agcgaggctt ggcctcagga gcggaggacc ccccccccc cccctcgag 360
 cgccgcagtc caccgtagcg ggtggagccc gccttggtgc gcagttgaa aacctcgaa 420
 gccccgctgg atctctggc tgccaccgc accccccgc agctacggtg cgccgcggg 480
 ccagcttct ctctgcctg ctcccgta aattccctg ggagacggaa aaaaaggaa 540
 aggaagtcgg ttctccagg gccagaagt ttgagcctaa ttagtctca gacttctaa 600
 tgaggaatcg ctatcagtt tctatctg gagagttg gatggaggga cagaaggcac 660
 ccaggattg caggggggg gattcagga gagagggtga tgaggacgg ggtggcctt 720
 ccagtctgg ccagtcctt atctgcaca cattgtggc ttctctag agccgttgc 780
 cccctgggg aggggagacc catagtacc tctctgaca ccgcgcacc ctgaccagt 840
 ttgcgggtt ctcaaaggc cagctctga ctgctgtt gtgtacctg cccccccag 900
 cccaccgta gagatgctt ctccgtgac ggcgtgggt caggccaggt cctctggcc 960
 cggtgatggc ccgagcgct gctgtgctt cctgcggc ctgcagagga ggctgccat 1020
 cctggcgtg ctgccagct actccctga gtgctgaag atggattcg tcgccgctt 1080
 ctactggc ctactgcca ttcccaggc gctggcctat gctgaagtg ctggactcc 1140
 gcccaggtg aggcgtctga cctgctgcc agccatatc cagaaacagt gcagaatata 1200
 caglatcaat ccagacacc atcagcatt ccaggttcc agccctggg cccaaggaa 1260
 ccttgggtt acagtgtg acgcagatt tctctggcc gaccaggct cctatgctg 1320
 ttgttacac acagacact agctggtt ggaggggcca gcgagatgac tcatggaggc 1380
 ctaggagtt caagaccagc ccgacaaaaa tggtaaac ccgtctccac taaaaata 1440
 aaaattaggc tgggtgcgtt ggtcaagc tgtaatcca gcacttggg aggccaggc 1500
 aggcgatcg caaggtcagg agatggagac catctggct aacagggtga aaccctct 1560
 ctactaaaaa taaaaaat tagccagggt tggggcggg tgctgtagt ccagctacc 1620
 tgggaggctg aggcaggaga atggcgtgaa ccggggaggc ggagcttga gtgagccag 1680
 actgtgccac tgccctcag cctggcgac agagcgagac tcatctcaa aaaaaaaaa 1740
 aaaagaatgc ttctcagac ttgacacag cacacgggc tgtaccgacc cctctgctg 1800
 gctgtctga cctgaggcc ccagttgagt gctgtaaaa aagtggcct ctgactctg 1860
 caggtccacc cacaggcgag ggcgtgac cttaacctg ggcctggaca cagctgacac 1920
 ccacacatcc cgagcttga cagcacact agggagctg tggatgggc tggcctctt 1980
 gagtgtcac caccctctt cccacagta tggcctctac tctgcttca tgggtgctt 2040
 cgtgtattt ttctgggca cctccggga tctgactct ggccccacc ccattatgt 2100
 cctctggct tcttctaca cttcatga gccgcctac gctgtgctg tggcctctt 2160
 gtccggctg atccagctg ccatgggggt cctgcgttg ggtgaggct tacttctg 2220
 ccaagggat gccctgacc tcagcattg ctgtttga ttcaagtt atccccgtt 2280
 gcgtgtgtg gcgtgtgtg ggggtgtgg tatgtatgt tgtgtgtga ggtgggtgg 2340
 tggtgaggg ggtggggcac ttgctcctt agtctactat ttactgatt agaggccagg 2400
 acattggaga aagtgcctg tggctcagac ccatatgc cnnnnnnnn nnnnnnnnn 2460
 nnnnnnnnn nnnnnnnnn nnnnnnnnn nnttcattt ctaccctgc attaaagct 2520
 cactctgt gctgccga ccatggctt tggacagatc aaggtaggca cggcgccac 2580

ccagggcact gctcttggc cactgctcgt tggcacaggg atggcgggag caggactgag 2640
 gccagtcctg atccctgtgg ccagtggacg tcttctgtt tcagattgtc ttccatgggt 2700
 caagaagcac gcgggtgctct catgggtccc ctgttaataa aatgaccctc ctgggagggg 2760
 tgtcacgtga tggttggatt tcacagcggg taacttgggg gccggtaatt ccatccccct 2820
 gctcttggcc gagttccgt gccagtgtgc ttggctggct ctgtgacgtg gctctgttct 2880
 ccttcactg ggcacaccca gcaggcccca ccagtcatga gcagtctgct agaatttcta 2940
 taggcaaatt atttccccat gccaatttag ttagatgggt tgttttgg cttttttc 3000
 tggttctgt ttaatattt taaatgcc a tgcctttat atttctttt aaaacattt 3060
 taatagtac taaaatcagt catcagctga ggggttaatt tattctgtt ttgctgggt 3120
 gtaagttcct cgagggtagg aactgtcctt ctcccagcca tggccgcccc gcattgggct 3180
 ggtgcagtag ggggggtgctc agtgggggtg gtgtggagt aagtgcagccc agttccacag 3240
 atgggaccat gcggccctca tggcagacta gggtcacatg ctgcctctg accctgtgtc 3300
 actgcaggtc atcttcccc agccaggccc tgtccaggc tggcctgaga cagtcttccc 3360
 tgatggaggt accatgagaa gaccaaggac aggagagtgt gtgtgagagt gtgtatagt 3420
 gtgtgtgtgt gtgaatgagt gagtgtgtga gagtgtgagt gggttttagg gagtgagtgt 3480
 gtgcgtgtgt gagtgagtgt gagtgtgggt gtgagtgagt gcgtgtgtgt gagagagtgt 3540
 gtgagtgtgt atgagtgaga gtgtgagagt ggggttgggt gttagggagt gtgtgagtgt 3600
 gcgcgcgcgt gtgtgagtgt atgagtgtga gagtgagtgt gagtgagtga gagtgggtgt 3660
 ggggtgagt gtgcgtgtga gtgtgagagt gtgagtgtgt gagtgtgaga ataaagtaga 3720
 cacttttgc actcttgcta cgtgcgaggc actgggcagg acactctcca tgtgtaattc 3780
 tcaacacacc ccgggaggta gatttatcat tatttccatt tgagagagga gggaccaact 3840
 taggtgtggg tgagcgtgat ttgtacgtta tctacacgca tctctcaggg ttagcttggc 3900
 aatgtctgt tcagggcatg gtgtgtctt taatctggaa acatcattt tgggttcaag 3960
 aatgttctt ttaggatcc cagtgcaggt ggagagcggg gagtggagag tgggaaggcat 4020
 cccttgttca tgcctcata ctggcaacc ctgccccgc ccagggactc tgcagccatc 4080
 tggggggagg ggcgtctcc tgacaggccc aggacagaag accctacccc aacagtcccc 4140
 gagtcgccc ccaggatgt cctaaccoca cccacctgt acgcagcagt tttagggcag 4200
 ggtcttgag cctgtggcca tgggatccag ggctcaact ttccctctg actcctgtt 4260
 ggtctcaggc gatgtaaaga actaaagtgc aagctgtgcc tgcactgtg atccagcta 4320
 cgtgggaggg cgaggtggga ggatcactgg agcccaggag ttccaatcca gcctgggcca 4380
 cagagcaagc aagaccccca cccccaacc cccgcgcgt ctctaaagaa aaaaaaacta 4440
 aactaaaaca caggatagag tgccttctc tcccaggac ctgagagctg gtatcgtgt 4500
 gggaggctcc tactttgcc aggatcccc aagctgggt ctgaagccc ctgagagccc 4560
 tccacatctg cacactacga agagatttt cctccgcag cagcggagct ggggggtggc 4620
 ggggcaccta gtgagggaga cattctcaag ccaatggcag caagggtcta cactgcaggg 4680
 ggcttgctg ctgagtggcc tggagccaat ggggggtggg ccaggcagcc catggcccct 4740
 ggcatcaag ctgtagaacc tgtctgcctg ctgtgggtgc acctacattg tttttatga 4800
 gaaaagta ttagagaaaa acatatcaat gaccagtaa ttgtgaagta ctgtctcca 4860
 cgagggtagc ttgatctcc tgcctaggg ggcgttggga gtgggcaggt ggaccctga 4920
 gccctaaga tgggccccgg gaataagggt tgggagcagg gccgggggac actgtctcag 4980

ccctagggga ggtgggagg gagctggga cagatggcct tggttggga gcatagcctc 5040
 tgatcagcat ctctgtgtt ggacagaacc tgctgggaact acagaacatc ccaggccgt 5100
 tcttctgca ggtgtaccac accttctca ggattgcaga gaccaggtag cccgggctt 5160
 gttctccct cctataagga agtctctt tccacacctc ctctccggc ccccaacctc 5220
 gttcccccac cctgggtgac tgctcaaca ggggtccca gagcagccc atcagcagca 5280
 cctgcaagct ggcaagaaat gagacttca gtccttgca gacctgcct atcgagacca 5340
 gaggttaac aggaggccg tggtctgac gcaggggaga gttcaagaag ctctgctctg 5400
 gggagctga gcagggcaat gttctctt ccacaaagct ttctggggg acaggaatgg 5460
 ggagagtctg tgtaagaaa aagaaggcag tgtgtctcc ccaggctgtg attgttaag 5520
 gaggagaaca cagggcgtag ggagctaacc cagacagaac gcagggtgtg cagggacggc 5580
 aggtggagct gtgatgagag atgaggagac ccaagcactt cctcagggtg gtttaagag 5640
 cctctgatgg ccggacactg tggctcacac ctgtaatcc agcactttg gaagcccagg 5700
 tgggcagatc atcttaggtc aggagtcaa gaccagcctg gtcaacatgg tgaaactccg 5760
 tcttactaa aaatacaaaa attagtcggg tgtagtggtg cgtgcctgta gtcccagctg 5820
 tttaggggc tgaggcagga ggattgctg aacctgtgag gcggagggtg cagttagctg 5880
 agatcacgcc actgcactcc agcccgggtg atagagttag actccatctc cgcctgccc 5940
 tgccccccc aaaagaaaag cctctgatga ggggtacctc cctgccagac catccagcgg 6000
 gaaggcagga tgctctcta cctctctg gcgaaggggc tgaggagga aatgatctag 6060
 gggagctata gagatggctg ccagtgctg tggcctggag ggagtgggg cgatcctgga 6120
 ccatctccc ctcccctg atctgtgccc gaagcttccc agcagctgaa ccagctgga 6180
 agccagtggt ttcttgctc tttagaggca ccagtgggca ggggtcggcc agatggggga 6240
 gcagtgatta cggagcctga ccagttagag agcgtcacgg gctgtcatgt aaaaggggccc 6300
 ttactgaccg tttagtcta agcctctag aatgtctaga gcagggtgtc cagtctttg 6360
 tcttccctg gccacacagg aagaattgtc ttaaaataca ctaatgatag ctgatgagct 6420
 acaaaaaaat cattgaaaga actcataatg tttaagaaa gttacaaat ttgtgtggg 6480
 ccacattcaa agccatcca ggctgcacat ggcccacagg ctgtgggtt ggacagactg 6540
 ttctagagcc acctgcagag agcatcagct gctcaggctg gtcccatc cctgtggtca 6600
 ctaccagat cctgttccat agactgagt ccagagagc tacgggagtg aaaatgtgag 6660
 cagctgctc tgccatcctc atgaccggg cctctccact gctgtcctg cccaagcctg 6720
 tgtactact gaatttgaa ttgagtttg aagtagaaca gggatgcata ttgcttagga 6780
 gaaaacatc cagcctagtc tgtgttgtt ctgcagagt agctgtctaa agttctgag 6840
 cttagttaa gtgtctgta aatggtgaaa atattgaaa tgctttatt cctgtgata 6900
 ctactgtg tctgggacca gcagcctgg cattgggct cctgggagc ttcttagtc 6960
 ctctcagct aagcagcagc aggacgctg agtcagcagt aggcctgggc cgagctgggt 7020
 ggtgaccagt cctctgctg tccacagggt aggtgacgcc gtcctggggc tggctgcat 7080
 gctgtctg ctggtctga agctgatcg ggaccagtg cctccgctc accccgagat 7140
 gccccctggt gtgaggctca gccgtgggt ggtctgggt gccacgacag gtgaggggcc 7200
 tctggctgac atcgtatga acctggctg caggttggg tcaattggg agtcttagtc 7260
 ccacctagg gattctcag tcatggctt ggtgtcact tgagcattg gacatttaa 7320
 acaccacacc aaactctgg acatgtactt ttatttaat taattaatta attattttt 7380

gagacagagt ttgcctctgt cgcccaggct ggagtagagt ggtgtgatat tggctcactg 7440
 caacctccgc ctcccagggt catgtgattc tctgcctca gccctctgag tagctgggat 7500
 tacaggcgca tgccaccacg ctgactgat tttgtattt atagtagaga cggggtttca 7560
 ccatgttgac catactgggc tcaaactcct gacctgagt gatctgcctg cctgggccc 7620
 ccgaagtgct gggattacag gcatgagcca ccgccccgac ccaaactcta gaacatttaa 7680
 aactctgagc caaactcggg gggttctgat gcagggtcag agctgagaac tgatgcatgg 7740
 ccagctgtgg ccgtttctaa cctgaagcag tttgcccc ctggtgacat gtggcaatgt 7800
 tgggaaacat tttggtgga taccaccggg cgaggcaggt gctggcaact agcgaggagg 7860
 ggccaggaat gccactaagc ccctgacggc gcacagcctt ccacagcaaa cagtgatccg 7920
 gccccaaatg tcggcgggtg cgagggtggag aaacacagtc tactggcagg tcctggggag 7980
 acagaacaaa ttccgggggag accaacaggc tctgtttgaa ttgtgcagct ttatgggggt 8040
 acaacttcag ctccaggcgc ggaggctgca ggctgagcca caaccaacca ggggtcctt 8100
 gagaaagggg tggtaggggc tgcgtcgtgg aggagcaggg ctgtcagcag gtgaaggacc 8160
 accctggggg aggtggaagc ctctctcag tgcctccggg atgggcatgg gtcccctggc 8220
 tgagcaccgg gcagggatgc ccagagaaga aggcacaccc aggaaagtca ggaagcatag 8280
 gtgactcaa accctctcag agccgagggg acagattaag ctgagaataa cccgagcttg 8340
 gtcttgctgt tgggggctg caaaatccaa cagccacaga agagagaggg tggctggatt 8400
 tagctctga gtcactctg cctgccagg ctggtctgtt ctctgtggc tctcctgga 8460
 tctgttcag cagacttgag gccgtggtga acactgagag tctggtggg tgacaggat 8520
 gctgggtta gagtggagat gtccagctc cagtccagc ctggcctggg ttagacttg 8580
 caaagtagct tcaaagttc ctgagctta gttcagttgt ccgtgaaata gtgaaaatgc 8640
 ttgttatct ttgttatct ttgtttttg tttttttg gagacgggt ctactcctg 8700
 ttgccaggc tggagtgac tggcgtgat ccttggtca ctgcaacct cctcctggt 8760
 ttcaagcaat tattcccc ttaacctcc cggagtagcc tgggatttac aggccgtgca 8820
 cccaccacac ccgggcta ttttgtatt ttgagtca agatgggggt ttaccattg 8880
 ttggcccatg ctgggtctcg aaactccnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnn 8940
 nnnnnnnnn nnnnnnnnc ctacccctga aaggcaggt ctccgcagcc agaaaggct 9000
 tttaagatg ttgacatcg gtaatgtcca gaaactcag aaacattta cagtgtagg 9060
 ctgtgactc cttctccc agtgtgtga gcattgtct aggaaactac ttaaaaagct 9120
 ttgattctt ataacagctt tgagaatgag ttattattt ttccattt gtcagtgagg 9180
 aaagtgagcc tatgaaagat gaaaaataaa acagaacttc tcaaggccac acgaetggga 9240
 agaggcagaa caaggacttc acccgagtcg tctgtcttt ttctgaatg gtctgtctag 9300
 aagtgtgca atgttatgat cctctcaaag aaccagctt tggtttcatt gatctccct 9360
 ttgcttggg ttctagtc attgattct gctgggcct ttattttc cttcttcta 9420
 ttattttca gtaactta tctttttt tttttttc aaaaaaaaaa tttttttt 9480
 gagacggagt ttgcctctg tccccagggt tggagtgc aa tgggtgac tcagctcact 9540
 gcaacctccg cctccgggt tcaagtga tt cctctgctc agcctccaa gtagctggga 9600
 ttacaggcgt atgcccat gcctggctaa tttttgat tttaataga gacggggtt 9660
 caccatgtg gccaggctg tctgaactc ctgaactcag gtgatccac cgctcagcc 9720
 tccaaagtg ctgggattac aggcgtgagc cactgtgcc gccctttt ttcatct 9780

taaggtagaa gccgggtct ttgattgag accttctc ttcttaata tgggtgtta 9840
 aatgctgtaa atttactcc tagcattact ttgctgcat cccacagttt ttatataat 9900
 gctgttctt aattttatt cggttctaaa tactttgtga ttccattt gactctcct 9960
 ttgacctgtg gattattag aagtggtta tatgattct tctgtgaagc atgggagta 10020
 tttagttcc aaatagtgg gggttccca attagtact tgccattgat ttctaatta 10080
 gtccattgt gataagaaaa cgtacttagt gattaaac ttgttctt tattgagagt 10140
 tgtattatgg cctgaatat ggtctatct agtgaatatt ctgtgtgtgc ttgagaacat 10200
 gtttctgcc attatgggt ggaatgtct gtaaatgca gttaggtctg gttggtatc 10260
 tcaggctact atattctgc tgatttctt tctactgtt ctgttgatta taaaagaag 10320
 aatgtgaaa taacttcagc tataaccatg actttgtcta ttctcttc ttactacca 10380
 gttatgttt catatattt gaagctctgt ttttagtat aaaaacatat agaattataa 10440
 ttctcttg gaatgatac tttttctg ggcaaatc tctccctga aatctactt 10500
 gatactaaga gagctactcc agcttcatt agtgttagca tatctttcc catctttta 10560
 cttttttt ttgagacag aatctctc tgtgccag gctggagtgc aatggcgtga 10620
 tctggctca ctgcaacct caccctccag gtcaagcaa ttgtgtgcc tcagcctcc 10680
 aagtagctgg aattacaggc ttgcaccacc aagcccagct aattttgt ttttagtag 10740
 caatgaggtt tcaccatgtt ggccagcctg gtctcaaat ctggcctca agtgatccac 10800
 ctgcctggc ctccaaagt gctgggacac cacaccagc ctctatctt ttacttta 10860
 acgtattaa ttgattgtg ttctgtgtt taatggtatg ttatgggc agcatataga 10920
 tgggattgt tttaatctc ataactctg cctttaatt ggaacttat gccattata 10980
 tttaatgta ttatgtgt ctgtgactt agatctacca tgtgtgtt tgttctgt 11040
 ttgtctatt tgttctgt tccctttcc cctctctt acctctact gattatttt 11100
 tatgattcca ttatctacc ttatgggt gattagctgt aacggctata tttagtttt 11160
 gttgttgt ttctaagtga ctgtttaag gttgtggt aacatctta tctgtctaca 11220
 gtataatta aactcaact tcatgtgata taagaacct ataacaggcc aggcgcagt 11280
 gctcacacct ataactctag cactttggga ggctgaggga ggcagattgt ctgagctcag 11340
 gagtctaaga ccagcctggg caacatggcg aaacccatc tctacaaaa atacaaaaa 11400
 tttagccaggc atggtgtgc atgctgtaa tccagctac tggggaggct gaggtgggag 11460
 gattgctga acctggaagg cagagattgc agtgagcaa gatcogtcac tgaagctga 11520
 aactcctgg ctcaagta tctctgct cagcctctg agtagcttg ttacaggca 11580
 tgcaccacca catctggcta atttttaa tttttata gaaacgggct atgtgtctca 11640
 ggctgatcaa aggttcttg cctcaagtga tgcctgcc tcagccaacc aaagtctga 11700
 gattgcagat gtgagccacc attcctgca ggaacagtct tagattatc cacgtagtca 11760
 ctgttctgg tgcctta tcttctac aaatccagat ttcatctgg tataatttc 11820
 ctctacctg aaggatgtta ttttctc tgttcaggc ctgtgtgt taaactctt 11880
 cagcatttt tttttttt tattgacag gattactct gtcactcagg ctggaatgca 11940
 gtgtacaat tatagttcac tgcagcctg aactcctaga ccaagcaat cctcagcctc 12000
 ctgagtggct gggactatg gcatgcatca ccagcctgg ataattttt attttactt 12060
 ttgtagaga tgggtctc ctacgtgcc caggtgtc tctactct gggctcaagg 12120
 gatctccca cgagggatc tccacttg gcttccaaa tgtgggatt acaggtgtga 12180

gccactactc ctggtcttct ttaactttt gacttttga tgcctgaaag tctattttgc 12240
 ctccattttt caaagatagt ttgctgggt atagaattct agacttttt tttctttca 12300
 gtactttta aaaaaaagt atttattt tttttatt tgagacagtg tctcgctgtg 12360
 tcaaccaggc tggagtgcag tggcagatc ttgctcact gcaatctctg cctcctgggt 12420
 tcaagtgatt ctctgtctc agcctcccag gtagatggaa ttacaggcgc atgctaccac 12480
 gcccggtcaa ttttgtact tttagcagag atggggttt gccatgttg ccaggctgct 12540
 ttgaactcc ctgacctcag ggtgatccgc cctcctggc ctcccaaagt gctaggatta 12600
 caggcgtgag ccactttgc tggcctcagg acttttaaag atgctattct gctgtctct 12660
 ggcccacttc gttcaagaa gtgtgctggc attcttgggt cctctgtatg taacctttt 12720
 atccaccgct ttaaaatat tcttatcac tggtttagg cagttcata atgtggcttg 12780
 atgtagtgt ttttgttg ttgttttt gtttctgt tttatgcttg tgattcattg 12840
 aactcttag acatgtgggt ttgcagttc atcaaattg gaaaataaac acccatctt 12900
 tctgaaatc ttgtactgt cccctatgc gattccacag acttctttg cagaatcccc 12960
 tgcctgatt tcaggcaact cgaagggtt ctacagctc acttgggatt ttacgcttc 13020
 tcttttgtt gttcattt ggatagttc tgcctcaca tttagctt ttttctgt 13080
 aatgtctcag ctgtgtaat tgcaccaagt gctgttccg tctcagacac tgtggtttc 13140
 attctagaa atccagttg aatctttt tttttttt ttttttta agatggagt 13200
 tgcctctgt gtccaggctg gagtgcaatg gcgcggtct ggctcactgt aacctctgc 13260
 tcccggttc aagtggttt cctgcctcag cctccagggt agctgggatt ataggcatcc 13320
 accaccatgc ccagctaatt ttgtattt tagtaaagac agagctcac tgttaggct 13380
 gggccagct cgaattcctg actcagggtg attcagctgc ctggcctcc caaagtctg 13440
 ggattacagg cgtgagctac cgtgccagc ctcaattga atctttaaa atgtatttc 13500
 tacatctta cttaacagt gcaatcttc ctctgttt ttttaagta tatggaatt 13560
 ggttacagt attctttta tgcctatta actaaattac attggttac agttactct 13620
 ttaatgtct gtaattctg tcatctta ctatgtact ttgggtct tttttatt 13680
 tttatttta tttttgaga cagggtctc ctgtctacc caggctagag tacagtggca 13740
 tgatcatgt tcaatagc ctcaacctcc caggctcaag ttatcatct acccagccc 13800
 ccaagtgc tggactata ggcatatgc accatgtca actaattt ttttttgt 13860
 ggagacagtg tctactaat ttgtcaggc tggcctcaa ctctgggt caagcagtc 13920
 tctgtctg gcttccaaa gtgtgggt tacaggcatg ggccactgca ccagccata 13980
 tttctgct tcttgcatg cctagtaatt ttgttggg tggatgctag acttgtgag 14040
 ttgaggta ttgctgctg gataattt tattctata atctctga gcttctct 14100
 gggatacagt taagtactt aggacagtc gatccattt ggtctactt ttaagcttg 14160
 tgagctggac cagagcagtg ttacttag ggcaagccta attggccca ccactgatt 14220
 ttgtaataa agttttatg gaaaatcact cccattcat tacatggtca atgtcagggt 14280
 ttatgcaata ataacagact tgagtgtg cgccagagac ttatggccc acaaagcaa 14340
 aagttttag tatttagccc ttacagaaa acattgcca accccaggcc ttgggclaat 14400
 ctcccaact gctgaggtaa aacctctgg agtccctgat gctccatgaa ttatgagggt 14460
 ttttactct ggtgtgaatc ctggggttg tccctgtaa cctcttgt gactctccc 14520
 cactgtgggt ttgggtcatt ttgccagc ttgcctga ccagttct gctgcacatc 14580

cgagggcacc tctgcagatc tctgcagctc tgtctccggc tgcctctct gctcctgtga 14640
 ccttgcggtc agctccagct gcaggcctcc tcagacttcc tcccagcatt gccccctgaa 14700
 ctacaggaaa cccctgggct ctgctagggg gtccctcca tacacatggg gaccatcggg 14760
 ggaaaccgta ggcagccggc ggggcagtga tagactcacc tccctgttt cctgtggcc 14820
 gtcattggct ctgtcccgct tcttagtggc catcatgtcc actgtccgc atcttggagg 14880
 ccattgttc tgtgtttg gaaaggggt aaatctgggt tctctctct tgtgtctt 14940
 aggtggatgt gcccgggccc acctgattc agagagtctt tgcgcgggt cacgatgtcc 15000
 agtcacctg agctggcag caggtggcat gtgcacctgt ccgcagcctg cagctctgcc 15060
 gtccacctg ctatgtgc cacatagcat ttatgtctgt gttgtttc ccagagtga 15120
 gagtggagac tgtggccgg tggggcgct tctgcctct gggatgtct cccagtaac 15180
 ctggaggcag ccgcgctacc ccacactgc cgggagcagg gtctcggacg cactctct 15240
 tctctctag ctgcacgc cctgggtgct tctctcag cctgggtgc gtactcttc 15300
 gaggtgactg gataccagcc ttcatccta acaggggaga cagctgagg gctccctcca 15360
 gtccggatcc cgcctctc agtgaccaca gccaacggga cgatctctt caccagatg 15420
 gtgcaggtag gcggagccgg gaggcaggat ggcgtggctg aggcctcagt ggcctcggc 15480
 ctggctcta cctgatga tctgtgggt gccaggggt ctgaggtcag ttaggacagc 15540
 tgagtctca ggaacggaca tctcagttat taaagaatcc caggttggat gaaactcag 15600
 cgagctcagg gatgtcacgt ttgtttcag ggcgctct cctgtttg actccagctg 15660
 aggatgaatt tacgtgtc ctccagcac ctgggcctc ttacagacaag gaggcggatc 15720
 ctgcagctga caagcactg ctctgttac ctgtggggc ggtgggtcc ttgtgttt 15780
 catgggtcac tctgtggct tacccttag gaaggtcact caccatccct ctctctctc 15840
 tcaggacatg ggagccggc tggcctggt gccctgatg ggctctctg agagcattgc 15900
 ggtggccaaa gcctcggta agacgctgt caccacacc ccaggtctcc cagtgcgcg 15960
 gctgggctag gctgcctgc ttctagctt gccttatcc gttactagt ttagaaatt 16020
 gaattcatat ccaagtaata catgctcatg atagatacat atgtattgt tatatatgat 16080
 aaaactggat ctataatgag gcatgcctc ccacccatg gtgtgtgtg gatgttga 16140
 acagcctct ctgttttg aaataaaagg ttgtctcg tggccctgc cgatgtccac 16200
 ggtgtaaac ctgtgtct atttaagg aacgtcact aaaggggagt ttgcacatg 16260
 agctgggtg agatctcat gaacaatcat attctatgt gtctocacca ttagatata 16320
 gtgggtgcaa ataacctcat cagtagtagc caaatgcaa ataaattagg aagtatgat 16380
 tttaagtat tatcttgg ccaggcatg tggccaggc ctgtaatcc aacacttgg 16440
 gaggtgaga cgggaggatc gcttgagctc aggagtga aaccaccta ggcaacgta 16500
 cgagacctg ttctattaa aaataaaa tagctgggca tggagcacac ctgtgtacc 16560
 agcttctcag aaggctgagg caggaggatc acttagacc gggaggtcga ggtggcattg 16620
 agctgtgata gtccactgc actccagct gggcagcaga acaagatct gtattatct 16680
 tttaattgaa agtttaatt taattgtaa taatggctat gtttagtaat aggcacaa 16740
 aactctaaa cattcagcaa catgtttat tcagctggct cagccatcg gccagccct 16800
 cctgcctcc agggaggcag ggaacctc gtctctca gtgtctgtt tgatcagca 16860
 tcttagatt cctcctgc agctcgtcc ttcactcgt ccactcctgc cagcttga 16920
 ttgtctgc ggaagacacc ttcgtctgt ctgtaccg tcatttagc ctcttgcgt 16980

ttgggttat gtgattota aaggttacag cccagttacc agtgtatgt actgtgactg 17040
 tgtaaactgt gttactgcc tagcccaggc tgtgccaggg taaagttcct tctccaaagt 17100
 cccagtgctc taacccttac ccccttcaaa ggagttttt ttgtttttt tttttttt 17160
 ttttgaga cagagttca ctctgtggcc caggctggag tgcagtggca cgtctctgc 17220
 tcactgcaac ctccgttcc caggtttaag caattctcat gcctcagtt cccaggtagc 17280
 tgggaataca ggcatgogcc accacgccc actaatatic tatacttta gtagagacag 17340
 ggtctacta tgttggccag gctggtctca agtgatctgc ccacctgggc ctcccagtaa 17400
 tttttttt tttttttt gagatagtg ttacacttg ttgccatgc tgggtgcaat 17460
 ggtgtgatct tggctaccg caacctccg cccccaggt ccagcaatta tctgcctca 17520
 gcctccaag tagctggat tacgggtgtg caccaacatg cctggctaatt ttgtattt 17580
 tagtagagat ggggtttct catgttgatc agactggtct caaactcctg acctcaggta 17640
 atccgccac ctacgctcc caaagtctg ggattacagg tgtgagccac catgctcagc 17700
 cctccagtaa ttcttttt tttttttc gagacggagt ctgctctgt cggccaggct 17760
 ggagtgcagt ggctgatct cggctcactg caagctccg ctctgggtt cagccattc 17820
 tctgcctca acctccgag tagctgggac tacaggcgtc cgccaccacg cccagctaatt 17880
 ttttgatt tttagtaaaa acgggggtt caccgggggt ctgactctcc tgacctggg 17940
 atctgccctg ccttaacctc taaaagggt gggattacag gcgggagccc ctgggccccg 18000
 gccgtaatt ttaatggaa aaacaaggc tcaattggg ggccaaggct gacctcaaac 18060
 tctgagtc aagggtacct cctgcctcg gttnnnnnn nnnnnnnnn nnnnnnnnn 18120
 nnnnnnnnn nnnnnnnnn nnnntggtct gggctaatt ttgttttt gtagagagag 18180
 tatitgcat gtgcccagg ctggtctga actcctggg tcaagcgatc ctctgcctt 18240
 ggctctaaa agtgtcgca ttagctgtg gagccacct acctggcctg attacatggt 18300
 actgtacct ttccactct gtatatact caagcacatg ttacacgca catatatgt 18360
 aatatttag gtgtgtatc ttagattac aaaactatt gccgtgtga gaaattcata 18420
 atctgtgta catittgta atactttg agcgatgtg aatattactg accaggtctt 18480
 taccgttgt tcctgtagc atctcagaat aattaccgca tgatgccaa ccaggagctg 18540
 ctggccatg gtaagacccc agccgcggga aggaagacac cagctgtgg cctccagggt 18600
 cccaggcctg cccctctgt tctctgcat ttaggaaga ccatgatgtt ggtgatgaac 18660
 tgggagggca aagggtggcc cagatgggat ctctggaat attagttt gtttgggtt 18720
 ttgagatgg agtctcact tgtgcccag gcaggagtgc agtggaacga tctggctca 18780
 ctacaacct tgctctctg gttaagtga ttctctgcc tcagcctccc aagtagctgg 18840
 gattaaaggc atatgccacc atgcatggct aattttgta tttagtag agatggggtt 18900
 tcacctgtt ggccaggctg gtctgaact cctgacctca agtgatccg ccgctcagc 18960
 ctccaaagt gctgagatta taggctgag ccactgccc tggcctatgc ctgttatct 19020
 taaacctga gactcagagt gtggcctgg accagcagcc tgggcactgg gcatctctg 19080
 ggagcttact ggaaggcag gatctcagg cccaccccag atctccgaat caggatctgt 19140
 attctcagg gcacgccag gggattcatg gggctagctt agaagtcaaa gtttgaagc 19200
 cgggcatggt ggctacgcc tgaatccca gcacttggg aggccgagg aggcagatca 19260
 cctgaggta ggagttgaa accagcttg ccaaaccgg tctctactaa aaatacaaaa 19320
 attagctggg tgtgtgtg tgtgcctgt atcccagct cttgggaggt tgaggcagga 19380

gaatcacttg aacccgggta ggccggagggt atagttagcc aagattgcac cactgcactc 19440
 cagcctggca acagagcgag actccttctc aaaaaaaaaa aaaaaaaagt caaagtttgg 19500
 gaaatgcta gagaccccat gttttcaaa gactgtttt gtagacttt atgagatgat 19560
 caagcagggt tggccacaag gggagacagc caaaggctca ggaagataac cagttttt 19620
 ttactcaaag gtcccttagt taccagggag gccacagcat gcctacttag gccatgtca 19680
 gaggacacca ggggtgtccc cggaaggata aatcccaatc tgtgattta ggctccgcc 19740
 cttttcggg aattttcitt gctaatgt aattcaata aaggccccc gcttaagact 19800
 ttcatatgt tattaattt aggcgggtc taactccta atgaagaaat attctccct 19860
 ccttggaatt cgaatcaca ccatttctc gagaaacgcc tccacnnnn nnnnnnnnn 19920
 nnnnnnnnn nnnnnnnnn nnnnnnnnn nnnnnngtt tttttggg caaccggcca 19980
 tcatctggg aggcagcatt aaggcccatc acttgcct tcaatgtgac tgcattctt 20040
 ttacacgaaa aagttttt gtggaaccc ggtgtgtggc ccattacct cctgagtgc 20100
 tagggttgt gtccggggc atttatctc gcttcacc cctctggat ggtagatgc 20160
 tccctctgt tctgcgtgg gaaggcgggt cctgtgtcca caggatgat tgggtcaaa 20220
 gtgttcaga gctaggatct ctccaggct ctgtgtggc actcctgtt ccagcactt 20280
 tgggagggt agccgaatg gtcacctaag gtcaggcatt tgagaccaga ttggccagca 20340
 tggcacact cctgtgtgt actaaaaata gaaaaattac actgggtgtg gtggcacatg 20400
 occgtagtcc cagcacttg gcagggtcaa ccgggtggat cactgaggc aggagtta 20460
 gaccagcct gccacatgg caaaactct tctgtactaa aaatacagaa attagccagg 20520
 cgtgtagtg tgtgcctga atccagcta ctcaggaggc tgaggcagga gaatcgttg 20580
 aactgggagg cggaggctgc agtgagctga gatcgccca ctgcattca gcctgggcaa 20640
 caaagccaga ctctgtctc aaaaaaaaaa aaaaaaaaaa aaaggctagg cttactgt 20700
 gcaagaatgt ggctgttt ctctctcc tgaaggagt cgtaggcca ggccccagg 20760
 atgattctc cgagccctgc ctctgcct cctctgtgg tttgtccc cctcccatc 20820
 tcttctcc ccatctgtg tgccttcc cccagatcag cctgtctgc ctctccca 20880
 ggtctacca acatgttgg ctccctgc tctctacc cggtcacagg cagcttga 20940
 cggtagtga catgtccgc tctctgtt gccacgtt gacgcctaa cgtgttacg 21000
 ctgacaagga gtctgcctgc cctgacccc ggcggcgt ctccactgt aacgtccgt 21060
 ggagaggcag ggctgggggt caccactgt cctcagggt gtctctgt tcttattct 21120
 catagatgt cctgcagtt catactagaa agttccact ggcatgttg tacaccctg 21180
 ttatccatt tactctggag ggggaagcag gagaatcgt tgagccagc aggatgaggc 21240
 tgcagtagt tgtaccgca ccgtgcact ccagcctgg caacagagcg agaccctgc 21300
 tctaaaata atactagaa gttccagca cgcaaagc ctctagctc ctggtgccag 21360
 agtcaattcc tgaaggagc tggagatagg aaggggctc gctctgtct gaagcagccg 21420
 ggcatgaagc ttagccaga tgcctacgg cccctctca gtcaggaca caggatggag 21480
 gtgacctgt gcttaagga gagaaggagg cgtgcctgg cactgccag tccccagct 21540
 ggtgacctt gccctgtgg gtagggggc ccacctgga tggggcagg agacagagtc 21600
 ggcaggaacc tgaaggaca cgtgtctct gagcttct ctatagtcag ggtggccaa 21660
 gcgggctgt ctgtactgc accctaagc tcttgctc ggtcccttg cagtcccg 21720
 ctgttcca agcgtgtg ggagctgac tccctcga agatcagca caggagtgt 21780

gactgagggtc tcccccttc cggccccctgg tgactgacgg tctctgtgtt gcctccagg 21840
 acagccgtga acgctcagtc ggggggtgtgc accccggcgg ggggctggg gacgggtaag 21900
 gccccccatc tccccctgt gcccgcagcc ctgagagtgg gagaaaggga ggagggggcc 21960
 cacagagacg tccccctggc tcatgggccc tgcccccgg gactgcacag ggactgggg 22020
 ggccacacag gagtaggggg accacaggag actgagcagg ggctgggggc ctggcagtc 22080
 gtgcacctac cccacccct gtccccagtg ggctctgtg aacaagaggc tgctacgtg 22140
 cgtgtgggg ggacctgca ctccgaggt cactgtgtt cccgtgccc gcaggagtgc 22200
 tggctgtgt gtcttgagc tacctgacct cactgttcta ctacatccc aagtctgcc 22260
 tggctgccgt catcatcatg gccgtggccc cgtgttga caccaagatc ttcaggacgc 22320
 tctggcgtgt taagagtacg tctgttct acaggggaga gcgctgtgat gcggtgtctg 22380
 aacgcggagg gtgtcattta tgctaccca ttttctgca gccccctg tggggctggg 22440
 actgggaagt tagggcagtc ccggaacaga gaagtggatg gccaggagat gggcccagag 22500
 atgttccga ggctcagtg gaagagctgg agctcctgt cctgacacct ggggtctga 22560
 ggcgagcact gaaccggggg agggctccct cctgatccc ctgcccctat cctacccctc 22620
 ctgcccacc gccccagcc accactctgc ccggcccagc tggggggagg gacaggagac 22680
 gtccctggg accagcagg ccagcggaa agcctgcac cctggctcag aatggcagtt 22740
 cctttttt ttattttt ttttttatt gatcattct ggggtttct 22800
 tgacagggg gatttggcag ggtcatagga caatatggg ttgggggtaa ggtcacagat 22860
 aacaggatcc caaggcagag gaattttct tagtcagaa caaatgaaa agtctccat 22920
 gtctactct tctacacag acacagcaac catccgatt ctcaatctt tccccctt 22980
 tccccctt ctattccaca aaaccgcat tgcacatg gcgcgttct agtgagctgt 23040
 tgggtacacc tccagacgg ggtgtggcc gggcagagg gctcctcact tccagtagg 23100
 ggcggccgg cagaggcgc cctcacctcc cggacgggag cagtctctt aactaacac 23160
 attttttt gttgtggaa gaagcatgga gtgggtcac ctacttact tggcatttc 23220
 tggtagccc cagcaagtt ccaggtaaa ggtggataa tttctgca tgccgtcgc 23280
 atgccagggc ctttcgctg ccagtgcgt ggggcttag aacagccctg aaacgtgtc 23340
 atgtccggc gtggaatgg atggccgtg ctgtagaaa ccaaggctca gccagggtg 23400
 ggcaggcctg acctatgct ggggtggaat ccccccagg gctaagccc tgcatttgt 23460
 cccagggca ccttctctt ggcaggctc caagggtca cgtggctcc gccccactcc 23520
 tcaggccagc tctgtccct gacaagcccc tgctgtgcc ctccctgagg ttgaggcca 23580
 gggaccggc ggcaggctc acctgcctc agctcagatg gggagggcat tcttctt 23640
 cgactgaag catggcctg tcagcagct ctgtcccaa gtctcagg gctgctggg 23700
 gtccatgag acctttact atgttggg ggcagaaggc tctccgctg gtcagcagg 23760
 ccatttggg gctcgggca gctccgggc attctcagc tgtccctc tctagggt 23820
 ggacctgct cccctgtg tgacctct gctgtctt tggagggtc agtacggcat 23880
 cctggccgg gccctgtgt ctctgctat gctctgcac tctcagcca ggcctgagac 23940
 caaggtaacc ctccgtggc tctagtggg gagtgtgct ggggcaggat tctgggcat 24000
 ggtctatgt ttgagggtc cggggtgatt gtggtcgtg gtgctgta aggggaccgc 24060
 tgcctggcag gtgggcagtc acctgtct aaaccatgt gttctccac tgttggggg 24120
 ccgtgggggt cccccctag cccccctc ccggtccct gcagcacgt aggttgggtg 24180

ggggcttccc gcttgggaca ggccaagcct ggtggaggcc acccggtcag accgcctcc 24240
 aggactcact cctccccaca ggtgtcagag gggccgggtc tggctctgca gccggccagc 24300
 ggctgtcct tccctgccat ggaggctctg cgggaggaga tctaagccg ggccctggaa 24360
 ggtgcatggg cgggggtcaa ggtggtctga ggtcactccc ctgtcctctg cccccactc 24420
 cctgtgttc aggaccccaa gacctgtcc ccgacgtct ccagtcaca aggatgcagg 24480
 catctctgag tgggtggac cgtcctctgt gggcctcagc cagtggctgc tgcagcaagg 24540
 gtggtggctc cccacatctc actccttccc tgcctctaaa gtccgggtcc tgttctggg 24600
 ggggtgatt taggggagct aagggcctgt gagtctagg agggaaacag ctgtgtctgt 24660
 caccaaacaa ttgtctctg tctgtccacc cgaatcccc aactgggcga ctgagccgcc 24720
 acgagatgga gcactctggc ctctctgtcc cctgccctg gccagagcct ccttggcct 24780
 ctgcagagca gcttgggct gctctgggtg gcgtgacctg gctcgggct gtctcccag 24840
 tgtccccgc accgtgcctg gtctggagt gacccatgt ctgcagcatc gactacactg 24900
 tgggtctggg actcggcgag ctctccagg actccagaa gcagggcgct gccctggcct 24960
 ttgtgggct gcagggtgggt gtgcactggg atgccttagg ggtagcagc tgcgggaagg 25020
 ccttctgtg cctgcctccc atggcgaatg tgacatctt gggctgtgat gctggaaggc 25080
 ccttggccg gtgtggctc tgcctctgat ttaacagtt ctgtcccca tctggcctc 25140
 ctgtccctc cctgtggaag ggggagcggg ggccccagc cctccgaggg gtcacgttat 25200
 ggcttctgt cactgccaca ctgtccttg tctggggac acacagtga cgagggtcag 25260
 tccctgtct caggggaatt gtatttagg aaacaaaaag agacaggta ggctaggcgt 25320
 ggtggcacac tctggaatc ccagcactt gggaggccaa ggcgggcaga tcacctgagg 25380
 tcaggagttc aagaccagcc tggccaacat ggtgaaacc cgtctctact aaaaatacaa 25440
 aaaaaactag tcagggtgtg tggcgagcgc ctgtaattc agctacatg gaggttggga 25500
 gaatcgctg aacctgggag gtggagggtg cagtaagccg agatccact actgtactc 25560
 agcctggcg acagagtgg actccatctc aaaaacaaac aaacgaaaaa aaacaggtgc 25620
 tcatagaatt tcataaaaa cgtattgtca gggctccag aggtgaaga cgggttcta 25680
 tggaggccgt cctgttcaga gccgcaggta aagtgtagg gctgggtccc aggcctgcg 25740
 tottaggcct cacctaggag cctctgagc actgcagggt caacatccca ggggtgtggc 25800
 cagtgttgc agagaggcag gggctctgt tctgtgtgt aaatgtgcg tcttgccaa 25860
 gtcttagatg gcagaacgtg ggggactagg gcgtgtccc aggcgccag aggagacatt 25920
 catgaactag ccatggaaca ggaggccaag tgaccgtat acccaggtg tggaccacag 25980
 ccgacctg tcagagttc ctcatccc aacctggccc acgaggctag tttatctc 26040
 atcccatgt ccagaagagg tcactgagc ccagagaagc caggtaatct gccacggtc 26100
 acacaggatg gtgggccag ctacagatt gggcatgtc ctacagaact tgcctataa 26160
 gtgtacgtc ctgtgtcata ttgcagagc acatgtctc atggcttct gagatgattc 26220
 actaaaaa atactctct gaccagaca tgggtgtca cactgtaat ccagcactt 26280
 tgagaggccg aggcgggagg tcaagggtt gagaccagc tggccaacat agtgaaactc 26340
 cgtctctact aaaaatacaa aaattagac ggcattgtg cgcacgctg taatccagc 26400
 tctcagggg gctgaggcag gagaatcgt tgaacccggg aggcagaggt tgcagttagc 26460
 cgagatcgg ccatgcaact ccagcctgg taacaagagt gaaactccat ctcaaaaaa 26520
 aacaaacaaa caaacaacaa gtctctggg ccaggcgctg tggctcacac ctgtaatccc 26580

agcactttgg gaggccgagg taggaggatc attgaggcc aggagttga gaccagcctg 26640
 ggcaacatga cgaaacccca tcaaaaaaat aggaaaaaat agctggacgt ggtggtgtgc 26700
 acctgtagct actcaggagg ctgagggtgg aggatcactt gagtctggga ggtgaggct 26760
 gcagttagcc atgatcgtgc cactgcactc cagcctgagc aatgagcaag accctgtctc 26820
 aaaaaacaaa aaatttaaaa aaaaaaaatc ttctctgac agcattcccc tggggctgcg 26880
 tttcttca ccattcactg gtatggaggt gaagccatac ctctcggga gactctgaga 26940
 .tggcatgtct accaggctgc cgacccgtgt gctacagagg aacatccctg ccctggctaa 27000
 agtctgtctg tctctcaggt ccccgcttc cgtgtcctgc tgtccgctga cctgaagggg 27060
 ttccagtact tctctaccct ggaagaagca ggtgggcaca gtcagacatc ctgtggcttt 27120
 ggtgattttg taaaaatcat aaatgcttat tgtaaaaaat atgggaaacc agctgggcac 27180
 agtggctcat gctgtaatc ccagcacttt gggaggccga ggcagggtga tcacctgagg 27240
 tcaggagttc gagaccagcc tggccaacat ggtaaaacct catcagtact aaaaatacaa 27300
 aaattagctg ggtgtggtgg catgcacctc tagtcccagc tattcgggag gctgaagcag 27360
 cagaatcgct tgaaccagg aggagaggt tgcactgagc cgagatttg cctctgcact 27420
 tcagagtag ggtgagagag ctagccatgt tgtccagaaa annnnnnnnn nnnnnnnnn 27480
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnn nctgggtga gcaggataa tcgctgcaa 27540
 cccaggtagc agcagttga ctgagtcga gaattgtcc actgcactcc agcctgggtg 27600
 agagcagcga gtactctgc tcaaaaaaa aaaaaacaaa aaaaacagga aaccacctcc 27660
 accccagtc actttggtga tcaactcata cccctccct aaacacgcat atgtacctgc 27720
 ctgtcaggat gtggatata gttgcgggt ttacgtaat gggaccatt catacctgt 27780
 gctctggaac ccacatttt catgcagaag gttggaagga tgccttcca gccgaaagtc 27840
 cacatcccg gggatcagga cagagcaggg ccgggtcagg agatccagaa gccccgggac 27900
 agaaggtagc ggaggagac gagcaggggt ggcgtgacc cltgagacag caatcgagg 27960
 aggtctgagc cgcagcaggt gtcaacaaga ggtgggcca gagatgcaga gcatccacc 28020
 caggccacac agcagtggc agagggtccc agggccaggt gctaggctc ttctcttc 28080
 actgaggtca cagctgaagc tgggtcagct ccgtgagagt gagggtggc ggtgtgtga 28140
 ctgacttct tggctcaatg tgacgtcagg gagattcacc catgtgttg tagaatcagc 28200
 tcagatgcag tgcactggag gtggataagc agaattggc ctggccgtg gatggaggg 28260
 taccctggag cagtaagaaa gggccgttag tcacctgaaa aatacgctta cagagactca 28320
 ggtgagaccc tcatggagtt agtgacactg gcctgggtg cccacagctc ctctctgcac 28380
 acctccagg actctggaag gccctctta atcccttct gtgaactgac ccatctcac 28440
 ttctgagctt ttgtgctt aaacatttat tgtatttct gcagagaagc acctgaggca 28500
 ggagccaggg acccagccct acaacatcag agaagactcc attctggacc aaaagggtgc 28560
 cctgtcaag gcataatgg gccaccctg ggcattcaca gtttcagggt tgtccggaa 28620
 ggttctgtc actgtattg gatgtggat gccgcctgat agacatgctg gcctggctga 28680
 gaaacccctg agcaggtaac ccagggaaga gaaggagcc aggcctggag gtccacggca 28740
 gtggggagt gggctcactg gcttctgtg ggtgactgg aaaatgacct cgtgtctgt 28800
 ccctggcatg accctcttg gaagagtgt ttggagagag cctttagaa tgacagactg 28860
 tgcaggaag caggggcagg ggttccagc ccgggctgt cgaggcatcc tggggctggc 28920
 agcacctcc cggctacca gtgccactg cgggggaggg acggggcagg caggagtctg 28980

ggaggcgggt ccgctcctct tctctcgcc atctgtgctc tccgagagaa aaccaagggtg 29040
 tgtcaaatga cgtcaagtct ctatttaaaa ataattttgt gttttctaaa tggaaaaagt 29100
 gatagctttg gtgattttgt aaaagtcata aatgcttatt gtaaaaaata caggaaacca 29160
 cccctcacc tctccacttg ggtgatcatt ccagacccct ccccaaacat gcatatgtac 29220
 ctgtccgtca gtgtgtggat gtatgtttac agttctacat aaatgggac atttataca 29280
 tgggtccttg gaaccacat tttcatgca gtcatttgca gtgaattatt tattgtgata 29340
 ataaatagca ttagaatata agatttttaa tctctcgctg gtattttgt ctatatatgc 29400
 atcataattg acttacggag cctctgttc aacgtgtgcg tgggttagag acgggatcgt 29460
 gctccttta gatgtgtcag ttgaagccct tgcctctat gtgactgctg ttgaaacag 29520
 ggcttttagg gggtaactag gtttaatgaa ggtcataaag gtgggccctg aacgatagc 29580
 tttagtctc tcgtgagaag agacgccaga gagctgttc tctgcacct cacacccag 29640
 ggaactccat gagaggacac ggcaaaacca ggccatgcgc ccaccaggaa gaaaggcctc 29700
 atgaggaccc cagcctccaa aactgggaga agatgaatct ctgtgctagg cccgcagcc 29760
 tggggtgatc tgtgacggcg gcctgagcag gtgaggactg cctgcatgt tttatttta 29820
 tgaatgctt gattgagtct gggggtaaat cctggaggc ctgtggcagc ctgagagggtg 29880
 tgttctcct gcaattct caagaagaat gtggcctgcc ctgtgagcc tegtctgcc 29940
 cgttctgcc gggcagtc gcccaatg agcgcagcaa ggggagggcc tctgtaacca 30000
 gggctgctgg ctgcggggct cccactgga cacgggagcg gacattggag tctctcat 30060
 ccgctcact ctccaggct cctgcctcc catttcct cctctctcc tcttcttc 30120
 ctctctct tctcctct gctcctcc tttctctt tctctcgt tttctctt 30180
 tctctctt ctctcttt tctctccg tctccttt ctctctct ccacccctt 30240
 ctctcactg tgtccccag gctggtctt aactcctgg ctcaagcaat cctctgct 30300
 cagcctctg tgtggctgg accacagaca catgccacc gccaggcta attgttaat 30360
 tttttata gagacagggt ctacttgt tccagggt cgtctaaac tctgggctc 30420
 aagtatact ccagctcag cctgaagtgc tggaaatag gtgtgagcca ccatgcctg 30480
 cctctctca ttcacaagt aacogttac cctgccc ccaatcatgt cgtttctgac 30540
 ctaggcagc tctcttct acataaagt aacctgtcc aaagctgtc tcatgggcc 30600
 cccctgccag ggctgaaga ggcagcgtt cacattggc ttgactcac ataccaagg 30660
 catcatgt tgaacctaga catggtcat tccagggt gggtaagg aaacagactg 30720
 tggcgggac taggactat cagttcata aatctcata ccacctga ctgagcgtt 30780
 atgtctctg gaactact aaacatgct ggtcagcct tccaggaagc aggcacaagg 30840
 acgtttga caactggc agtaattta agaagtagga agaaacctga gttctctga 30900
 attcgtaac atctgactg taggacacac gaataatgcc gtggaatatt gtgagcgt 30960
 taaaagaaat gaggtaagg ccgggtgtg cagctcacgc ctgtatct agcatttg 31020
 gaggccagg ctggtggat actaaggct aggagttga gaccgtctg gccaacatg 31080
 cgaaacctg tctctactaa aaatacaaaa attagctgac ctctgtgaca gactgagact 31140
 ctgctcaaa aaaaaaaaaa aaaaaaaaaa aaaaatgagg tgaagctta agttgaaca 31200
 ctgatttg ggtgaataa agcaagtgc agaataat ccaatgtaag atgctattg 31260
 agtgaacaca cggaccaaac aattctatg tgggtacaaa ttaagaaag agttctggc 31320
 tgggcacggg ggctcacaac tgaatcca gactctgg agggtagtc ggatggatca 31380

ggaggtcagg acttctagac tagcctggcc aatatggtga aaccccatct ctactaaaaa 31440
 tacaaaaatt agccaggcgt gttggcgcgt gtcaggagtc ccagctactc aggagactaa 31500
 ggtaggagaa tcactgaac ccgggaggca gaggttcag tgagctgaga tcatgccact 31560
 gcactctggc ctgggcaaca gagcgagact caaaaaataa ataaataaat aaataaaata 31620
 aataagagtt ttctgcactt tgggaggcct gtagtcccag ctactctgga ggctgaggca 31680
 agaggatcac ttgagcctgg gggggtcgag gctgcagtga gtctgattg tgtcactgaa 31740
 atccagcctg ggcaacagag tgagac 31766

<210> 6

<211> 548

<212> PRT

<213> Human

<400> 6

Cys Arg Pro Ser Thr Val Thr Asn Lys Phe Pro Ile Leu Lys Trp Leu

1 5 10 15

Pro Arg Tyr Arg Leu Glu Tyr Ile Met Gln Asp Phe Ile Ala Gly Phe

20 25 30

Thr Val Gly Leu Thr Thr Ile Pro Gln Ala Ile Ala Tyr Gly Val Val

35 40 45

Ala Gly Leu Glu Pro Gln Tyr Gly Leu Tyr Ser Ala Phe Met Gly Cys

50 55 60

Phe Thr Tyr Ile Val Phe Gly Ser Cys Lys Asp Val Thr Ile Ala Thr

65 70 75 80

Thr Ala Ile Met Ala Leu Met Val Asn Gln Tyr Ala Thr Ile Ser Pro

85 90 95

Asp Tyr Ala Val Leu Val Cys Phe Leu Ala Gly Cys Ile Val Leu Leu

100 105 110

Leu Gly Leu Leu Asn Met Gly Val Leu Val Arg Phe Ile Ser Ile Pro

115 120 125

Val Ile Thr Gly Phe Thr Met Ala Ala Ala Thr Thr Ile Gly Ser Ala

130 135 140

Gln Ile Asn Asn Ile Val Gly Leu Thr Ser Pro Ser Asn Asp Leu Leu

145 150 155 160

Pro Ala Trp Lys Asn Phe Phe Thr His Leu Thr Ser Ile Arg Leu Trp

165 170 175

Asp Ala Leu Leu Gly Val Ser Ser Leu Val Phe Leu Leu Leu Met Thr

180 185 190

Arg Val Lys Asp Ile Lys Trp Gly Asn Arg Ile Phe Trp Lys Tyr Leu

195 200 205

Gly Leu Ser Arg Asn Ala Leu Ala Val Ile Phe Gly Thr Phe Leu Ala
 210 215 220
 Tyr Ile Leu Ser Arg Asp Gly Asn Gln Pro Phe Arg Val Thr Gly Asn
 225 230 235 240
 Ile Thr Ala Gly Val Pro Pro Phe Arg Leu Pro Pro Phe Ser Thr Thr
 245 250 255
 Val Asp Gly Glu Tyr Val Ser Phe Gly Glu Met Ile Ser Thr Val Gly
 260 265 270
 Ala Ser Leu Gly Ser Ile Pro Leu Ile Ser Ile Leu Glu Ile Val Ala
 275 280 285
 Ile Ser Lys Ala Phe Ser Lys Gly Lys Ile Val Asp Ala Ser Gln Glu
 290 295 300
 Met Val Ala Leu Gly Met Cys Asn Ile Met Gly Ser Phe Val Leu Ser
 305 310 315 320
 Met Pro Val Thr Gly Ser Phe Thr Arg Thr Ala Val Asn Asn Ala Ser
 325 330 335
 Gly Val Lys Thr Pro Leu Gly Gly Ala Val Thr Gly Ala Leu Val Leu
 340 345 350
 Met Ala Leu Ala Phe Leu Thr Gln Thr Phe Tyr Phe Ile Pro Lys Cys
 355 360 365
 Thr Leu Ala Ala Ile Ile Ile Ala Ala Met Ile Ser Leu Val Glu Leu
 370 375 380
 His Lys Ile Lys Asp Met Trp Lys Ser Lys Lys Lys Asp Leu Phe Pro
 385 390 395 400
 Phe Val Val Thr Val Leu Thr Cys Met Phe Trp Ser Leu Glu Tyr Gly
 405 410 415
 Ile Leu Cys Gly Ile Gly Ala Asn Met Val Tyr Ile Leu Tyr Ser Ser
 420 425 430
 Ala Arg Pro His Val Asp Ile Lys Leu Glu Lys Ile Asn Gly His Glu
 435 440 445
 Val Ser Val Val Asp Val Lys Gln Lys Leu Asp Tyr Ala Ser Ala Glu
 450 455 460
 Tyr Leu Lys Glu Lys Val Val Arg Phe Leu Asn Asn Gln Asn Gly Glu
 465 470 475 480
 Thr Gln Leu Val Val Ile Lys Gly Glu Glu Ile Asn Ser Ile Asp Tyr
 485 490 495
 Thr Val Ala Met Asn Ile Val Ser Met Lys Gly Asp Leu Glu Ala Leu
 500 505 510
 Asn Cys Ala Met Ile Cys Trp Asn Trp Asn Ile Ala Ser Ala Gly Val
 515 520 525

Val Cys Arg Leu Asn Asn Asp Leu Arg Pro Ile Phe Lys Phe Asp Leu .

530 535 540

Ser Leu Glu Glu

545

<210> 7

<211> 548

<212> PRT

<213> Drosophila melanogaster

<400> 7

Cys Arg Pro Ser Thr Val Thr Asn Lys Phe Pro Ile Leu Lys Trp Leu

1 5 10 15

Pro Arg Tyr Arg Leu Glu Tyr Ile Met Gln Asp Phe Ile Ala Gly Phe

20 25 30

Thr Val Gly Leu Thr Thr Ile Pro Gln Ala Ile Ala Tyr Gly Val Val

35 40 45

Ala Gly Leu Glu Pro Gln Tyr Gly Leu Tyr Ser Ala Phe Met Gly Cys

50 55 60

Phe Thr Tyr Ile Val Phe Gly Ser Cys Lys Asp Val Thr Ile Ala Thr

65 70 75 80

Thr Ala Ile Met Ala Leu Met Val Asn Gln Tyr Ala Thr Ile Ser Pro

85 90 95

Asp Tyr Ala Val Leu Val Cys Phe Leu Ala Gly Cys Ile Val Leu Leu

100 105 110

Leu Gly Leu Leu Asn Met Gly Val Leu Val Arg Phe Ile Ser Ile Pro

115 120 125

Val Ile Thr Gly Phe Thr Met Ala Ala Ala Thr Thr Ile Gly Ser Ala

130 135 140

Gln Ile Asn Asn Ile Val Gly Leu Thr Ser Pro Ser Asn Asp Leu Leu

145 150 155 160

Pro Ala Trp Lys Asn Phe Phe Thr His Leu Thr Ser Ile Arg Leu Trp

165 170 175

Asp Ala Leu Leu Gly Val Ser Ser Leu Val Phe Leu Leu Leu Met Thr

180 185 190

Arg Val Lys Asp Ile Lys Trp Gly Asn Arg Ile Phe Trp Lys Tyr Leu

195 200 205

Gly Leu Ser Arg Asn Ala Leu Ala Val Ile Phe Gly Thr Phe Leu Ala

210 215 220

Tyr Ile Leu Ser Arg Asp Gly Asn Gln Pro Phe Arg Val Thr Gly Asn
 225 230 235 240
 Ile Thr Ala Gly Val Pro Pro Phe Arg Leu Pro Pro Phe Ser Thr Thr
 245 250 255
 Val Asp Gly Glu Tyr Val Ser Phe Gly Glu Met Ile Ser Thr Val Gly
 260 265 270
 Ala Ser Leu Gly Ser Ile Pro Leu Ile Ser Ile Leu Glu Ile Val Ala
 275 280 285
 Ile Ser Lys Ala Phe Ser Lys Gly Lys Ile Val Asp Ala Ser Gln Glu
 290 295 300
 Met Val Ala Leu Gly Met Cys Asn Ile Met Gly Ser Phe Val Leu Ser
 305 310 315 320
 Met Pro Val Thr Gly Ser Phe Thr Arg Thr Ala Val Asn Asn Ala Ser
 325 330 335
 Gly Val Lys Thr Pro Leu Gly Gly Ala Val Thr Gly Ala Leu Val Leu
 340 345 350
 Met Ala Leu Ala Phe Leu Thr Gln Thr Phe Tyr Phe Ile Pro Lys Cys
 355 360 365
 Thr Leu Ala Ala Ile Ile Ile Ala Ala Met Ile Ser Leu Val Glu Leu
 370 375 380
 His Lys Ile Lys Asp Met Trp Lys Ser Lys Lys Lys Asp Leu Phe Pro
 385 390 395 400
 Phe Val Val Thr Val Leu Thr Cys Met Phe Trp Ser Leu Glu Tyr Gly
 405 410 415
 Ile Leu Cys Gly Ile Gly Ala Asn Met Val Tyr Ile Leu Tyr Ser Ser
 420 425 430
 Ala Arg Pro His Val Asp Ile Lys Leu Glu Lys Ile Asn Gly His Glu
 435 440 445
 Val Ser Val Val Asp Val Lys Gln Lys Leu Asp Tyr Ala Ser Ala Glu
 450 455 460
 Tyr Leu Lys Glu Lys Val Val Arg Phe Leu Asn Asn Gln Asn Gly Glu
 465 470 475 480
 Thr Gln Leu Val Val Ile Lys Gly Glu Glu Ile Asn Ser Ile Asp Tyr
 485 490 495
 Thr Val Ala Met Asn Ile Val Ser Met Lys Gly Asp Leu Glu Ala Leu
 500 505 510
 Asn Cys Ala Met Ile Cys Trp Asn Trp Asn Ile Ala Ser Ala Gly Val
 515 520 525
 Val Cys Arg Leu Asn Asn Asp Leu Arg Pro Ile Phe Lys Phe Asp Leu
 530 535 540

Ser Leu Glu Glu

545